var title_f18_58_19360="Angiogram after embolization for postpartum hemorrhage";
var content_f18_58_19360=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right uterine angiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right uterine angiogram reveals occlusion of the right uterine artery (arrow) after superselective uterine artery embolization. The procedure successfully stopped the bleeding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_58_19360=[""].join("\n");
var outline_f18_58_19360=null;
var title_f18_58_19361="Large pneumomediastinum";
var content_f18_58_19361=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Pneumomediastinum on plain radiograph of the chest",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The films demonstrate a large pneumomediastinum.",
"    <br>",
"     Left panel:&nbsp;posterior-anterior (PA)&nbsp;view; bilateral subcutaneous emphysema in the upper thorax and neck, marked by blue arrows).",
"     <br>",
"      Right panel:&nbsp;lateral view; pneumomediastinum, marked by red arrows.",
"      <div class=\"footnotes\">",
"       <p>",
"        &nbsp;",
"       </p>",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_58_19361=[""].join("\n");
var outline_f18_58_19361=null;
var title_f18_58_19362="SIS tamoxifen patient";
var content_f18_58_19362=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Saline infusion sonohysterography of a patient on tamoxifen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 260px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEEAYoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5VxXtHwz8M+HpLTw5qGuWAu4JLe/ubpCfvrFjaPqOa8XFfRHgbSvGcnwGvptM0rSH05o5mjv5pP8ASo4s/vFjGOAcHjPPNdFGy3OXFKTiuX+tGesWGk/DC+ivrkeFNIsjZWUNzuviI4tsqllBIzzgehNUdX8AeA7zwdol2dCsbJtQQ3CC2dmd38pn2jP8A4P5Vwfg/VPGFhealHqHgu11qC4trG3ltJk3BABtiJBB69/StC/uviBZNa63deHbKLTTMtvDp4kwIxGGBAXOQCoIz6Voo2lozkcm4E3gbwL4Kh8LxXF7pOm6jrc+mLcpa3l0YvMPzf6vGSzHHTtxXi/gPw3Y6p/wlNxqtpIsdpptxcWy4IVZFPAB746V7RY674iv7fXdRs/AmkQ3NpZq9rK7hG06JkIAjU856nAxz+VdDoWh+ONK/sLT38I2epaNBpj2rWtzdxKXZyGkd+uMnAwf50Xtqy48zVk9/wDM4D4Q/D7wprfhXRtP1TT3uNZ19Z50vt5H2RISvyhehzz19a7bwz8B/DVhLfXWv6es6w6hLFDFLcGOGSJtojy3XjJ+pGKxdU8W6/4Uu7vToPAlrYX9v5lxYmC4DLaWy7WmVSOoOOenXpVf4d/FHxD43nXRJvC6+IbWJpruW3WYR8F96bmbj5T0B61Li7aDTbd2/wCrnlHirwT9p+M994U0e1hsvMvxbwwLKZFiU4P3jyRg5r1O/wDgJo0PiI2Gb+C1mthcQTOpLDyWAnG0f3gQVz6gV51a+JtTuPjs+vWWjs2pHUDImnIctuHGzP4V9E+Brvxr4q8Oaf8A2vplxGYrnz2unlCSzIJS3lc4wvAX6LVbajm20km7+R5ToPw68HeIvC+jPYWl/a3eoa/JZmeWTPlwJkkEDjO3aPqT2rvNX+FHhTRfGkVnpGmTRg2hb/SCZVJ7Mmc9O+a6G6ltAmi6Q/he751O4m2W7BQ7ZcuikEdMjPTha6bQrzUG8YzRR6DLbWtpaJCkcjqWjUsWzuyQSfTPap5nF3FKPPHlvvbufN2p6ZBpV1qNtcSNDNbyKY4yM71bOeR0xX0J8DvFR1jRDY3dxGZbXbHCuQCVA7dzWD8c/BEN1GniLToQCq7blUH4Bsfoa8x+H2uR+GfEltcTwAxQkBiPQ9T9a1latTujKN6FQ+vaTHOcnHpVfTr231Gyhu7OQSQTLuRh3FWa4D1VqFc/4r8IaN4ptmi1a0V3IwJk+WRfx/xroKKabWqCUVJWZ4Zq37PGiXgbyLp4WPIdV5/LpXmfif4AalpMhNpcG6gBzlIHPH4Aivr+itVXktzneFj9l2PiGH4Ma/cSGOKAs+eQIXH9K2rP4AeIneIzW+d3GFIXA9819iUVTxD7ErC95Hh3gv4EWWnywXGsvAdmMwQLuLf7zn+g/GvZ9P06z06HyrC1ht4/7sSBc/lVqgGspTlLc2hShDZaiHODjGe2axJbSzudVYSTGSZISrRDlcE88djW5TVRVJKgAmlGVgqU1Utc417G7vc2sbywNExRT5SkKnbJPPPtUeoeFLK6kElzZgi1QnzkPLnHpXcU10V0KOAVPUGtVXktjl+oxtueRy/CXQ/EejudZxcSygmJ9uHjz718v/FX4TX3g/UpBp8w1GzUFnkjXmI/3W/DFfaPiXWrXTnURTSfuwcxW5G5jjgV5n4p8XWCaSY7mwzcOzZR2656k+prppqVTWWxye19g+Wn0+5nxQUKkg9RxTSK9Q+IumaVqM732k2v2A45iLcP7gdq8ydGRirAhh2rOrR5T06NdVVdEZop+3v2FNIxXPKDRtcSkpaSoGKKKKSgBackbOrsqkhBlj6DOP5kU2ijQBVUswUYyTihhtYgEHBxkd6QEg5HBoFMR6V4A0+1uvhX8Qrme0tpbi3jtTDNJErPETIc7GPIz3xXN6V4wuNN0WPTU0nQp41mExmuNNilmbBztLsMlfauv+GuB8IviWOrGG1wMf8ATQ15Wf0roneMYtdjlpJSnUT7/ojoPE3imbX5zLLpWiWOUEe3T9PjtwBnOflHX3616d4S8DXtx8Hr3UZv+EegFyjyWyz6aJ72VQcZSTBKZPAP8q8Rr6z+CvxE8P6Z4H0o6p4ki09LC3e2m0x4t7XDE5V844A9BTpa3uTirwS5F1/Q+e/HPhbU/CJtYtUt7P8A0yBHDRLnyyByhPZumfWuSmk82Z32Im452oMAewr3H43fEDR/HmgWdrpttZ2E1vqU0mY4yoaHbgOxxyx9K8McAMQpyAeDjGaiurPyNMM24+9uIOOozSUUVznSPAycivb/AISeKYLTwpb6bqmrFLZ9btQ9uXIUW3Jk4/u+teJj5eec/WnGVwMA4U8ccV2wSitTCrT9orH3FZfFjwnY6NDf6MIIJLm+FtJBJLmQrvI8zJzwBkjsM1meJNU0K7vtS1+58QWQ029EDW0Mcv70tb7iwI/hDHgHvXxusrMyDPCdBnjHrStMzMxGQCMAE96agk7o55UZS0bPpmE2+sx+Ndds9YtI7a/tbOZoJbj50bfuMY9cAYrrPDHj+XxX8T/ElvpMOjZsdOaG1aZysdySV++f4vTjtXx0XdVwGby84z2NTWa3TT7LYuJHxtCcls/SnKCluONPkW59eapqWiWnhO+0rXbjS4/EdnpF/L5lpKGizJn90vc9Rge1eW/sweFNc1m+1K8srhrfS7dVaaMOUF1KMmOMkc7cjJ/+vXE2fgu6hjWbV3+aTB2Bs5+pr1vQ4JY/Dcy2rmOGMcrE2Dkd+KfsnbcwdaK0Wpn6XpsWi+Mbu+vJ/O8QJes0t2mCiy7+dvt2r6Y0jUJ7jUNf+xiO6MFzHEiGXaqr5StwcHuzfnXy9Z221GDxEq7EmR2/zz3plzqkmmR77e+kBYnckcpAYg/5FOpQ50TSr8kmfVumzaXEfseUNxpUSSyZ58ourZOfUjdn60ujX91f6nPcxxxvpE8MT206sM42kkEdc5P4V8pJ4iu2lBcMI5FAKCTlhjH4966TwJ4iv7fUyLW9msbfbny3YlHx2xWLwrS3NljNdj1vxnrstl4dVX87zZ3K+Wygh1z/AD714fr2nzRxLPZ2MzMAZJBjCrnsQa9+iutM8Y6YLWWLy9RgAkU8AeZjjB7/AEqnqPhW/wDEujump3AsLlPk2xoB5uPU06c1TVnoZTg5u8dTjvhz8SH061htdQgxanEa4+VIyOuK91tp47mCOaB1kidQyspyCK+WdQmm0JG0i40+MrE5fMnJP1NeheEvEbW7xXMU4SA4X7JGx2geuOlFajf3ol0cS4e7LY9porndN8WaddWzTTyi3CsV/ecZ+grRsda0++ANtdRtkkAE4J+ma5LPqj0FUg9maNFAIPQ0UiwooooAKRCSoJUqSOh6j8qWkJABJIA96AForJudfsIZ/JE6M/cg/KPqafaatHPbS3DDZFGfvkjDe4NVyvexk60L2uP1PV7PTiFuJVEjdEB5NcfrXjVbWGK4vQLezkYx+QG/fMff0FQau1nrt6sixu16sm2MMcKAPcVzet+Gf7Q1DbBAy3UrlPsxbcFHds9q6qdKK+I82tiZydo7HLXviM3WpTGJJJ7d2+7EMiJfdvWs3XIp7kv9qjdSP9UGGTjHbt/+uvWLT4eRQ3UTLst4Uh2zIrcuexJpmj+CLufUEvvEtwIrK2b91bBgQ69tx7fSuj28Ec6w85PY+a5vDLT3e+6jmWFuBuU/pnrWdJ4E+3X8Vn5ZiNw21JJOCMn619F/EXXNDg12wZ/Jhgt+CdoIK+yiuRvfGehah4jtZ/sxg0u3bdshUB5D7mtE+ZaoTnKL91njfj34P+IPCWmyX0UC32nN96dFyyAe3Ye9eWN1PGK++fGHxC0a28CygIhubmAolvgHyweAT/nrXw54g8p9QmaBQMsScVzyg2rtWPSw9a75W7+ZjkfnS7v3ZUKOTndjmhs5yT1pCOM9q5GrXsdor7c/LnGO9NoxS49qlq4CUUtHWiwxM0Dr0pfpSjrzTSEep/DYg/Cj4jhlH+otjn/gZpbS002T9nO/uo9MA1SPWI0kvSuSUK8KD2HNbXw+TRV+AHjv7O9y2tOsRuFbiJUDjZt9+ufwq3oek+KH/Z8v7WHWdMg02YNe/wBleWpuJYgwzIWz8oyB+Vd1m0l5HmuSjKTb+0vyPBsda+tfhrpmh2fwetrEpZi5v9Pm1CffZ+bJMFOCN54QY4H6V8ljHORnjivpf4Qnxzb/AAzgh0jXdHs472QraWF3EHmmj3BWYE9F5/Ss6StexrjNYrW3/DHfahr9jH4Wn8SeHNL0jUbCyslit0k0/YY5SVBXnlgB3r5c+MVlDp3xD1WG1RYkdknZEUKqu6BmAA6DLHivoj4gaj8TfCVxd61Fr+l31vZWLCTbZ+XGnzLlVQ9Wzj5vavlDWtTu9Z1W71LUpTNeXUhllkPG5jTrS93bczwdN87lfRf8Ao0lKOTzxSVwtHpEx5HIHAxxUkMJbJ44GRk9aIghXGCW9qmRBFKpZQ+zll/pXfGN7NmMpW0QjRAorhlLZxtB547/AEpqoxONuScn1zWhYWE19dx21rG0ssjhVjRcnJ4xx719CeFf2eL6G2iv/Fc0cbvgLaQncVPbcR/IVTcVuYyqtLTU+d7O0mudoVDtBI4HAPrXc+FLJdIYP8u98N5v8Q9hXp/iT4U6po++eCwH2ZRlfLXj8a425VLew8q6UIynGNvJrWCjumcdSrKWj0NixuNP1a5FtLceVgdM4zU51G20S5lt8yLGRlVLcfU151JOtvMZ7dmRzxu9DWVqWrzXT7bqQ4AHQfeqm7amap32PR/EHjG2OlfYreONRuxvAG4+9cVb38ZLSyqzbSPlJ4IrmTIVZJGfnbnBNPS7e4OVIwTkg96i5qqVkdeupLNeqVR40XquK9W8EWMOtWn2m9R7awtx82wdc9wa8R0tw8qAMemWyc5r1Twpd6ykP2ewlO1wP3Ljhh6VTvYykj2IaPYaebS/8NTs6QkPu3H5j6Gu08MaqPEO2W6PlzIxCoOxHXFeXeHbvUtKZbS8sHS9mG4LjA2+vpW7HNdWMlnqcEWZt5DMzYVR3yvrXJUhdGsKnK/I7zxZ4L03xEoeaNY7lVIWQKDn615Lc+FtQ8EX6XVzFHfwtwsacID6mvb9I1e11KyE0UyuMYbHBz9Kh1KxGpWFxas6fZmUrulGWVs9vasIVZQ0ex11aMKi5o7nC2T6L4p0vTorKIi8Ry7KV5yOvPpTPEXh2ZrNXtNPlF0Wz+6PzRAd8eprq4fDtroulC40yMQX0UZzJAm/f+B60T68mmWitdBG1KYDdFzluP0qlPX3TJ00vjdjIttXn0bTjBrURNxgbGU4JbAO04+op2peOkgKw3FuTLtBZYn3LkjjcR0FZs2nxeK9QlgXzI4gDiUS/MGzk4FbnhzwiNP+0C6gjukkJAMhwxA6ZqpKC+LcmDqS0jsZd54qvFsLpp3kaPZkNCNpz6A9qbY+OrLTtMgzFeStOuFCncEP1Nbuo+GBPEUit/kZSTH5mAG9M9xWBL4JuEsk+1NIVz9yMg+WOOB6/WhOmwarRdzP/wCFharNqyx2cUbRqo8xG5I/+vVDUdW13W3uLicTRWsQKiGKMnPqPU10mneE9FsruRNRYO0hDZicrt4/iOa7gXenadbQqZ44ogNqlj29zTlOMfhQoQlUXvysjzPwro9y+hHVIrdmvwSiec2wAZ64IrSm07UVu7WK/SNolbzMQnOHPqDxXQzeJ7DUJJobUSywQjebhF+TI7Zq5b63pgs4rkksWXgpGWP0GKHOXYXsqblZSOa1XRNUu9VjYR2trbQx44/jJPU+mK3tKfSLeBv7LlEly/ykgkkt756VHr/iuC0t1FvZzXc7jIj24x9c1xd54lmls5I9LgEWo+YBIDDhR7BvWnGMprXQmUoUn7jubraxE2rLaAo2oKSGhdjyR05/CvP/AIr65qOpXdrbwmeG4jk2+UsmIx7+h+tb1loumWupnVPEW+a9ZQyxwuSS3pWF4vf+1NTa2g0tfKKjygCdwHJyfSt4RXNsc0pSUd/kcFqUOiWGtiLxBcTao6qGdIX6MR0z7Zrn/F76QsKT6DBNFvO541OQvoM0zxHpktte3DkpGAcYTn681ylxcSxqwKSFnPfgYrpFGOzuU73xBqC7ovmdMjK9elcxd/vnlkJwzHOBxg+9dJ9tjtLOaMxHzpByT2rn7oq43IDycntWU9TtoabIyztUHK54wD/WmFSOD1qw6AA57dDUQBw2OnfPWuaULnoJjBkHIPI5FJj1zUhQjB9TwaTaecZ/LqKnkHcaTlAuDwc0mMU7aSMqDj2pD15qXEY0UvenFCF3FTtPAOODTaVraMD1X4cb/wDhUfxICAFfKtck9v3hrpdIs/CkPwNu0PjCG116+Xzrm2C75ZFTOy3Hop4J7c1zvw0z/wAKg+JJwCPKtRz67zXc+B30y9+CGt6G2iRQXiWD3aSSxHzLsg5Mwl6Kq8AL3rr1aVjzZ2UpX7/oj5xOWJ47V9A+EtZ8JS+FvCWr6xrj22o+HwYU06JDumJcNvLdlHp7V4AAd/ydq+1Phjp/h66+F/hTR5bCwuNQvLf7Ubc2/wA0oWTlmkxxj8z0qIvl1NsWk0rnLXnjPw58Sl1mPXvFUejx3Fu9lCskfyqgkDK4HqQOc18z+MNN0/SvEV7Y6Nqi6tYwttjvFj2CXjkgfp+FfZ/i67s9AGt6hLpPh691+ygb7Nb20G+OO2MihfNGM78/5xXyd8ZdPt9M+I2rwWqCOIlJSqrtUM6KzBR2AJPFKoueN+hGGko1HHW+v6HEKMsASBnjJ6CnSALIyo4dQSAwGMj1pEAY8sFwCc460yuO/KtD0OpoQKQEYx7iDxg47d6v6dpstw+6NH2jq56VLpViHkXzDiMngHqfrXqXg9Y5k+zOiKpGMkYwMdK9SMe55tavy/CaHwkbTtBvY7meJftGcpKeuf6V9C6d8TdPvwIxFvdDknscdwK+entYbNnQYfccLg8ir2iH7OXkLfZ2xgMx7+wqZ0Yz3OaFWULtM+nh4o059MNzeERwkYYE5xn1r5E+KFzZnxRdPpkpa2diUz/Sut8VajHa2PktNuaSPO/dwT9B0ryLUJorgtHu2v1yamlSVPY0lVdW1+hhalMVJk8w89QOKyJpMkocsQcD0FW9RD7ijRg44BB4+tUAq8s3Bx/D3okdVKKSuO27iOOo5GamibGAV5yMYPFQRKx5PCnnOK0LO1cxhtoCt0z0FJIdRpLU0tMbIASPdJnrmvWvA1v9rvrGKa7IkZgdrHBA68GvK7WMrgYCbeSw6mvQvDV9Y2MttdxzFZYyPkc9BWi2OKe59OXemLqukIDE9wYz5SS5w2O2KqXPg6CLSPL1W8keTbujVAQyEdCCP61V8D/E3R9Qg8lAY7jIVgSAg+gr0d70LFHIq+dv/wCeZBA/GvPlKcHY64U6cle55Z4Tihknns4bya3vi+AWTqv8q09VubmyUwPdTzuhAKdExnqT60a74htrXWb1J9nklApSIAOp9c/4Ve07WLDxOLVIIggX5f3hBZsetW7/ABNGVl8KYzQprqxsGklvY1tPMZkVDlpB6HPQ/StaXSBq+bsNC7SoFDEYdB6fWsLWPsWlXPmztbwlXIjMqsyt7Ba6TRNXs1sjcyyqkj43xqcgds46iplf4olws3yzMSWy1bw2ZDoujxXUTAAuX3yE+vrRdeI9VguoZbyymsNOiUCQkFiSen61oa54stNNvRMt6ktv5eCi4YBs8dOhpY/EkWqWrQvakySJlYFHmE+59BQuZ6tFPkj7sZWMW48XS6ZcyXNzJO9oFG3jcrse3tT18dSazBH/AGT5MKHiV5v4fUCqGvT/AG2IW10IrS1tYzM0cTBzu/2q5OGDSo7Fm+02/mYLoQMKBnvW0acXq0czrTSsmdBot5p98t3ca5fW0arJtRhuLk59utZepapDZ372lvbLe2zyYiaQnk+rZrOurqBYw9pBbxrHg+fu4J/3fWpvCFmms3k51GfDxAus2eB36d625VHVnPfm0Nex1O9TTL2O7SG2s2+REA2AH+tVdS8YTWGlL5MKWjqgiESqf3g9R6Vp6xaaZd20FzDeNK0TjzzFGWBI788cVyGteJrae7uGayimEAKLJOcmQfQcZoik+gNtHS2mrjVrd7mBYYbyOHhmfdsA9vXvWn4e8U2unaTDbwac8ycvcXUmPmPcn9Kw/D1pDa20GpWU9sZ3PNuozjjpn0HrXBa9rUZv7mC1Z/sQbDRRsR857mm4KenQIzlF3R67YTaN4w1O6bUrmSAxMDEiuEBUe9dA+mWWj6ZfXaTJK7JmNmYNkDpXj3gWKVpZTMP9FVNzSxDkHnArm/H/AIz1dYbmytZRFa/dSMjkKM5J/nSdJt6PQpVItWa17lHxh4iiuL4+ekZIY/u1I5yT1xXOahe2VxGqSRRRLjkqMt9PpXAT3krXTuZSTnjPc05b0s21yT65962Uug1RsWddSJZfkQsrfx9Kq+H9LudZ8Q2GnWQRrm6mWGMSfdyxxk+1TvNC9uFZnc9CM9Km8KQ29x4o05Jrw6bbNOgkvCC3kgH72O+PSol3N4PSx7Fe/s4Qrqy2p8WW4hiiEl5JJBs8liQEA5wdxzjkdPpXOzfs9eIl1s6Us9sZWtnu0bkBgrhQufU5Br3K/wDGXhe/sB4c1XxX9rlWOO4m1gwKitskDLHhRjOB/k1eb44+DzfOfOdoUg3RzeUcly2DH7cBTXHzT7HTZd7Hzp4++B994W8P3uuW2tWWpabZIvmSw8fvC4Qx4BPIJ61naJ8F9b1mWwitLm2ae70w6qkXTCb9oUn1Jr3y/wBR8A6r4K1XwX/wmEEcdzI12b3YNqs8pk2qDwSPr3qHQvGPgvwxFY6pDr6X8un2f9ixWqJtedfNB87rwuOefQ1am7baibkup55a/s03NzezpF4o01rKFAZbmMbwsmSChGeCMdawofgBqlz4rg0iz1awmt57VrxL1dxjMYfZ+eTXtHhfVPBnhuLxFZ6F48t7fUtSkF2b+RFeKIs7HYik4JAJzz3FZWvfEvwraeEdS0GLWIr+5t9HkgttQiQoZZnYgqMdCcI3HHWiLk3sKUmraniPxp+E03w1i0yWXWIb8XhfaiIUZNuDnGehz+leVAZ4FelfG/X7XXvFlvNp90bq2gsbeAtk7Q6xgNjPvXnJABU7ufbtVcvc3pSvG56r8OMD4M/Ej/dteO/3zV7w/qfje++Bmv29nLbxeFbAqs7un72QMwyiN6DIz9aqfD1WHwa+IWcBT9l9+rHFd1p3jjwOv7P174aZruLUltQjQKpHnTls7lPQjOM57Vctkcl/fl6/oj5tORuI6fdz7V9RfDsfETVfhTpdno+qaRYQMQlnasuLqaIOMuD/AHQTyfQGvmGQEggqBg45r6m+FPi/wtpnhzw74g1LWLe3u9Lsn03+zzzLIWcHf14UD2ot2Na70RoeFvAvi3wV4k1i+svF3hl7u+jaXUJbxSRGd3BIyMZY18y/EmHVYfG2sJr8wudRE5Msy/dfPIZfYjGPavetI8Z2XxE1rxpb+K/EVhp9nJEINOnlUIixLLuGBxu6dzmvEvi1rNhr/jjVb7TJHlgaURxOVwroihQw784z9Kmcfc97cmi2qlktP+GOLIwfpSYpT9DR81cSjc7zvrBM4DFW7AgZNdx4LuYbS5RLpGmhc84Pc157bybdmCFG3jFb1jdEsrqQuPujpnFeweDJHqHinSIgiXVsyRRyY4HUVzHi3StW03SYb5pGktJDhHXnH4Uf8JMsmk/YpnLt6EdPbNY+p+Ibp9LawMzNbE52scjNSKKZk/2ozwBrhizA5O41iao/MkiqyqzDg8HNT3UccsQCt84Gd3QGsy8klkGJCTIg+91zipN4rUpXZZhlvmB7fzzVfacjA6c/4VYLYIdl+me/4UsRInDIgz7dKix1J8qC1XauJMlcd/5VYQNECgZih5PPNSo8QlRQo3E8jtWj9lEq+bEu2Qd88H8KqxjKd9y5plzAYYI5kIVeCT1NdCLVHUyWZPk4ydwycVzdrOpiMkzoXTnaRzXe+FbaDU1gWzJAf5ZUA+YeuKpGEtNSt4XjHnyTQkR+UTsO0/Me1em6D4jtotAe31ua8jmRw/nIWLN/s+wrb8EQeH7COa2hIW6m/dvFNHhHx3BPRq0vG/hu107S4c6hbxRS8MCMsR7VhKUW+VlpO3MieN/D2u3enDT7WVbjzEDNv4YDnknjNdB4itIdE1FdTszLbrCAWAhHlY9M+prxtNefSZ4LGzsfMfeCkrjHAPX616VL4sMWkxym/gkJI82C6lBY+wGKznTkmrbGkJpp33KnirxXNqtgkhito4g2IioEj5PTP92uK165tbWUPG9za6mSN+4/ITjqKh8Ua3BLdtNYWqQqeG8uUMik1n6npElsINQumW7t5wB8sgLE9x6jpW0IKKMZycndlmw8UWlrdyy6jZG8iON6q+Mv6kVY1rx488TDQLY2UMq7JNj/ADAE8jIqo8Xh26eOOG0mhZly0ZfO046kk1ix21hHG0caT5BJG75e/ar5E9WQnYu/aFhukRvNmkfpCPmz7H1ro9P0LU9auy9w/wBlDJ8iC3JUDsMdq674UeHGsFOtG0cpJykjgM2PUdx6dK9B1LxZp2mae91fzRxeWAWjMihvy61hOs07RR0QoxavN2PJIvA2uvaC2+zHy2kyZGULx/Otyx8N3+io73epR2qFfKCFMoAfWq+tfH3QbSVEtbCe6Gc5ZgmP51xfir4/ajdRFNHtYbWJvlO4CRiPx4/Skvay3QSpUlszuotM0KxLxalrMs1sE37bYEj8gDisrR/B+heJ9Rn+y/bxbBj5cLqIwo9W714RH441SKeR/PAR23Nx1zXSWHxe1nS5hLp8luuBtJMecj05rZwlbR6mKWqTWh7jL8K7W2gjtLWWWJCCzzq+NvoMntXPaz8Gr2KDzrC9S6ctkpjk++T1rg0+NWv6nJsu3TnjZtCqB710yfFZLu6sY9R1GQxoPnit12IPTPc1CVVW1NJeyTasy/oWm6jFrk1hJFcRmNT5qqu5V46kjivKfizcxHUpbfTUdoowRJK67WY9+K+gNA+IA1S4+x+H7CNmY4Zy+Me59TUXiP4SRaw81xKyNcSfO3OAzflVe15X7+hnGjfWGp8XzRnaTtIUnirnh/RbvWNSgtLWNmlkcAAKSa90j+EZi1KSK6s5NiuFLuw2g/hXeWS+H/hbZpdLHp8uqOgUYfLgHuT/AA05NLYtVL6HiXxU+Hc3hi0sHS0kjjaPMkj8bm4zgVjfBG0S6+KvhuOdFki+1ZKOMrwpI4+or1Xxjq158QNL+2Xhi8iLIiEYO1fU15Z4I0vUn+JOjW2g3K2moSTkQzuMrGcHLY+maJX5bsKctbLU+ztOGlSXl/Nd/wBky6pABDcvboDsQs2xGzzux1Hr+FcW9pZyW8ulaL4YtRZPYnVoopYvna4M33Wzx+H4dK89tvhh490awnjtNatFvtRvxdS2oIDSFJP9aW6YGQ2PfFdjZ6d8RbrRo7ez8XaW1285nRFhAkeEuR5hP9zPQY/HtXIoqOqZ0yfN7tiK006x0P4n2Fno+iac+jy6bdyrNtEu+4B3ON3bBAXHoT61q+FfA3hXX/B2nm5sLOPWL/Sf3jKoDqHOWcL7MTg/hVDwL4L8d6Lp5kvNc02yaETJD50PneUHk3O3BA+YgHrxRpPgHxpDLHq+meM9OkuWthaRSC1DIYN5bg9M5JPSiUr7SHGFt4mX8a/AOkaX8PvEGpaXptsl1ItvBGtum7y1STbkHHDEYDe4718h3AZDsZXRk4cHg19k6DpvjnwprUfhu08R6M1i9rLex3F1b/xB/nGM5zlsk5wBmvJ2+EuveNvFss9zqFh9s1K0GrPKoKxlZHIHAHU4z9K2pyfVk+7F6I8HYeYoVhjp9ahkJC5VcdunNekfEr4Y6p4EsdOuNXaFWvWlVY1Yl18tgMntyCCMHoa8+HzyjaFVjz14rS6exrCZ6l4AiK/BD4hMFYgvafN6nca9ZdtHuv2fPsegWumDWItHE86XFkfMK5w8iyHAznODzXA+Ftbubn9m/wAXaY6QJbWNxDsaNMM298nce/QVoaofGGmfs6W66hqWn2ukXO0RWjoTdzQluAG6Be+MdO/apeph1b/rofPwU5CsMDHUmvr74bfDrwbqui+F5b9bdtRm0VmayCcyZYZlJ9R0/GvkBFJJbOQDjGcZFfUXhLwj40PhfRdZtvFOjWE1xpwtLO3mBV/JZshAf7xOOlOW29i63TqeYfHjVrXVLmIWnhmDSlsLqazFzbRbIp0U8A8csMZzXkb8HBbcAK9C+MXjbXfFeuiz137Mn9lM9ssNqmyMMDhmx3Jx1rztxzxnHbNTUbS0N8PG0FccrsrByAwz0Peo/wA6cMArnkdwOtN2n2rmlzPbU3VjsY5EWU559B0H0zU0U3ktscFWJ654NVSyFmLFmPUgj+VPRQVaRmRVyVA7j3r0zxWi6148bEBx8owCRyRVOaczYJY7j90g/hUJy25QFYngMw6VHvCEAk7e5I6c1LZSiIoIDZILKcZJzimSyEEEKdwHzYPJqWRVEblBgHgMByPemvEpjG1XCnq1ItNdSkqsxGD07H0qe2STazxNnA53mkmWMfKTwBycVJapJESBweenOBUrQ0buixBbvMdscTPMTwR0BrpIIpI7XbdRBZFGFOdtP8D2dpeanENQmMMZ5+Tr+VdR4vuNLtpltYHS5QdJn57dQO341aMJPWx5zdW/2i5PkIyIpPXofxru/CzLpQgmaQEFc7lk2kGuc00xTagAiuLdz8wHPH0q74lNtbxRrpwLRkgnCkfgaEuoS10N2+8Xz22pGaxYrg5LMc4Pv613EPxB1DxFp1rZ6j9naSI8TvDhgPT6V4SZSoIVsEkNkjNSnVbtJthmZiBjg9R6Umk3dj5XayPRr7UobS6DRC3kZn6hjj8q6HVdZVobGWCPTp5Cg+78zAj1X/GvHbS6J3kpknrgdB/nvWrpsjZM25iccZ4wadiXGyO513XLTWLRLYaXb2tyG+eaMBS2PanXHjC/sLFLSCGEQxrtaTAbf9fSuGXUWUSGULJx8hOB9TWbPqCq20MTnkg5x+VFg5Tfk1QXN/5+1YWwD8pPWtCz1S5EyzR3TLg85wBXLR3kZSRpEjZicAhcYNJbbpXURA4zz83AphY+h9I+J7aJ4cg+1K11sfG2FwvH1/8ArV5H8QPGra3fTTW0TW0TncIjJvJ+p71nQ2V2YppowqxKAGEhxXMapCwmDAh3I4GcY+tSoKLuhp30ZUkuPNbDNuHUUxpmyokzg9Md6ZuBIx8hzUUp3oozyOAe1OxQrbuAfp1oE2OpIbOB6U2TlBnIYHnPPFIclhtwOe3GBQwsPErJvJZy/Zgffmpra7dZg5Y5J45xVY5Un5tuOMHpg1F8wXK464HPSkVY9s+EnjrTfCd/9ovLVrqRwSP3gG0+oz3r0fUvjVdXt0ba0ghs4G/jD7pMH8gK+UlmCN13d8+mKvWVw/mqXkYpnpnFRKEJO7Qk5xVk7I+z7XXoR4a3SSWzXEmNsaNvklJ4ySa5q18MaBc3creINNkimbDtJPMCq89ABVCfw3eeG/hvpWqywQwSkeZeuzKWhDMPL29yeRnvWz8ONY0PWriDT4o5r7VGJeSVmztQHlj+fSovFJyiyHCbkotG/wCL4tJh+G9zb6XF+6jiAiESFAD68180/D7U7bRPibpGp6tMIbO1lZpJCC3G0jt9a+g/i/q0en6LJo32YRmT94gEgO5Mn5iewyOlfMXiOWMn9wyMemxB8o/GnSjeGvUqT5Z2sez6l8XND1i/0i91G78iaKz1BJUjjbCl/liHuSBWr4F+I/g7T9N0XW9R1lYr9dMi0mSxVCzR7GJ3kivky+BQtubnOT6VVJBTDEgVMqMXobwb+K59t6b8WtD8TeFHT/hKrPw9rLlsu0W7ylDnGA/BJXHfjNedeEPHPh/QrPRtPfX2uktPEU08lywYCS38tgJCPQkjAr5rE3ykd8ccckVGspLHd93NKNGKuU3KW/Q+rrHxl4c8TeOB4g1PxDDYo2iz2zW8wOIWLFRt+qktjrx+W14F8beENI0/R9avNcjjm/s6LSGtSMsnlux8w45APXpXx+ku1ckDb161a+1FhjqSRxjqKv2Kat0M7yTv1PYPjv47sfHWjeGpYJIjeRfaDcRKCBEC4Cde5Vc9+teLLAsiEDcNoJ69avOkuz7jLGOfqarYcyOx3BCB14+taKCirIhSb1uej+E1KfAbxyrYGb21HPHrzXpWv+ONF1H4Ei3m1S0kzpcdjHo5VTN9oQgeaTnIAAyB0988V5z4cUD4C+M2IbH9o2wCjqeK7HUvFWjr8AyJ/DNjZRXNuun6ezRqZ7mZR+9nBxwo/E571nJK40z5yaMhfvAn29a+j7P4nQ/bPhz4et9Vgj0W3ht21HcgGyVTwGc9AMDpXzgAMAYI7ivq7wXN4X8SfCbRtJtfD1rDc3840k3bQoWWXbuaXdjdnAOKcvQ0qeb7nifxz8LaPoevNfaP4ls9cfUZpriWK2H/AB7gtkAkMR3PvxXlqnDDJ4r7k1nwhonw902+1u20DS7mSdrezitp0EyIN+wvkgfMQcn3HWvk34u6RZ6P8R/ENjp4EdrDctsQdBnBI9hkms2uZXia0an2JI4w8HijI9RSEH06UoU46/qKxTd9EdR07N8zEY6YJNBbzk3ORtPPXmpI2PnYARgBna/fvz/OoSArNj5+QBivQZ5CJCQyfKPXPPJNRqing7QfTJ/zxTipjY/MNx7jue9JvUOhUqE6/jSsC8gRztYLv9Ov6VPHcFULOoPUEZqrGw3Afw55I4OKmaRgocrnHC8df8aQ2inPIFXcOY+v58VYs2Dq27gDpt7mjaCjADBznHY+1MWMgBkdSST8np70i3ZqxqaRchHxcH5QcY6bf8adq9+zogO1znhl5NZhk8yAtuO4dyKjjSSQE5444B54p36Ct1ZatJ5osCPcFHORzinzXtxdSkBtwPbNVGn2xFCjMxHVeoFLawkTZ+YccHFLyHbqy1CGU7l4PcPTrZEubkFwiMOu48Go72eQgASA4wOBiqqzkOWc8npxTEldHU6DqX9j6rBN5cbrGQ2yUBlIz3rv/GfiHT9W04fZ9OtIriUD95aNhR9VPSvKLeEvCZnkDKBnGfWpbRninzbN5hIx8w7fSnbqQ4p6j72OWJnVzkgDBLdKzWlZXLSN8/r1ArV1G4WSDkr5v8Q2gViyDAIB5HX/AGqCkWPMUDKnAGD1610nhaK1ubuEXbyRLkDcoBzXLREpErkEpnGc9PwrY0W8t4ruJpQ5iHJwefrTE0ez+M/As+k+F1v0uj9llUYVSBn68/0rxC/Leay+bvA4BPSvcPDmr6RrWLHV7429mVC7pR5hHsB2rnte+GEn9oz/ANjR3V5ZjmO4Ee1T+dJdmQnbc8laNQG6kHpio9uyRQRgAd+fwrc1jQ7nSbh4buN0YHncOhrIlCqCoyeeDmqsUncrna2fl+YHp60rAKcY3EDrnpUhQdMjJGdw6Ux8FcDPJ/Wiw7kZYqM9cdQaYWU8sF9M46VMFyOAOODjp+NR9Aw3Ag9c0rFIZkKMfxA8c9al37SuWPmHk+v41C2Qq4O3JJ9803cxBOQSf/r1LKtc9BuPiJqeq+GdG8PXgD2ensxQ7jukLHjcSecZIFdx4C1zTtJuINQijht7yAh8tIVU452nHXNeGRr33bScHJrq7VLFdLAt993qL9WZsKg9hRGK2Mql273Or8deK4fEGr3d1PJ5tzO5bhyVCjooHYCuRnt21BiwUQ24GQp4J96yJWSHG2TMmecDkHPStDTbqQuw2LtCkku3WmrbCae5k6paiFsxAsD03GsRiAxCjJA7N/nFdNq06vGULhhjoOlc/IoAYFQN361Mkb0n3IEbYmCpwec56/40K+18HLuABwegpjAbCCTwMYpZQGWMqoHYnrmpOiy6ku4AAquFxzntUtpIROucnnPJqrllXG4sMn5QfaponfcrkKAvHTpxzTTIlHQ6FpQZFEhb5ecL9OTTzPbfZWd1xg4UHmsuxjGd8kuEwev86jdkR32KsjHIG7371rc5OVN2PT9Glz8AfFxHR9UtxkDH8NW/GPgLxXqHwu03xTrF7a/ZLG1jWDTY12tBAThWOOMnqe/41S0MD/hnnxEZDgtrEAwvTOyu+8Z+OPD0/wAChY2+qQStPYw2sOkoo8yCZWy0rtnPvjpXPJu/zNII+aBtLOX59FHJ/OvcPhroXjubw94al0Z7a0019SMtoZV3FZCpUysOTt6ivDwFwME56GvsjwL8WvB9hb6bpdzNZ28dnpECtdkcmTHzRDjtjP405SaWiuXNKTSbMfS7j4leGblfD2iXGja3ZGCW6S+2Fo1YMS43Z+9uOMc9a8d8Y/CbxIvha78YanqNhNe3Sm9uLLcTchC3zPjGOOp7V7D4d+N/h2az1IXmm6fb2a3cUFlpyYAKGQl5T8uM8hjx2FO+Muv+FX0nWvEGn6/Z3s15pJ0u3sISCwZpN2/OeABngjtULezVgTlF3TufHfChuCfQ+9MwO55+lSSY388/SpBFGRkFfxcVHs7u2h3c1jqQqyIJkTIU7QM8H2qOeNgx8xScDPoRS2yF8sjAAEEDueamnikZ1DBxgEAnjNdu54+zKMxyVKOcKfTvUbqyy/vAEzycdasSxILj5pTyu7K96jmwx+X7wGeDnIqDVMrspI656j0NTeVIuMBmCjJy3T6U2ZgXUFcEgcYrX8MiJ9RhF2zLCzAMD6ZpFNuxmvayyAOjjaT68mtSz8N3U8TTbMlRnj1r6f1D4D6Dq2hR3Wh3hS7dBIj8NGxx046V45rVnqXhO9ls5yiywlgyt1IqYTjPZkzU4pXPMLuGSMhMfPnHHGc1GInRdzD5vStS+Y3d7vZCrnPT39KSxJZxbTlTEDwXHINVYd2YsYIlAZiBn8x/nintIRysjc/KpzggVt6naJvWNVRyeFZOuTWVdWiRnbtyVPOKLFKSZXhVriQZJYA9TWk8ca+W/kooKhW2nOT6kVVt90B/cboyOee9I8jNLkN8zdaaCTb2Hy/uZmMIcJnjng0+fUGliQBEVhn5lGMVDPJJIfnypPHPeqhCqvynnPNAJX3LTMCuSDj0JpjsD8vUdMLTDIpXCkgDhs9qYp2gYbA7j1NMdibaQu7cFXoB34qxC5XaSSxAJGPp/n8qr78htpwuOcj9as2TmKRGGMDgg0yWdDoWqSWV1HM0UMig9HHFel3PxGubjS5I/sU0WeEZGYKvA6Vyvg7xTLolwk0Fnp12ytgLPAH216fffGC8u9PFpd6HpsIcYwIS2foDUyvdWVyUotavU8UuvtWqSyEymRz82JHrBmgKy7ZG9iFOea9QvdVtpRK/9k2yrIuDIyYI+gFZlj4SW8kkFws8NwyeZFCICCyno3Pb3qzNM86KssuxRgAYoIO3CggY4r2Pxj4Hs9L8JiCGfT/PssTG8RGL3zP1hU9Pk715O8TZZCre4IoTuUUDkKVGdo5amEAEYztx+NWZ08sgt6YxUPlsFXcMbunHahlJlds/x8enNKFEgYAZCgMR0zTmxnJIIGe1Rkbs/MABzUs0Q4EMMMNwJwTW/oN1IsMsK7ITgZcj5se1c5IdiAKGx1H41f0uK6upljtkd2PZRn86S3JnG6JHij+2tgHyhnknmrcc9p5fl28bmTqWc4Fa+p+H4rPS0u7icCc/8sQec/SuQkYvNmFtoz90/rT1RC9/YS4kJdtoB69Ogqud7gBsL7Vakt9vzO3BGRniq6lHGWbHJ6VLNotW0IJsbhnAGByeuBUYLebgnnOR7VM2WlJKjHr601htcFhn+HGKRsn0I23PKAkZOOgHQmnDbnI2qBz65pMqQwZsOOmKkmKjcseM4yeOlAN9CYOzxAAttHIAFELNIwLY356kcVWjJzvD9OOlORpM4HbnPrTuQ4nuz6JNpf7Mdzcyz28q6jqkVwqRNkxjGMP78Zx6EV2niTQNFv8A9ne5n021002FpYxTwTIP9K+0bv3hkPoc9P8A61eZ6YWH7Nuqsctv1yPIx1wgrsfFvhnxvZfs/wBj59/YrpFuiXE1hDDtlWNjlS75+bG4EjH54rGXr1IifOSxkZOevX1r7D8G/BbQm8IeHjfwwSPF5epTzHO+csM+Uw/uYwOtfHx24bqDkZPdhX094d0D4kzafpmp2PiDTk1C9tYEOnNxJFbKSUJHocc465qpX6OwTfc8e+NmuR6/qVjqEXh0aMwWSAtDH5cU4R8BlGO3QmvNGkeRdrdBx9TX0/4h+GfjH4nQW/iPxbrWmaSWTyLa3ljaMR/MQF2noWP4nivmnWrCfS9XvLC8RkuraVoXB4wwODmhS7G9Ls9ytuIUpggg5xjmq5BBIxU4V0XeWAwc9eSai6dhSknJam0fI7GynKSh0jXDfdB559q6EwpfQxKD5Up5PeuR0m8+zz/aJI/NQH5VJwOB/wDXzV3S9WS0ut+RtHO4nOOK6OY8qVNp6G9J4PvHSbyIiQqliz8cAdjXNyWrQ5EmdwOMEfpXZaZ40MDbeXRuCCePrXWeG7Dwr4jvY47ydraWRgGPRfeloQpSWjPHIovNb5c/LjBPBFWrKb7K4L4POCGr33WfgSZZSdFnDhgWQOfvCvKvFXg7VNDufs+o2clvJu4DjA/D1qVJPZml7nqXwf8Aipb+HkNlfGSWxcDAB/1Z7kV2vjix0r4lXNodHhkS7dflnkiwrDtk18z2EKwSRx3IeMA5IHT86+pPg5rMdvp6WMF/ayhlDpFKdpz6KaxqR5f3kdzSMr2g3oeN+OvhjqHhx1N46eY4zG6chv8A69ec3fh/VISZUt5vK/v4yPevrzxnf/2tq66PfxR2kuMqspEgcZ6g9u1cJqN1Ho2bTUILSSwDH5YX5I/zmrpyclruRP3JWjsfPsmnNFGjvMBKwDAq2dvf8DWVcWxR8hxtxkkHOTXreu6H4c8SNJHoSTWdyQS4ByGPpXlGsadc6LfNb3DAEnCgjGceladAi76EKzoI/LflwOMelRSEFQ8WB7VDLEwQMuEzzjuRREiqo8xip9hQXZbhPIzKGZsg4HHIqJl+XaQp4zgetLIu0tGCCo5z6UwBmYrjcM8CgtLQUBW5Y4OOcUA4QliDu/SmAZ+XGM8U5wBzjd2FAyTd06jgcVsaXHGwIdlJOAARyaxIyD99iCOpxWjYsPLBAyxB5HWqRnNWNyzV0uj5J2gc5Arfs9XuQ6l4PMKj5WbtXPaPIiXR892CgZIU11VzdhbMNEjSKuOqY/WrXcxkbXgsXOqeIrSK8soby3kkDSRlvLLr/dB7Zr6D03wNLNIZNRu5IbnJSQwvv/cH/VwgkcBR3xzXz54d8YNoMkNwtvAZgODJFuwa7zRvjDcrGZby8DL3UjaB9AK56sJy+E0pSgvjR6Rqvwq0m+0mOx+16h5NvvNsjzZSNm5JxjnNfLfi3w6dE1S4gdsvHIU2Z5Yjv9K9ztPjXHIHhmlVHIJWXyxgfQd6wXm07xXrslzI8s8/8d3PsjRV9hSoRqRvzhXnTdnBHgF/GPKG+Ng23I+XH41nSORCAU68bj2r0/4i6XZ6XqMkdtcC8QgfvBhsH8K8wuypc7i556V0MiOpRdcK+OM/mMVGT8xwOMYyB1NSkkFlAJbnOelNyWBGDuAJGfSoNkSW5h35uF+X0zzWta64dKdv7NYoGGCcc1hhNyqWB4Oc1ds7L7Qu1B84OSTSu+gpJdTTgury/RztU5GWJ61mmCW3lIaJSVBxzmvR/Cnhu0k0mVpQ89yR8kcfJA9TXGa7YXFtM4BEfJ4Yc4qmjKMk20jBuPMcqXYMCe5qJEVdyttDYxzyfrT7vg5VgAR0Hai2QMSQQeefeo3N9kQSxsWA5246/wBcUkmEA2hi5468VfukK8fd/u+9U3AwTEpVs9Tz+VA4yuQFNyjIzt4B9aR1WNzgDeQeO1TMh8snAAzwf61VAywIJGTge5oNY6ixtiRCwwAcZHapEkTorMGJ5PtUSboldQf97jNP2Ey4GdufypDaR7Dpvyfs5XuWyP7fTPt+7FepfFL4n+G9R+Ci6dZXqzajfW0UH2QZ3xlcbi3bA2/jmvLbRR/wzdNggA+IFyvr8gr1b4+xaVYfCtLS6TS4mMdqdOgt0xcF8fOzf7OO4/Gsp2clcwhezsfKXlHjCkqvJwPevqfR/FPgu21XRPGt34h8vUE01LFdNQZ8kqrAtJjr7D3FP/Zlh0uH4W6xe39pbTE3cisGiEjyKIwdgz1PXArf034J+B59K0h7mzzcSYu3UTkPcAgt5WM9BkDIweKU5rZj5XLYht/HPhvxr4F0dvEPimysNSs7mO+uQVCkmNyQoX3GOma+SPG+pJr/AIz1fUrZD5V7dyzqGHIBY4z+FfUt18LPA1ldJqOoaDdxw6i0VlDpAky9rI7EeYxDdwM9TiuP1Pwr8NfANhoi+ItP1DVdUv7qRf3Uu0IkcpUkjIHOAMd+eRTjaO2w1P3r9T5qZAUAC4YZy3XdUDHLEjIGelewftKweH7Lx69l4Y0g6YbaNUuiPlSViqlSq5wAAQPrXkDgh2BxkHsKmpsrHXSlzK5rGbaQqR/M2WIXrn3qF5MkqQvmA8YzzUcaFnPllm7bxwM+tK8mTtUsVPO/GOnetrmKik9C3BKXWRlPTge1aFjfSREyo+wA8fnWRbyJFNkkllOeRwalO4u/mZC4+UdM/Q+lNPQynBXPbfhv8VtU0i/to5LvzYAdpSQ7ht9K+ly2gfEnw/8AZ7yMMpAYDPzxt6qa+ArRyfuyEEZIAFdTo3jDULBovIuZoAvB2NjNZzpKWq0YoydPTdHqfxI+GOreFZzLDnUNMOSJguWUehHauY025FlDFcQokkkZx5ZYqQK9Y8CfF2OXS1h1iGa4mUYLu4Jb6g8dKyfiLpui+ILP+1dCtVhmyWZEYA/XAqoOW0jCbjuipoWsQa5dQyJdyWl+FClZW3jHpk9K6Z59Pu5xaX1rDJc9QSyndnvmvn92mspGlk8yM5I3Zxk+9auk+IXSUs+2aYcq5bDVdiXHsd/4k0SKOcfYNORJ8blkSTawP0rgdUtLy+d7bUDCzpnb5p5z7Guqs/ilYurW/iLTy0bnCzRna6joTn0rC1yGy1SR7vS7wMiHesUoww56e9VF9AtZ3Z5/f6bc28rtIhQA469KojzSGTMbY9eteg3GrRMIUv8ATvNVQAcnaDTdQ0G31hlk0i3Fudu4p5gYN+FFi+a255krfMNow5J60SEYXluPQYFb2reGL3TMC4gdHfncDkYrFmiCZHIUH5ec59c0rWN4yT1RGMglgQO5xQhOMHqeox2pBENmcjnrURZnON+W7DHQUrlJXLMONuxhldw5zV2zgXe3zKuM8E9az41cHcQVUkqG28EjrzV2B23KiMW3dqpETNvSo5HlYIisenLgAfjXU+ZHFbsL4u3lgfdkBXp2FctbQQiEMTKhJwdozmtO3EP3pp5DGoICMuPoatGDRR1a9V3CwGUKvQtgkiqT3O75cPuHPNPmKPc5hjVV55J96ZPbEwPKuflIUgH9aBrQdPcq2DExyByevNadjqDK6NcuzRADcAxFc/G2wAdwemOSfSrkTyKW+QsQMYYcEmlcGj0S21NL7Tfs2n2Uag9XfBY/jXGaxol0jvNNCyxjgkDj860dCbU0uYzZx4yOBjOPwrrL3Tde8TxpAdmxfkEagLk9zgU3qZ/CzyKW1iDffy3TJ4AFQtlN56gHrXT+KvC11o140V1GzOAOMgce+K5yeHe+fm57VmzaLuiFnycDAya3ND8/zFW2hDOeMnjr3rFjgd924n1AxWrYGS3ICMFY9CDyB60IctrI+i/hhCmgacxvRbxSS/MxbDO3sK5L4ttpMty7WaRLMwyyRrls+pPTFaHwxiivY3ETBrgx7RNPyU+lcv44+wadqhjjZ7y7GQzkjaTnsB0p9bnMviPLb2025blV5GCOKpxOYvmVenGD0NddqyGZcyqwDfwha5u9tRECFQgk+vP40nobxd9GVpJHkdmlw390U0MFJBVSOv0oRFJ+cAhRyf8AGpIV3SZfHbAFBeiIZmATc2F9O/FVgjShJCOM/eI/StmPSZry5cLGFIIyD15q5eaL9lQE4bd7+lFmwVRR0W5zrxmMHgdjknrSAN6KR94+grQuFZYwrowiYj7w71VZRtByc+mOlFilK+56rbBl/ZtkHBc+IRxjqfLHWreleAtc+Id14f1XWNXgR9ZjmjSR15hitxjkDGfb9aoufL/Zow3UeICT/wB+xXtHhT4maAfCPg2HVE0jS4by3uYJGU82gVSoKjqu/vmsZSaXuomKTd2+p5Vrei+M/Ak1vo/hWebV9GEg1SC5srffG7Y27jjPTpjOK7y/1/xt4W8G6T4j1TUdJ1BtOG+TT1QLcQ+arBWkbtjd93A7enGpa/GXwX4UtrfQrXVdWvorC2SCO6s4I/LmI7jd0I6Z6Vy/iOHwJe+GtDsT42i+x3eoi81ODO6e4eRvmZ3HTYCeoxxn2qVK+jQ3C239f1/wSr8ELrx54gl8Q6jpOvWgeULHJdalumLSYO1Y+eoH4e1eSMnirxl4n0/w4qPd6nYPJb28O4AqQxZyzdOuSSa9t+FvijwZ4VvvFGnaN4hg0zTIb5J47qYeY91bhcGJM9855AzXmHwf8U6Ppfxqj1q6uE0/S3kuHBfpEjBtqn1PIFVfexUV1LvjXwj8TfGMsf8AbWgSSyaTAlsDHGA209GJzlzxyfT614jcI0U8kcgYOjFWB4wQea/QpvjD4BO5V8SWWe4+bB/SvhjxjqkF34u1u5tJVe3mvp5ImVOCpkYgj8DWM5c697Q1pNwfLHVGKySYC54bLFh3HOealRVUlN5O/wCXnrjGars+CMAbQeo4zTwUZFZVw4G085z74rfqaNOxLGRGSQMNu+8x4q9E4mCvtJTPQHrVCQKVX5t+eef1+lSBgsny5UqPTt7f41SdjKcebXqXbhDD9xgMnk1D9x3cswC9MUwXfmJhx8wHA9f60jyKUJzsJ707mai1ozTtNTlQcM5BHD5xn3rvPCniaeGA2yzRPHKMEOK8vtXXO3PQcHvWnZoYUDop3KQB83SmiKkEtDu9VuInuCZHXcpOARkE/WuPvpPKulaM7Qep7Z/wpt1qjOmxlyQMhsdKw3k/eludnByTTkyadNs63T3gv50j1SfyUPHmKM47dK17yys9LmT7LqUVxAw+/ggjjONvr2rhbe+KPnpnnkcEU66unlfKfeI6rxj3/GjmH7N3PTdIubbUk/0i0t5igHyNLsY1m+JL7S7eU/2VFdadP0IVwy/ga4G3vH35DAHpkHrU11eCZMyoGYd807k+yaZoX2t6k8XlS3byg9A1QJcERMXjiYMOAeDWW8rSld7bl+6Oeg9qa/8AFsK7eiilc15CW5dH5RApxknPFQZ2g7emME5/lQo+UMuS33TzUb4AXJXjkDHSlc0S6FiCYEBJGYj+Fc9KtRu/ybHBGe/J+lZ8ZAcAJ171owQsZGjdTHMCQVz0z/WmiJpI1YZLgAIzsvqVGcVecR7A7TecAACmCuaoW8IgO7c+OgXPOfb8K17T7IwVrqOXBGPkAq0YsypY1lmGyJgT0A4/Crn2BvskysiJJuUqM5NaczW0syrFBIqKO6470l7bRRKkgMa7mz8r5IFOxNybSfB9xqNzbwpJGryNgF+g+tehQ/CfT7AR+ffy6jckjdFbJhR/wI8VP8IbuCPWYV+wxXRPAM2CAfWvcb5fDl4ytq11bwbeBEj7B+VY1KnI9gipT0TPDL7QII2xFEum2qDaTNLuLflWXpsyabqTqZpZbQElhGpXcPrX0NqOk+Fbi0BtJbGFwPlfIY4+hrx3x9p2oCB1t2ka1HIuPL2KQOw6U6dXnJnTcHZsyPE6+HNWthLA5guQOUVi2Tj+ItXlep6ftkaVGRgWxgE4FdLZ20lkXdpYzvBG5/mIpltY2lxeqt1evKjnd8idPwqwj7pxEcEkkoBJAB6hc9uK7TwR4Jv9evY9ts+w4+Y8Dn0r2j4Z+BfBt8yyXpnnuR0jlO1T6nIr2SW60Hw1ZFgbSzhRfuxgbiB7Dk1zVK3K7JXZ0whzrmvZHmkHwjtbPRMS3rwXhQAfvdqqf0rg7D4XzXOqyxQbryRWwZkzsX/gR4r0fxR8VtFdBDb2UtyeqtKmADVfw14p13UwJZrxbS3VT5VvDCuD9TRGVRq7Mpxpxlo9DynxV4Yt/DV1LaahxKefk+bH415BrUUZvZvLLsrH8q9x+Jh1K4vHfUXh2ueFV1LGvOLjw7efZ2lVI4YBkl3OST7D1rpV2jGMkne5xtpZLLKqE8k7T3rq28MxQ2yXF26wxtjaG4Jx6VQsd1hPtSMM7HhpB096s3KXdxKhuJZGLn5cjt+NNaIqTbe4w2JAH2N2KH+JuK29G0WO9KfaZJAoPzHZ2FdP4VtNI0/TZJdUnG7+EN3rP8S+IdOe3aLSgQdpGQeM57e9NWW5k5OWiOT8axadbuY9OhDAADc7ZPTrXEOWaVcKATycjArb1OaOd2jXJk6t9azbq38pd0jksTnI/XFTLU3p6aHr/iG30iH9mPTv7LupbmVtWVrneu3bOUO5R7Abee9eFyZ25Abdjg54Fe1+GdPXVvgXpOmFykV54pSJmxnaGVQT6Z5r2PVf2cfBkmmzpaTX9rc7PknkmDqhHcrgZH4iuZ1Iw3e51U03ey2Pi6U7yWU5fA+bPAquGYfOhYgcHnqa9E8efDHV9B1z7HpEU2t2ckAnhvLKBnR0PU8Z7/hVjxX8I73w14HtvENxqdlNMDGbmwj5ltg4+Xfz19v581d7lxnFI8yk+QnAw+fXPFR7QF5yDnIJ6V6t8M/g7d+OPDt7rsmtWGmWVvKYt9xnkgZPToK4bSPDmoa/4j/sTQof7RvC7RxeScBwCcsM9BgZye1To2aKSMI/Mevbt3qFzl2PvXeH4XeNy98V8N3p+y7RONuNu7kd+fXiuEmQxzOhBBViCCMGsMRsi6c4y2ZbIwjHB+b+LsT6Uw7ixO07u47VK0jy5WIEwpyM9vf60yOVw2EGSVxx3H+NdDIVxgZmSQDvyalWQoSFLPzywNQuWdwzAjnnFDSMCMHAByDU3tqU1ckhB4JIHf8A/XUhZfJ2EgYPBP61C7s4yenAJzzT4jGVdncAKBgHqfpVIlrqxyMSVCON/PPTNXbWQIhCswlI6nNZbsCPl/EnqalikyQwbDbuQfT60KWtiZwui9NLJliZGzj5ccj8aqj5mVidx6EgflTYyXZyeFIOKkjUyJl2AGc7R1PFO9yeXlJkiDHfHIozwEYdBSMwQMCo3g4yDjIqzYwsyb4/LbZxg9SM0shjUgbFYk7m+XkVVjPm1sZ8wKuxi+Xv1zinI+1wWBKjH3qZNL+9JUDb0/GkQOVUOSWxwKRrbTU39DvrS3kAuULL6YDVuy6lo0txGrWkWzr8qkcfWuHj47YYnJbODRJMUztb5WPGSc1alYwlRUmbmuR6dPckaWjxxsM8Nn+dZz2EiHfsZvlx9D3qiLrZsKE5z09qtC9cyMFb5j0OetK6ZfJOOwqfKQoDBgeua1IYvMUyoZy56u3XP+TWT5m9txccHnjnNbelzNLIkayEIW7H0704mc9CNLeRnKgszDgAA9a3NIgilniW6PlP35JwM11tlbaP/Z+7E8lwRjdwecc1X0ez0+4vFFxHcxgNwUGfoeBV2sYc9zUvLazsgFt5Hm3DJZlHp71z9zYMySyBZMZyGGAK6/X9P05bT/RZ7iR8cPKgQk+w6msOO0vLiwAa5lMaHoR+lFzNGj4OtZI3jY21zOcZHkr2r3jwQplS2Y6XYIHUmRrwnzEI9AevrxXBfCDRn1G5Mc19cRxqOVjiO7H+96V6zeeEvskbTQahK0KLzHcDcT+IxXLWqRfutm9OEvjSIbvwjHqGrC/s7ywjjQ52wWwYn2zmuY+KdtdtG0UfnSR8ALsKqPYcYrpvDmqw2qSQDVLcspOLdR9315+tc94jkv8AW9T2KjzbG4jCMy4+gqKbkpavQdTlcfdWp4vHY6eGMdxKkLbtudu7H5mtJdJ0VLVxBq00k7dcQgIPofpmu91TwnJLH58+hSFug3R7Rn2X/GtHRvBct1A8k2lNFg/KjhY0x9B9BXQ6sbXuY8knpY82s9RtdPtXhTUb2SQ/KPK+UfnVqzht75w2qTX8lq38Jk5PtXdar4GmdvnWO1iQ79iKAijPrnJroNC0LQLGCOW/uhKyYB3MAoP0FTKrG1wUJN2MS28N+HtVhjtdN0e55A3zyZUD3ya2PE2jWGmeGGtrGeNm2bQofn86m1vxEmqQtZaVBJ9lDBWdPlB/H0qxD4e1DUNOjtooLXTbRgN8mS8zVj7Rqzkzb2d7qKuzwIaBq91KWhtriYknDBNwXFavh/wdrOpSiIR3DgnDK0R2r7k9K+kvD+iwaNYi3id5ifvSSfeY1poiooVFCqOgAxSli7fCjWOCb+JnhMPwOuSRN9vt4ZsdNm7mtCH4Y2uj2sk+qyrdSKpIEUR69q9L13xXo2h5F/eIsg6xodzflXh3xL+Jc+uq1johuEgbgheCfrjmqpVKs3rsRXpUoKyep5j43uLd7qSO2VolRsAEAmuGd2BkLyFF65FdpcaBfGMSXDrAJCSoJBYiufvdIa2VmunCqf8Aa5x9K7Hc5oOK0OfgkRbh2RDIx4DMuRzVe9kHzF2XrxtHardz5MYPlSYz/FjHtWPOSWyDnbzn1qGbxV2e4eAnCfCnwqzuoiHi2PLNwBwvWvrbWbyxg0q+kvryG2to4j50ruAI1I6mviO5kMX7N1oUOMa+54PIPlivL59TvZEKfaZWD4JG8nPsfWuWpT59bnVQbVz67i+MfgvwpaRaDBq2q3sVjarbR3NlEnlynHUbuQR69K5PxFpfgi58M+HbCTxtbGyuL9bnVIQwaad5Dksz5+XYCRyP8K+Y3kaVjnduHPv700uTGQXyB2qkraobpXtc+pvhd4i8P+HtT8UaZpPjKKw8MWd55scVzGkv2uHbhwrEBskjGR7cGvMPgh4k0nR/jYuq3MqadpDPcMu45EaMG2rx+ArybzCRjJUY6DvTcnaDx70rplKja+p+hL/FnwMVkUeIbEBsk4zz9eK+B/FtxDeeKtZubQg2817NJER02lyR+hqiJTgYPI9OKhc7mJPUnNYVVFRXKVSpOMrtk6sVBAxhl5z/AJ9qaHwWyM8fTBpx2GNmZvmHTj7341CDxW0pctkWlckPABDdaaRyT2pV2kZbOe2DSHkEsCfepbuhocpCAHGWzkZqQMzZBC7+pz1qJCATng9sdqQE4OT16n1q4uwmrjmbIOAME59aeoBUsMkjkgDt0pgI5DHgjrT1LFlVeOgwpxnmqQmJHj5i5IIHTFWLSYq2fQHB9M0ySJ4VK7SA3B79/Woiv7vdtx/nrT1RLSkjsdBt9Mu51S+f7NgnLKQcH6U7X/D4tB5mnX8NzbcYIPzVyAl43Hk449Pxp3nSLuR2Yp0xnp9K051Y5/YSTumQuqq5VidwPOOlOdgjKYmbIUck/pUbuWxuHQUnK9vzrK51W7k/2jJZivzkdqhJypzjPvSDBHQ59aQ8nmlzNjUUthT056U5HK/d4B7imscdCRjpQBk+gpX10Au2oVdu9gpB6d63tIAdw32kIOxxwPauaiVpAcHnvWlawP5iKDIFGdxJreLOarFdz03w7f3Vo3lI1vKmcn91uyfWvU9B8cQWyJHNc6bArKFP+jEMB0HNeM+F7hrYgEyTKOQqSbc+1ehWFhLfsWhs7e2QLuZ523MfpVtJo4JaM1tVt9H1S7eeHXkZh97bnr7ZroIPCVg+hLcWOt252rudAN7H8q4aTQLm7jeOR4I0X7+0fe+ldV8O/B1zfzeTZSTQwpyzmbC/kOtZz91XuEVd2R638NG06z8PIqzR+fn5mfAcjtkV2cixzx7WTzI24ORxiuT0LwNb6ZdpcvcPK6/wnlRXYjgYFedUacrpnq0VJR5ZKxzZ0/w5o84Z7eCKRv4ihb/61bqyQR24kRkWHGQV6U64aBIi1y0axjqZCAP1rJu/EljBLDHCTOZDtBjI2j8SanWRV4097IfcTrqqoLElgjZ8wqdoI7c9aZqWl6heWrRDVHjJGMxxBefrzWskylFZ2RSe24Gnjdk5xt7YoUmtgdNS36nCWPg7U49Rie71Jbi0U7vLkySTXU6loVhqNssE8C+WpHCjFalNkcIMtTdSUncUaMIoq2GmWdhCIrS3jjTOcAVcJwMnpVO4muwP9HtVf/ekxVe+lnNmyzeVGxHKhicikk5MbnGC0RDqnibS9Njd7i5U7OoXmuB8T/FMJYuumWqgyAgSSPnj6Csnxh59ru8vT/NiY8SMvWn+E/B6a4wlnxCMAk+UePoa640qcVzSOGWIqzfLFHnLadeavevcyRkISSzdFFbGieB77Ubo+Q3kxjBLIDur2+w8D6LYgs0U07gdZJD+gGKw9b8Q2nhu5klsUx5aFDE3KDPr3yK0Vfn0gjKdFwtzs8E8dWUPhqcw+ZKZQMFmfcfevKNUvWuJGeZiqjHU5r3/APaG1mHV/DXhHUZbdPMuFuGOwHttAH06181X8uJjiNFX2Naxk3G7GqaT01ILiTg4JVeM8c1CgW4Y7PlQHIZj0qLzNrtv+ZDwe/H1phdVdTET16Y4pXOpQtoj1G8JH7NNqFbgeIJOT1/1YryIs2dxPOa9Yvix/ZvtBzxr8hP/AH7FeTZzmsJu1jShs/VikA/xc0uw7AxwBnGM1HmisXNXN7Dh3oDYQjg568U6ZVRyqusgwDuXOOnvTE+8MjPPT1p81nYN1cXjAOKYetP+9JhQeTwKYwwxBxx6VnN3Gh+eCOR6Ck/woB60o+bJB5HQetXuAAjHNJzjHrSU5juwcnI45pKVwHkrtOc57YFLEyo+6RN6j+EnGaizjjv3qWIxZXehPqc1spczJa0EjOX4O09QadEM8A8nOSe1PeOPIMb84yS3Az6Cl+zOFLBN3HY1ok1uQ5IngJMCiRn9FA6USgJEM/e5HXPNNgAYDggoOVPc+tRykho/MVTtHGD/ADq76GdveI2UlAcnv27UwA/h1qSVmCj5id/XAx+FRMeOfwrNtXNo3sGdpBU9aaWJ6k0nT60D61jzlWHsAMfNyOvekHAJ/CmnI4NAzye1Pm1Cw4Hj+VLwR1/CmH3qRWO04UbfpVRd2Jk1sqtk87uMAVtWgnkBjh2kf7WOaxFZixwFBHYVq6N5EkyCdW9MqcY+tdEGc1ZPc7PQNKulmV9kcwx/e24rvNNt9QaExQrGhPXfJ0HbFcxoV5YWDRSC5R1XOY8ZJFejad4hbUbaKCzgjjOD8whDEe9a6I8+bbK+iPp9g8S6hZvc3WcsVkJzjtXsmnfEzwpp1mkfkzWJAGYlh7/Udfxr5z8QST6XfvuupnXGV2rjBrl9Q1m5u7lS0kgRepxnNY1acZ7mlGcoO6PtTS/G+l6pbvJYiZyv8LADP61j6p8TdOsVcMIRKBwrTd/fivlrRfEmqWURSC+W2Q/xPwTTdUurif8AeT3Cz7vmMhbjJ9qzWGhc1eJqdz6Ef4y2cp2SWcUq91zkH8TWBrXxVluZo4dM0O0hUnJaUAk/SvDDepECRKpaNeRnAB+lOtfEe983Cr1z8owTWiowWxm6k5bnv+m/EW+iAjmsY5SCAoyAg9/5122m/EjSjCv26dRKTjbGM44r5ZfVoHdJizqh6LvzVpPEMUsbiC3EZwfn3YzROhCQo1Zw1R9g2niXR7yNWi1K3X1BcA/rU51mwb/V3Ib3Wvj7Q9SWG6LyTfMRgbufxxXcWGptvEy6g+7HyqG6H6elY/VFfc1ljJJWse8azNJdIIINQNsWHXIUiodP8OKT5s+p3k7OOQjbV5rg/Cmo6i00PlRRSNJjc8oMj8/SvY4s+Um7hsDNY1E6eiNKFqzbkY0fhnT1dWk8+badwWSQkVsxRpDGI4lCIOgAwBWN4i8RQaKFEiNI5GSB2FcH4w8fyrpy/ZyIEcfOUcBqmNOpUNJVqVHRbnY+NfENrpemzJ9t8u5ZflWL5n/+tXzL4onvb2aRRezeWxLHzW5Y+teojxZB4U8OeH7z+zba+bVGllmmmOWWNSAQCerc/Ssu30b4a+M7tl0m9utJv/OwRMSfNZs8AFiODjpiumlaktvmc1S9V3vr2OK+KqOPhv4CjyWKxXR3evzrXi13AfLffHGh/vHqa+u/F3w1tr7wp4etfEGuxaWunJLCZFQOJGdsjGSOwrlLbQ/AHhuFptL0a+8U6najYHlH+izSHgnnjA57H+tXComrRVwcXH4nY+Up/vkHJUD8BRpdw1lqlveNEkpglWTY4yjEEHDDuOK9a/aB0SCxTw7rmn6XBpEeqWreZZxchZlY7j+O4Y9hXjUrk9tgI+6OmKbaOmk+aJ798VfG1z44+BWmajd2FjYuusND5VopVCFTrg+ua+ej14r1jUHA/Zt0pBg7tdlzxzwgryY1z1NErGlDW/qIKUYAPGTRxSVhsbBS9aTNLk49qSaQw5FNpRSUpO4EgK7QPfk96apIORkH1oPQUcVd2hWFJ5FBbKqOBgdhSD3o9cdKOZsAWnAEk+1M+lOyVyN3XrinGSSswHhsgg4GK0NNvfIZd4RgCM7u9ZqkclhuJGBz0p3zEc9PauiE3e5nOCkrM3tS+zTp57DyJCc4TvWRN87Fo9x45J605IeE3bljJIBars1lGIUlt5gQBg7uAfWt37xhFqnpcypd+7LNknk80xmJCg9hUjZjXGBgnP19P51FmuWbS0OlCHrR2pT2pBWTepQA0lFHfrUt3GOJ7UqkbhnpTc8e1KCc5q4yuxD1PBIzn1q9DfMsWxggHU8d8/zrOFaVjb27E7powexYGuinK+xlVStqaOnSwZyr+W3f6V0+hX+pw3PmWcLzRqSSxfGVA61y8UMMEi75EkiP9w4Oa6vw3eNa3dpLFF5se9d8LE7ZB0wcc45roRwzs9i7e3821ZLuyO5gCDJJnHvWUL+Z33J5PBJ2AZzTPFE1zBezQ3csexJGVdvJwDWPFq0UG2O2CFiPnYjOKbZEYNq6RtR28+pXLsbZ5JBjAzhauyaRNp8fm6nFHtIyI2fmse0vr+d2WGRQp4z6U29t765uB58jSoOOvFF+wWdx95cJNNutLdI27AZNJNvECs0q72HAyBg1UuTPaR7GKqW4BXr+dZZSVyxVmkKnnnrSbLjG5qM7WzGORgz5IKg8AitCyu7d1R3XPqF4GPeueaKaSMHyiuOCc4GfxrR0eQW8m0su7ORuGRRcHFWOhguI4Ss0cchBOBnp0/WvTPhn4autevUuJoXjhHPzDg/hXn+kypDdo91JFI2SdhUnH9K+jvhbf/bRvkiEFrGNvzOI1PuKUnZXRjLex3PhvSbjTljhs4PJhH3pWxlvw6108lu0i4aeVf8AcOK57W/G+iaSoQXKXVwfuwWxDsfy4FcP4q8VeIr+zdkEWiWZHG6TdKyn19PpXCoTqu5281KjG17nU+LE0e3ik+1XFvE+3HmXM5yfwrwXxIdJjkuDbai2ou3yosUXyj2ovbFtVnWO4ae5IyGklYgc1qaX8PwsYZWSVj0G/AU12whyK1zzpzTdyl4vtL7VfhX4Zu7a3lhbTp5bOWPggI2CHPpkgD8a47TprnSkLAIGHctyD616TpF3Hod1c6b4ku1fQtRQxXEUZyUP8Lg+oOK5Pxj8M9Q0jV7WfS5ZNX0C8bMF1Ed+0ddr49B36U01F2Zes1c9K0jV77UPDWnJqs/neWuRuwcA+/fj1pgkWORQqDaR8qqM47HAqHTbX5IrdFdsIqmPJO30wBWzq93pPgDRjr/i24SOcL/odjn95M4GQCOuM4z2Hf0Lco00YxhOrI8a/avuoLS68NaFEC09haGSZ8/xSHO0jseM/iK+eTx1ra8XeIb3xJr9/qmoymSe7lMjE9OTwB6AdKxCc5Ocn3rjnLp1PbpQ5Y2PUtU4/Zz0XnO7W5z9PkFeWGvU9YUj9nTQDu+9rU52/wDAK8r71FXp6E4faXqwoopKwZ0C9qKKKADOaSlpKGA4nrSZpQMkAdaSqbe4BR9aB3opAL0+lFJQOvWmmAuTnPenqxwQDjvmmfhQCR0q4zt1E0X4mdipOJF7KXx371HO7u7I21Rndg1Xyep4wKRizfeya6HV0M1DW44sUyNoyRg7h/Km/dJH4GmnHuaPbtXPKbbLSAdaQ0vU0nepewxaTvRRUjFHWjp1pKKdwFzg+4pVOD3z7U2lHGSOlOLd7iLEU8meWyPftWtpWty2cik/Kq9COeawskcUFs9fpW8a3KZypRludFqOuPduGCKxJ+beOW96zp2eYB0gZRn5sd6hgePK4yCQAxOCc+1WmkjhjBZpHbPAzxW97rUx5VB2SOy8EwWrrtvLV5dxHypnLV1eprb21jK9toUqx92dj8prhtC8RXsQzppEDAABiMEn61taz4n1+XS/L1K/ikiIwEDDOPetU9DjnBuWpxWrzpLKVJ8puTjJJFUbWdrdwUbqcFj/ACxUM8qPI7MCWJzkHNVwRg9axc9TuhT92xoXOoTPJnzA6r0BHH5VNp+sG3dmeFWz39Kx88jHP1p6gYPzAcVEarb0LdKNrM6RPEWJ97IevAz0rVtfGF8TgvI0eQNqOcYzXCZ7ip7VyJFCA5PpVxq3djKeHjbQ9t0DVtUaPzbGWCzxzvkI3mtOLUNXM63Fwz3/AJQyQ2dpFZPwu0iRpUkna0AYcNeSDav4V2Pi26s1tfIn12KVo+VjiUIldC8zzZNc1kUD4w1S7kSBLe0srf171vN4jt7ayLPemWXGHwQoH0xXmEkKlzIlyvlYPLNtX3yTXLanr1hazFElN0MEFYOFz9T2qXJR+IpUnN2idd4i1o6lcsVV2Tv3AFSeEPjBqfgG48mzmW809m3S2UnKnjoDyV69q8ovdfvLlWjRzDCeNien1rIrlq4iL0Sud1LDOOrZ9L337UlwLKVNJ8LWVrdMhWOYy7hGemdu0Z+ma8H8YeK9X8YaxLqev3j3V2/duFUeiqOAPpWBmisFO2x1qCQuaSiiocmyj1DWjj9nnw5k5zrNxx6fKK8vr2n4heHr3w9+z74Ki1FIkkub+a6ULIGOx0yuce2OO1eK1dV6pGNBaP1YUpooP6VkbBQAScDrSUtCAKSiikAUUUUALnrRRRQAlFFFABSgkEEcEUUUXAdvbnpyMcim5NFFVzSfULBmiiilcAJooopsAooooAM+1GaKKcgCgUUUo7gKT9KOv5UUVbeoiSMlRuU4I6UryuQFzgD0FFFbN+6TZXJbL5pNpJxjOM1LdSsFZRgA+nFFFbL4TGXxlE0gPSiiuaR0AaM9faiioW7AOxNKrMp+UkYoooTs9AN3Tru6ldI3uptp9HxTNSvZbSdkiwTgfO+Wb9aKK7pfDc42l7Sxkz3U84AmmkcejMSPyqCiivNbb3OxJLYKKKKQwpaKKAA0UUU2B6t4tLf8M/eC9zMxOo3RyxJx2xXlFFFaVviMaHwv1f5hTtzbNuTtznGeM0UVkbDaKKKACiiigD//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The endometrium surrounding the fluid is thin and atrophic and small sonolucent microcystic changes (marked by calipers) are seen under the superficial epithelium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_58_19362=[""].join("\n");
var outline_f18_58_19362=null;
var title_f18_58_19363="Harmonic imaging echocardiogram";
var content_f18_58_19363=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Harmonic imaging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 305px; height: 531px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The long axis precordial view in a technically difficult subject is shown in panel A. The transducer of the instrument insonates tissues at a center line carrier frequency of 3 MHz and receives the resulting reflected signals at the same or fundamental frequency. Harmonic imaging from the same subject is shown in panel B; the instrument insonates tissues at 1.8 MHz and detects their first harmonic reflections at 3.6 MHz. The fundamental frequency reflections are not used. Note that this technique improves the visualization of the walls and valves by creating surfaces that appear to be more continuous. This technique is particularly helpful in stress echocardiography.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_58_19363=[""].join("\n");
var outline_f18_58_19363=null;
var title_f18_58_19364="Phenoxybenzamine: Pediatric drug information";
var content_f18_58_19364=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Phenoxybenzamine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38916?source=see_link\">",
"    see \"Phenoxybenzamine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/35/23092?source=see_link\">",
"    see \"Phenoxybenzamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F209081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dibenzyline&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Alpha-Adrenergic Blocking Agent, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vasodilator",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38916?source=see_link\">",
"      see \"Phenoxybenzamine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Initial: 0.2 mg/kg once daily; maximum dose: 10 mg/dose; increase every 4 days by 0.2 mg/kg/day increments; usual maintenance dose: 0.4-1.2 mg/kg/day every 6-8 hours; maximum doses of up to 2-4 mg/kg/day have been recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Initial: 10 mg twice daily; increase dose every other day to usual dose of 10-40 mg every 8-12 hours; higher doses may be needed",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F209067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dibenzyline&reg;: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F209053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: May administer with milk to decrease GI upset",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic management of hypertension and sweating in patients with pheochromocytoma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6091405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Phenoxybenzamine may be confused with phenazopyridine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F209110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Orthostatic hypotension, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Drowsiness, fatigue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: GI irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Inhibition of ejaculation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Miosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phenoxybenzamine or any component; shock",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal dysfunction, cerebral or coronary arteriosclerosis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Capsule contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; avoid use of phenoxybenzamine products containing benzyl alcohol in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F209062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Alpha1-Blockers. Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F209063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6091406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adequate animal reproduction studies have not been conducted. It is not known whether phenoxybenzamine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, orthostasis, heart rate",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Produces long-lasting noncompetitive alpha-adrenergic blockade of postganglionic synapses in exocrine glands and smooth muscle",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Within 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Effects can continue for up to 4 days",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: &sim;20% to 30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes to and may accumulate in adipose tissues",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily in urine and bile",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/35/23092?source=see_link\">",
"      see \"Phenoxybenzamine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; may cause dizziness; avoid sudden changes in posture; may cause nasal congestion and constricted pupils; avoid cough, cold, or allergy medications containing sympathomimetics",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F11445842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 2 mg/mL oral suspension may be made with capsules, propylene glycol 1%, and citric acid 0.15% in distilled water. Prepare the vehicle by dissolving 150 mg citric acid in a minimal amount of distilled water. Add 1 mL propylene glycol and mix well; add quantity of distilled water sufficient to make 100 mL (only a small portion of this vehicle will be used to make the final product). Grind the contents of two phenoxybenzamine 10 mg capsules in a mortar and reduce to a fine powder. Add a small portion of the vehicle and mix to a uniform paste; transfer to a graduated cylinder, rinse mortar with vehicle, and add quantity of prepared vehicle sufficient to make 10 mL. Transfer to an amber glass prescription bottle with tight-fitting cap; label \"shake well\" and \"refrigerate\". Stable for 7 days when stored in amber glass prescription bottles and refrigerated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A stock solution of 10 mg/mL in propylene glycol was stable for 30 days refrigerated. When this stock solution was diluted 1:4 (v/v) with syrup (66.7% sucrose) to 2 mg/mL, the preparation was stable for 1 hour refrigerated.",
"     <b>",
"      Note:",
"     </b>",
"     Although the stock solution is stable for 30 days, it must be diluted before administration to decrease the amount of propylene glycol delivered to the patient.",
"    </p>",
"    <div class=\"reference\">",
"     Lim LY, Tan LL, Chan EW, et al, \"Stability of Phenoxybenzamine Hydrochloride in Various Vehicles,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1997, 54(18):2073-8.",
"     <span class=\"pubmed-id\">",
"      9377206",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12699 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-118.195.65.248-47B75F185E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_58_19364=[""].join("\n");
var outline_f18_58_19364=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209081\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054905\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054899\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209067\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209053\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054909\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054908\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6091405\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209110\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054914\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054898\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054897\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299865\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209062\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209063\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6091406\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054904\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054896\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054912\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054913\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054903\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445842\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12699\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12699|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38916?source=related_link\">",
"      Phenoxybenzamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/35/23092?source=related_link\">",
"      Phenoxybenzamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_58_19365="Atovaquone and proguanil: Pediatric drug information";
var content_f18_58_19365=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Atovaquone and proguanil: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"    see \"Atovaquone and proguanil: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/10/41124?source=see_link\">",
"    see \"Atovaquone and proguanil: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F137595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Malarone&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F137596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Malarone&reg;;",
"     </li>",
"     <li>",
"      Malarone&reg; Pediatric",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F999503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antimalarial Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F999544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"      see \"Atovaquone and proguanil: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children (dosage based on body weight):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevention of malaria: Start 1-2 days prior to entering a malaria-endemic area, continue throughout the stay and for 7 days after leaving area. Take as a single dose, once daily.",
"     <b>",
"      Note:",
"     </b>",
"     AAP (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2009) states that atovaquone and proguanil can be used for prevention in a child &ge;5 kg if travel cannot be avoided to areas where chloroquine-resistant",
"     <i>",
"      P. falciparum",
"     </i>",
"     exists.",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:8em;text-align:justify;\">",
"     5-8 kg: Atovaquone/proguanil: 31.25 mg/12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     9-10 kg: Atovaquone/proguanil: 46.88 mg/18.75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer's dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     11-20 kg: Atovaquone/proguanil 62.5 mg/25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     21-30 kg: Atovaquone/proguanil 125 mg/50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     31-40 kg: Atovaquone/proguanil 187.5 mg/75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;40 kg: Atovaquone/proguanil 250 mg/100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of acute malaria: Take as a single dose, once daily for 3 consecutive days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     5-8 kg: Atovaquone/proguanil 125 mg/50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     9-10 kg: Atovaquone/proguanil 187.5 mg/75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     11-20 kg: Atovaquone/proguanil 250 mg/100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     21-30 kg: Atovaquone/proguanil 500 mg/200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     31-40 kg: Atovaquone/proguanil 750 mg/300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;40 kg: Atovaquone/proguanil 1 g/400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevention of malaria: Atovaquone/proguanil 250 mg/100 mg once daily; start 1-2 days prior to entering a malaria-endemic area, continue throughout the stay and for 7 days after leaving area",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of acute malaria: Atovaquone/proguanil 1 g/400 mg as a single dose, once daily for 3 consecutive days.",
"     <b>",
"      Note:",
"     </b>",
"     Consultants recommend dividing the daily dose in 2 to decrease nausea and vomiting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Should not be used as prophylaxis in severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute). For treatment of malaria, alternative regimens should be used in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute unless benefits outweigh the risks. No dosage adjustment required in mild to moderate renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     No dosage adjustment required in mild to moderate hepatic impairment. No data available for use in severe hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F137574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: Atovaquone 250 mg and proguanil hydrochloride 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Malarone&reg;: Atovaquone 250 mg and proguanil hydrochloride 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [pediatric]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Malarone&reg;: Atovaquone 62.5 mg and proguanil hydrochloride 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F137560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes pediatric strength tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F999554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food or milk at the same time each day. If vomiting occurs within 1 hour of administration, repeat the dose. Tablets are not palatable if chewed due to bitter taste. For children who have difficulty swallowing tablets, tablets may be crushed and mixed with condensed milk just prior to administration.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F999529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store tablets at 25&deg;C (77&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F999504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention (FDA approved in pediatric patients &gt;11 kg and adults) or treatment (FDA approved in pediatric patients &gt;5 kg and adults) of acute, uncomplicated",
"     <i>",
"      P. falciparum",
"     </i>",
"     malaria, including chloroquine-resistant",
"     <i>",
"      P. falciparum",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F137619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The following adverse reactions were reported in patients being treated for malaria. When used for prophylaxis, reactions are similar to those seen with placebo.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Transaminase increases (increased LFT values typically normalized after ~4 weeks)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylaxis (rare), anemia (rare), angioedema, cholestasis, erythema multiforme (rare), hallucinations, hepatitis (rare), hepatic failure (case report), neutropenia, pancytopenia (with severe renal impairment), photosensitivity, psychotic episodes (rare), rash, seizure (rare), Stevens-Johnson syndrome (rare), stomatitis, urticaria, vasculitis (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F999511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to atovaquone, proguanil, or any component of the formulation; prophylactic use in severe renal impairment (Cl",
"     <sub>",
"      Cr",
"     </sub>",
"     &lt;30 mL/minute)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F9922494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption of atovaquone may be decreased in patients who have diarrhea or vomiting; monitor closely and consider use of an antiemetic. If severe, consider use of an alternative antimalarial. Delayed cases of",
"     <i>",
"      P. falciparum",
"     </i>",
"     malaria may occur after stopping prophylaxis; travelers returning from endemic areas who develop febrile illnesses should be evaluated for malaria. Recrudescent infections or infections following prophylaxis with this agent should be treated with alternative agent(s). Use with caution in patients with pre-existing renal disease.  Parasite relapse is common when used to treat",
"     <i>",
"      P. vivax",
"     </i>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F999512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Liver function test abnormalities and hepatitis have been reported with use. One case of hepatic failure has been reported. Not indicated for severe or complicated malaria.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F137609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F137569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Proguanil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: Atovaquone may increase the serum concentration of Etoposide.  Management: Separate administration of atovaquone and etoposide by at least 1-2 days. Avoid concomitant administration of atovaquone and etoposide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Atovaquone may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May decrease the serum concentration of Proguanil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline: May decrease the serum concentration of Atovaquone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F999528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Atovaquone taken with dietary fat increases the rate and extent of absorption.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F137571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F137582\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed with the combination of atovaquone/proguanil in animal reproduction studies using concentrations similar to the estimated human exposure. The pharmacokinetics of atovaquone and proguanil are changed during pregnancy. Malaria infection in pregnant women may be more severe than in nonpregnant women. Because",
"     <i>",
"      P. falciparum",
"     </i>",
"     malaria can cause maternal death and fetal loss, pregnant women traveling to malaria-endemic areas must use personal protection against mosquito bites. Atovaquone/proguanil may be used as an alternative treatment of malaria in pregnant women; consult current CDC guidelines.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F999532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Atovaquone: Selectively inhibits parasite mitochondrial electron transport.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Proguanil: The metabolite cycloguanil inhibits dihydrofolate reductase, disrupting deoxythymidylate synthesis. Together, atovaquone/cycloguanil affect the erythrocytic and exoerythrocytic stages of development.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F999534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Atovaquone:",
"     </b>",
"     See Atovaquone monograph.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Proguanil:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Absorption: Extensive",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Pediatric patients: 42 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Protein binding: 75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolism: Hepatic to active metabolites, cycloguanil (via CYP2C19) and 4-chlorophenylbiguanide",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Half-life elimination: 12-21 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elimination: Urine (40% to 60%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F999560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/10/41124?source=see_link\">",
"      see \"Atovaquone and proguanil: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take any new medication during therapy without consulting prescriber. Complete full course of therapy; do not discontinue or alter dosage without consulting prescriber. Take at the same time each day with full glass of milk or food. If vomiting occurs within 1 hour of taking dose, you may repeat the dose. You may experience nausea, vomiting, or loss of appetite (small frequent meals may help); or headache (if persistent, contact prescriber). Follow recommended precautions to avoid malaria exposure (use insect repellent, bednets, protective clothing). Notify prescriber if you develop fever after returning from or while visiting a malaria-endemic area.",
"     <b>",
"      Pregnancy/breast-feeding precautions:",
"     </b>",
"     Inform prescriber if you are or intend to become pregnant. Consult prescriber if breast-feeding.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/58/19365/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009, 98-104. Available at file://aapredbook.aappublications.org/cgi/content/full/2009/1/1.7.13",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15548 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-0E8BE10A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_58_19365=[""].join("\n");
var outline_f18_58_19365=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137595\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137596\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999503\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999544\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137574\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137560\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999554\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999529\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999504\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137619\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999511\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9922494\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999512\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137609\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137569\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999528\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137571\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137582\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999532\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999534\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F999560\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15548\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15548|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=related_link\">",
"      Atovaquone and proguanil: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/10/41124?source=related_link\">",
"      Atovaquone and proguanil: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_58_19366="Light microscopy of acute tubular necrosis II";
var content_f18_58_19366=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F51526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F51526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Light microscopy of acute tubular necrosis II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 328px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFIAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDstNjb7IQ4Jz1zWxo9hHIpnWL94OA3qK5Xw14nsdUmEMRzk9D1r1KxitEjTfIkUZ6ZYDNepjOel7klqz3cY5Uvj0IdKtRcXMbMnyp6iuicwwryFQEUtskSqPJ27fUd6z/EtzBaWgkmYqB0wK8izr1VGx5k6nM/I5Txf4utdOkNvLbO8YOWZOwrGsfF2k66xgtYZPPj6Z9KpeOrNdTFvyFjmGQw/iFc7b6XDoReWJhvK7flzxX0lLC4d0YqK975nbSw8pSWuh3Et1bfZmiR8y55Uda2dBv7eSJY5gySDseBXI+FUilhllVw1w3QnqK3dPtZZrhvtDhnXutc9ejCKcH0OipGlZpO52Fvc+RIGtj+7Y8gjg07xLJHJZeWOGIzim6IBPGBswycc96zfGds7W4nhk2snpntXm04xddJ7nCkvaJHOFShUsMseMU2OIxsflBU84qp5/mIr+Z83fNW7WTKMjZ5716zg0em00rkpjLsEUbiw4FOkiktYdsylQan0SN4tQTPK54zW74iVNhdkJAGeBXNKo41FBamUqlpKJw+VSZmyAe49aTQJDMtwVUhfMxnHesX7Yz6hMxUpGjHGa2vBtw13aTAKqlHznpmvSq0nCm5eh0YhckLPfQt+I5ZLXTUFkCbgt8oPTPvWLazPqM62skhMqNmVuxxU3ivVhHqUFqBlSvz7eat+FrLck17JEU8w7VHfjvQo+yoKUt3t8znp3heT2t+LZj2OsXMmsTW8e7YCVx2GO9ddoVjPqN1Gs6lUTliO9VRbQyajsiiUN1aRR1rstECWjhYgGDjB9zXJjK/u+5GzsZqToU7Pdmg+mxC2ZFj5xwKwre2jklKCNUKtjB7musaO6aBtjKjDoR1rCfT5JiLkEieNuR2J9a8mlPdNnLTqyd7sytQslfzIuNyHIrKkjWKQgks5HArS86T7XNcyuFjVtje9Z2xptWeWVg0S/dx2r0qaaWr0OyN+WzK1tdxR3pgviwRzjP901f1GC4S3ZbGfz8HhlGTn3qhqmnQXjSTRMySIQyn3Fc7qWv6lDMiWOVjQ4ZR1b3rrp0XWd4PXrfY5MRVVNJtXT6HOap4KmvNbW4vo44Vd/maRuprovHNtdaFoFlZ2k7zLHGWWSFs49hXY3Ea6haadcXKgkrl0Y/ePY1Um0o3sskSSoJgm8R5yB7VssZKUoyqPSPToYwcL8sdEzlvhPBez6NNfatLJKrMRGkvWuh1PUrGOHy7+3/dE8cfdrT0UxT2ZgJCTwnlMYrnfG9hPdaayWwJkD4yo5FYqSr4huppd+h0fBBx6oXUNJt5NM+2aXKrRg7gF7Vp+FrsXzQq/wA0ycZPoKwPB2l3Ph7QNQfVZeZT8iZ6cVpaDpl1DpzXY3RozFkBBBINOpGPLKHNdX0Z00W6tB8+jWxtXIN5rMcEYIUe3FSaxYR3SQxpkzRvg49PejS512S7PluAMMSeat2jCKNZZOCThmzXHLmg1y9DCMpU5ehztxpgtrl4CpO/DDaO9UbiFEuAWAaRTjBrqPtsdxcuVIaMcA+lZ+q2kbSYDLvfpjqa3hVd7TPQpYhyaUi7o0+YfMSXCgYdT2rIu7pvtjrbruXrmnalp8emWUY+0utzJwYxW5olvBb2SLIoeQnLORzis3y0/fWtzOXJSvPdM5SZpJFl3hk/2hTdD1cRy/Z5gHHQEiuwnksvO8uMAoRg5HrXI6v4cAvIpLNiiKxJranVhUThUVrm9KtSqxcJ6djr4IoJLYYhw/Y5qSKaGF/IZipZfvdhWXpqSQeWhLP0yTXH/ELVrn+3ltbcbVRRtTON3vWFHC+2q+zT0PHry9n5nYSOyXEvJAJxx2rn/EQkCltmY+hyeoq74anaXTgk/wDBxuPenamGnVIz3bkn09K1hH2dS3Y6sJJtq5laHaCxsvlXaXy4Geg7VUlyXc3COybucGup1q0VJrNYAUjaMc/SoI4F37Xw6nsK0jXV3N9Tsp4hRlzNbnLXP2CcuY1MfbBOTVf7M0ZSWIFl4znt711N1oVvKheEKsncY61jw2V4lwwKEIOCT6V0Qrxa91/eehDERlH3X952nh54pLfynclguc9qh1K3jaR2l2bR3HWubRbvSbd54X3o3RSen0p4vJr0rNtKW3G/J5zXH9XXNzp6HmvDyUnOL0HR2MLXAMpcW7HgH+lRTW/2OcSR7iEOQPatYyx7MRBpMdCaIn+1M5RflAwd3WrVSW72F7aaeuwllqUF4u5SqMOMGku/3CM6LvPaszVdIMZaeB/mIztHGai0zW1hgEdyMkcZPUUeyUlzUvuKlh1UjzUtTz82F9qPiMSGKTz/ADMqw/hGa6TxZpFy6x3kKxG5KiKUnqV9a77TY7d4C8ciKHHLAciqWpWsRtnMJLHG1S3StpY+TnHS3KedTpqEmn1Of0kSWMVva3T+dHIn8J5B9K2rWxdroCBMMeg9KwrUJNYbg37+1lweeoroxe3DRschY1GSV6nis8QnzXOzER5LWLs4jt2aGMhpj94joKwdRsIkZ54wBKoySD1os757q52wgeXnBarcy5gkiXDbs/N6muf2bpPUyoVWnozK0+cXgkNxEhkUfLj0q9bx+VG7tEBgcHpWPa2N5ZlrplIVT+lOTxD/AGhf/ZmJj3jbk9K2nRUm/ZpWO6dGUm3DWJcsrhIxJvUMwO4YHWiq1lp9wt8XRg4X5cCis6kYJ6EVVFS3PIPDFy7xmS03R3A7irPjPxD4mu44BG7KEGPkJ/Or+iWyaa79GrpYIEnTzREXU/pXv+2VOpzqKOivS+s0OSurvuTfCHx5qlnp/wBm12clt3yGTrivSfFmvRX+gCeKRH4wVBryO8to53KiMKMfe6YrEljv7ImGO6m8vqEY7hXF9RpTre2Wjvcy/smjVioxdrHcHWGOh2VtLnzoj654zW3Jbtf2IeGMscYPFcDo1vLJKXmcbDz9DXcaFr32dDAwA5xuxRWpOGtJap3+80xGEUafJT1sJ4c0q7sL8yyqywtXY2cogvcJk5GT9KykvDI6hkIU/wAXrXQWtsjhGknWLI4NeZipym+ae55LpeyVmdNpTB54mVcAryaqeJpVjilyoYbTV7SrQxtGElWSMLnK1zfj6Z7S0mdDlmGADXm4eHPXUTmiuaokjzx7iTePJAOTg5rotEnUSMrqGIHNcIbmQkkD5u9aum3FwCCzA5HPrX0dagpRPeq0ny2PQBcw4JixuHT1rOv767uZPL80R5HAJ61Q0qRBc5Yk4qfVtOeRjPA4D9VOeg9K4VTjTnZ/ecSjGMtTnJITBq/kTkMXHPpWxpMCWDtHEm6KQ5OTyK5Z55/7aWZiWZflYV3lpJE8Id1IGOqjNdOKvFJPqa4u6s2YV/5NvdTF1UyS4EJPUdq2ftZsLBYCMkjaBTbvTkub+Gc4cR8qDTJLO8v70vBA3lw87iOM1m5wklzDThVUU9luX9A064mjLurIhOdw65rs9GskFyso6J2z3qrpCynTIUkGG25JHHNWdLvhDfvC6nDDOa8mvOVXmsebiKkqkpWR0L7sE9hzWRqdzGlvsilRZZT8ufWn6vqUlvbv9ngkdyvBArjtPlaVVkmZnm3E8/wn0rKhh7rnkc1Kk2uZktzp3l6eROp3biWYnqa5mwnZBKVHyE4yTW7HqM7Wupf2jl0B2ouOfrWTZ6fGbdgJWVyNwBPWvVpJwTU9TuoTcqbc+oQXyxzbTgq/PPep4dHs31A3EZbYTuMeePpVHZEbyHzBlI1OcVYs9Wh+0+TGjRr0Vn7mtnTla8PmViKVNqN9zY1GyTVMfM0PkjjacYFR2EFvZRssRDyHrK7fNim3E4jCuxzIeCB0xVS3jee7eTcMCsVB8lpPQUKEbXIPFFza6JA+szSMqqMnb/GfpVDw74ui8XXy2WkwhL5o/M2v02+pre1jRbTxFpxtL7KpkfMPUU3wN4U0zwhPPLpsbSXEg2mR2yceg9Kt1KMaDTi3U6djOfO5Jq1kb+j+C1Miza1cfapFOREv3Af61f8AFkRXT5/IjK7I/lwOmPSr8d+ojGeH9M1M1xFcW5SYD5uMV5HtKvOpz1MHUqOSlLY8B03U5p4nv4VkMkcu2TJx39K7C8vUnt1UkqXUYA7ZrqrnwDon2pp4Y5Yy5y8aPhWPrisPW/Dtxo919ohbzrL+IHqteu8bQxMlZWf9aGlLlleKlftczrGwktIJZt+VQfdz1rImv3ubgXH3PLPFbl1IZUUQHKM2WHtTZNJtJ3j2sR3IFVGaT5p7noYacKf8RFPT9+tag8tySAo+U9hUmp6vLaTJag7GXqf7wrYWNYFCQxlF6g1n63p9vd3UVxcOqbQCcnrUxqRlNcy07GOJn7Z2jouglxfWUenR3t7dQ2idNznANXbPUrPU7Q3VlPHcQ7fvxnINYfiXw5oniXSDpl+7QxcmKZR9z/GmeD/Dlr4N0VdOs7mW7RiWMrrgEewqXGk4dea/yscqhW5/L8TodO1ZZLtYNuCRkZHB/GjXdJsdTlW4uIwWiwQ2cEe2awoJbWC8VpLqPCtuwDkj8Kk12/kubaRNLkWQnkc4odB86lDTzKhBybTNMPBHuEagRRqOB3rnbvXfLngn8sNAkmHB7c1wklr4vGsRvFLKInIPytlT9RXYaro4u4QEYRTMoLopypb/APXXcsPRotc0uZPt0KTm7qKs0M8R/Eawj8S2+l3ICqQD5pyNuenFdNbzlnjeCNHgYZLg9/SvMPiD4cm1Gysr+3gVtStQEcf31BrtfAy3s2mbtpZkGHhBzipr0KKoKUNGtH/mRTVSMnCe3T/I2tR1m209PMmI46KO9Qadq1vqz5UFH64PesfxPoz34Se3O/acPGeufpUXhrSZrW5a4uJCmRhY8/d96xVKj7Ju/vD5pqfkdbc28LxMsnb1rDuojBbP5GSobPHpWlNcKiKqDcx6sRTG2vEwIIUisIN0zqo1GnrsMsr5ZbZI7dQsgGG4zT4JorSWS3mbdK/IYVz6XS2FyfKOTnnmrlmj3d2szqQoOc+lbzopJt7M654flu+hp3Fz1V+MdCemK57VRa3cohidBP8AeB9RW7qnlRxfvWCBuPrXDaroWoLNFc6fMXQv8u3kD1qsNGO7djz415UZXgdhoEMscbx+Yrx4ySKdJcvOsoYlYkzxWb4U+1pLJFOSrEd6ZrUzIrwrIWJB3YPSiVPmqOO50xTr1dtTN8OPBfW+s2yzIk7FjHuPNdHobfaNLiUvkFdsmfUcV4bfXt5pfipru3ilaIZ2qBwwr1D4d+JrbX9OvLONfs9x94o3UV2YzCtU/aw1Wl/LoLGVW686LWz0+7U6JEtrWXZF93pgHj6mp45iZCyH5VPpxSaZplvG4a6aSYA5IHStW4mhGFtrYRoeueeK8ipNXstTlTSdtyGVBNE6SZxjgDvWFdeH7d3V4iUfr06VvR5MhKHcucZxwKumAuu7aNiDv3rFVZU3ozSFeVJ2izmbC5Ok3BW55R+jUVa1T7MksbXQzx8gHc0VvyRqpSlG7KlFT95njcEd/JOIniI5wSa7+3tWsrIbCeANxqhFlb4QTI42nBYr1rU1O5S3WRVbngBT9K9OpN1JJWPWr1vaWSRjGMSSHcvU5xWTrBlgkaWJAY1UZUnk/StyBvMkzsPI7dKqXCgzZmAZFOR7VtSet2JScdDmo/F1tCEheylDMduQe9dBoc7XN5FlGVc52tWS0FjNqvmHaqnjHcn2ro2aCKePyD91cc9RW1bl+GC3Iwsp80ufU9AiGI41hH41tW9jcPEN2wqOmTXKeGbpp7lAwBjPXJ6V2pvrY7YwzKV4Hoa+exKnGXKjzcWnCXKdToClLIIwwy964r4vTbNMRQBhjgn0rr/D12knmW+4F1Gc1i/ErSxe6DNtUlkGa8/BP2eKXN3OCk1GunLueFG4ZSFj2gHjca2NJB2ANMu/3PSqklgslr8vD4rnGW6h1JIn3eWx/Kvr1FVI72Poq010O6ZGjuV+zz7pS3IHTFddZN+78qZsuRxXMaRYSIqSIRIRyBWoTc7fNaIoScfjXm17T0vscM4KTvcg1/RXt5luoNrZPzKP51saOTJZMAFJxyPWkskubr/X43KMfUVe0zTo01ZVnYiI8jHHNYVKl4cst0KpLmhyyeqIQYZohFMs1ux4VyhwD/hXQaRfiO2+xyxAz9Ny9G961L2KIxhCQ+RgL1zTdJsLeCZpG5ftntXn1KsZw1RxSqRcdShb6jILTIjzhio56Vo+H7ZZGkuW+Y5wCe1ZkoWPUbm3KlYZG3IV6CtbSZ47LfBIcKTkNWdVWi+XqRU+G8epthc53Y461x+oaPIL2aaxKqd24KeldK10JRiHJJ71RhLIJRM+D71lRlKm20YUnKF2cVdG6/tAx3sQjzydvQ1W1RVaTzEO0KOorT1K88/UZCmJI0G0MO1ZN4yCMo7delexTu7O1juTcnHSxSgJliYZ5J5Pc0o0SU3Ue9lcBwynPSnaRKPJnchcRH7x6E1f0yY3itLna27GK6JOcL2Kxa97ToWL618spvdWYHlc8ClsgvLEAgHJxWdrGlPIGk3ssnUAMf1pNOEtvAWkPDcnFZqCcNJakU5ykrM2i3zkJwuc4q3bnLdD7msW1u1Zz83ynnNW73UI7HT57kkMqjIz61lKnK/KluVOLiTarfG1JIIQYySTVOy1+7nIAhG1OQSetcNbX02qatGt3M8wcbzGBworsoIyIlbGMDjHf2rerh40lyy1ZooR5Ltamsnii9lkO2JFC8ZY1R1jxymjabI2rQPchj8yoO3tVWS0y24n5W/CnX2i2Wr2rWkgOccEnoaxjSw6knKOnkZ1KcLaKxX0KfS/FsMjaTcS2lwo3iKQYIFWptK1C0YI9wcAffTvXJ6PoM3hjVWvPtBa3QFCo+8Qf6VU1HxzcQaq0CR4TB3LuLZFdf1aVSbVB3j5mft6lOynqu5u63rM2kKjXQuTET80iYPH5VDbeL/D7nEUhmlcZDOpyPrVaLXZr22kiRVZpEy0bgYC1hDwFLIrXVjAZfN+Zo0bAB9M1rGjRStX930e5Uqk5K9Ox6DDqkAMcskEbRMMRtHyDSaneXU+nSi3iCt90EcHHtWd4b0ebRNGlm1ApGqZ2xsc7PpVax1aG6S7nimP7oEhWrldGLk3T1S6lScHHV2ZzraXPHdJ9mjkVg2X3A/NW5DYyQxpHI2GbJJFR6TqP2y9jU+YQ43KxPBNamqOYNmQWZ+jD+Gt69Wd1CRGHkpfw1qUNalk0q3heEgIQQ7EE4PaoNGv52kjlmeORD94L29K1rKOW9HkTQltw7irY8OJZxF44AhPQVj7WEI8k1qTWpzUrORhHXHS/wDJaL92WwNw65pNX1h9JufNt4AqdCIjhmNacnhyZZBNLlmX5guKgvtOkIHn2z4f7rAZqozo8yaXqTCFVp8rKUOqNfQTXNqZElj5kRutTWOtQXSnz1MbHgsBxVa1e1sJXiVj5r/f3elObQkvFeSCfar9l7VUo0/tKy6M7KNWD/d19+5sL9nSMHzQ7uMqAc4FCyEosf3d3JJ9K5ATy6TJ5Mi71VsCRfStO1u7uR2mt1+2xdMp1X8KmWGcdb6HT9V+1B3I7rS5BfPIHG3Ocetalq7Rp8x59KqTaxZRLi5juIyOqlDmn6TqllqNxtWOZEzhWYU5+0cdVojSqq84e9HREHiRp5EhdQSiA7qTwbdT3Vvcof3sDNlXx90119xp4it/mXcWHf0qtEyW0SQxRogByVQYrBYlOk6aR48oXlzIrF4JZPKMqpP2k6YPpWR4k0WY2zOpPmH72Ks32mO9wHsnUSs24k8itm8uGESQTxhZMDcx6H3qVP2bi6bNaFepSndLQ8zudOWbSjbxJtuR0YivP/Cttqfh7x+jMpEc5O/HTFfQDJZlvM8oHAwAO5rD8Qaak8DXNvGqXCjIAFdtHG2bjJaM7puGLnFz0Zv21yjBWEgHGcYq0jGUblYYHYVxnha/F3YmCTCzxkghutOS6khuZEn8xE/hx0rjlhWpOPVA8E+Zx6o7pvLjjVwi57gU6OaSS2ZfLwOpPSuSstb2vuV9wHHNbk960toZkYDPY8VyVMPKOjOaphZQaTRzOvSLNqsasxbb90g0ViX7MLuSRchun40V6cKT5UkexHDe6kmdBqXivR475AMST8EhVrl/Et4lxfG7jwqS8hRXT3fw2jubnzba5MDDknHBrH8U6TBpt3BGzeY0aYOehp4aph+ZRpNt2PNwsk6y5XoY9peu6v5RG8dqbLvaMmTOWpI2jabzOExx8lUde1l7JVSDbuOOvpXo04OUrRPSqOMNzI/sy8jumZFaVc5Ug9K6KASRGMTKdx65PWs7R719QDSRnynUfMDwK1fnnTc4PmJ0rWcpOVpGlCjGm3JPRnW+G7lIpkMhAGcmu8uVheCOSHLDPUdK8Q8Pi/1C/Hlu6lT07V7Dpt2qWEdo+RIRjnqK8fMaKhNNO76nkYu85uVtjf0Nmt9UhlIwG+U810viJPNsJ1BBIjJwfpXNWz/ZzBJIv3SMsfSuynCzWu4YKuvHuK+erNxqxmeRXfvJnzGNXW0muA3JRm+UdaZ4e17SPFMRmtwyPG+2RHGCpqp8XdBmsfEc0+mI4WQ5ZB0B9ayfCGjrpizzRrskuOZF9DX2M4KUIVKT339D2sNW9vJdFb8T06NI7MI8F1hO4BrfhuQbQMcyoOelcrpOhvLEJ55Q9uvLDPWuh0i5iZZYLcZQcKO9efWUWtNbEVqb5tGX7XVIY0ZzgcVd0qFtQl89p9uR8iCuG8QC4i2KAyZOCK3fCepzWbxmRSeMD0rOrQtT5oPViqUnGHNA9H0ax8oiabLy9BntVnUoQsTSIdrgjnFRaXei4geTBUnpkU3UpZn0ppFU7u9eG1J1PePLfM56nMTyE3D7ywJP0rXsENyMy8lMcdyKqQQLcyB2JdQMbgOn1rahtUhKyBiCK3qySVjoqSUVZblyHLuFiUgDviue8TtJFdSDf8jJzjtXX25Hkh+ACM1xPi+VLm+EMLHd3IqMH71XyOfDybqHM6HJG7SrFnyyTnd3NJdWzXLkICSTgCm21nLa3DFj8q8mtC31WxsJkkvJER5T8u49RXtO/NemrnVGq1epIo63pw0rTbWH5m8072C+tR+HbK5WKRwGKFvlD129jbW+qzJNI6vCV+XJyMUazZ2lnaEQOFZeQornWLdvZNamarc09d2cNr889pYXM8jEnIUY/hFXPCkxv9PnimG7yyNpPGQazdfdr6wlgjOJCPvGtbwPpZstNeSaQlpcE5OcYrrq8saGu9zoqU5Rak9h505o5W2J8pPQ9qh8Qab5+jTQKcFhmuhlcRum3GT696ih06e9EjF+nUdeK5I13FqT0sTKtfRs4Lwlo0lndtNMAZHwqheQBXfW1m5Jxg456ZxTUsfsibjEyjPBIole9gmSS1dDGBgxt3orV3Xle5FWt0RXmgw8gkDEdQPSsxZnHmyIChXgZ710r3AuAu+HZIByOtZk8SbWEo+XrU059JImNRnCfEHxJquiw2E+n2AurZzi5BTdtFRWtl4e1a7tdQgmxNIm7y1bkeoIrsp7Fbq3ZZY90bLgjH6Vjab4NtLWcyWUDwNjJ3Hiu+FekocuzXVdfU05Ve99PMjTR4Eugdhcr0VTjI9K6/TpFtbQxBQuOQB1WuZ1DT9RQZs59sqMMt1OK14cxwbpc+cwwWzkVz1/fSu7hdMg8d4vdJt4UcKz5+Yf1rz/AEHSZ49RmE0UmHGCSePwrvLtEuLVk3Dz0OVz6e1RaehW3BlPygECtKNR0abhEKtKLir9Cvp+kJbvvBLY4UZwBWta2jzXyKqeYoPPoKgS8QKI1GZO30rtPD9kjwoygYYZciuTEVpQXNIi3sY3sLodqJpZWaNUVDtGRxWsbGOeJ1cD0Bq0IljwIxtT2qZUGOK8SdRyd0cM6rbuYcFpGrMjNubpk9h6VQkTynZcAoDx7Vf1hngmUwjGepqoNpcBs+uPf3reN37z6m0Hpc47xR4V+3yC6t1WBwcl1HUVkPBLpsGNrFOm4eteqzTRyW/loo3elYmr2cKWLqkQ3ye3SuyjjJ2VOexrCak/eR5U1st2+7PQ8jNTwTPpEy3lkfLlT76YyrD0Nacum3FvNmO3Kx/xHufeoZoj5RjYYGe4616yqqWm6OuK9k7x1Rfn1S21qBri1UfaePMhPAFNS2j8qN0hWIg5GOcVgzWjQsJNNby5wOQ3RqfpmvzLcfZ78eWzcAHp+Bpew9391t+J00ad7ulK67dTv2lFzp6OeZB8pHr71jXY8lSVG1l+8T3o026TziGYsrdB6VY1CEPHICCFI4rz1H2c7PY4+TknZmZdTG302aeE7ig3GuDh8Xahc6zb2xhN1DMdpfG3y67TTXCPJBOAynghu9RW/hzT9L1A3SsGByUTb90mu6nKFJSjNXb2MsTSlGorbEd1dxQuqbWPHGaiS6aZSgGGHf2qLXNag0xyt3CZXbAUBcEe9Jpmo2tzatcWhOT8pXHIqY05OHNynZCrTS5epg3EcmlazFdKreWzfN712nlRXNshO0o3K+4rBvLT7WFSeQu2QVz2rStbaTS7yPTrwgJKA1vKen0qqz5or+ZHXWn7SCkn7y/Ixru3eCaVolOAcnA6VYgvJruNQ0br2zjGa63+zVtITvdSrH7o9aEt4Y4x0Ib06Cuf60mrNXMXjoyWquzg7pCJ8SIRtNFdneW9tMo3ouegxRWkcVpsbRxsGtSOfWmkQW6TCLH8WePxrF8dWkd5pEF1HMsrR8MVNcx4hhuZLA/ZZMuT86g8kUeCY5b2zu9NuGKsBujduOfSuiGGhRiq0ZbM8+MpUasVGO2tzHhtHAJZyoPIAqj4gSFIEa4j24/iJro7O2k+1SQXKsHQ/erO1fTDqAkgmyFHQ16NKS59T6Ccu2pX8HNYysY425PUnvXV3BtbT5mYAdDmuA0HQr7R755WGYewPevQtE0VdevoVumxyMgVOIcISc29DKnJOHPU91Gxp2taRbhWt2iRh1wOTWnZaja3su63cbveuS+JOlWPhLUrcxIQkycZ5BNZujXhLJcIyqAc8dDXOsNCrTVWHUzhToYiPPSlc9itpWlCvcMTEvGzsfevRNPdJLKLy/u4wBXk2l3qyw/uplcbckeldd4c1J98UZOxWOME9a+exuHdr9jwcZRfToWPFvhy31GFnaMFxyDivGLyCGPWZoYQC0GRICMc19F+ZHc7kU5PQ1ymveFbVkmuRCvnN1IHWngMb7J8kyMJivYv3jzbRPtd1bMpIWEfhxXb6LpltaR28iKjSfeNYl7p8kOnlLcbSOSfSnaRfs0McInGe7eld9a9aPNHY7qknUi5Q0R0Ou2MDSmS4QeWeQcdDVbTdIDyLJbqDF6VujyNUsFs0cPcBMn396v6DYrptoUlYb165NefKu4Qt1OP27hC3UtWcJt7f98qgHgCsTxLefYUAjkDMxChM9Kfe6qHcqz4wfkxSwabbX83mzYZxzyayhD2b55mUFyy56hr6fBDFZBlAy43PgdaZOqQfOzYT1PSqpvhGTAgAVeM1j+KNQdNPjSF/MLHGMdKmnQnOdn1JjTnOe+4zxR4qSEra2SGQKPnIPH0rM0a4S5mkluCFd+i98Vn29mUbMnz+YeeK0H063t4Rd3GQF6bTjmvU9nTpw5InU+SmvZ09+5LdQrfanbWSHarnLEddtcd8UfCNzc6jHPYsnljEaOW/wBX+FddZmS1aG7mBR5ictjO1aryWpS5utVuZWls7dS0an+I1ph6k6M1KD6W9XcxxEL8ql8K3I/BMdxpWnfZZQ8vlD5nc4z9K15rm28szhXYE4w/OK5S38f6U9oxu0MV0hO2M9Hra07UYdX05polMUbnGMfyqq1CopOdWNrsinUhOVomF4vultSFRMu6k7VP3R6mtXwfqkV/4dXacPESjA1y3iu38u+nivSzWs8Y2SJ3x2+vFS+DzJb2cirGwikbIyOcetdtSjGWHVtzphVnV5oPodK63lxqCh4pAi/6sj+Kux0d3ilZzH5SuuNh659TWIL1zaRMisNg+9UkV/K67nJ5PLe1eVWUqitayOKdGUp3Z1KNFcwbkYOqkj8ayvsLTzttxgHOfSsuDU0jleO3kUjdygNasWpIF3gY7ba5HRnT26j5GttSnd2U8DFgQR13VnNFcXDFG+YZzwK6Lz4rsAsdrL/DnrWX4pktbHw3qVxqLyQ2SwP5jQsVkIIxhCvO4kgDHOSMVSquK13CM3Hfc8v1zx9Dc+O9O8G+GJxLdeaW1K7UbkgSMFmjX1Y42k9s469PRNOuryexmiuXVzE21WIwcV5x8Hfg63gvUrrXb64RpLuzEaWzjL2pZgzIW6MQFUbgB/FxivQruJYbjCOQG5bB71VCTqRanuZJSlPmYhvrZHkLtlyMMFqQGGazE0Db4s4Ixyp964270PW43lktY/PjZ8h1bt710ukxCy0zyb+RRcztuPPA9q7atGEYpwldhCpNzs9iaOyW4vFV9oDcfSsiSKaK+m09nwYyTGT0YVZvvEEOkXa+bH5gzy3YVP4lnsdc0m31DTCVmgb5h0x7GhRqRa5l7r6noxqpyVOXUpaUbf7fsujtHQGuv8M3sMV0YIHJUkgZPeuI8lzGN69RuBFaOizpFcRecpXDfKw6596jEUlUiy6kVOLTZ6wFBXB71EilZCFYkH9KqWNy8kTYwxAGMGnXVw0EAPRx1rwOV83KeRyu9iG/USMRgELWSV5yf/11M8zxyMuCyyDcG7imsPugY9Qa6YrlWp0xTRHFJ5ZLEEnpVyGFbqFy4wT0qg/I2k5+lXLW8SGDYeopzjppuEr7o5bxAJrOR4o3JbbuLHoPasOHT3vYmkdj8vA/+tXZ35+2Ft8AK+vrVdLFhG22RQhIwPSuynX5IeZrCo4ep5Zr122mu6bctjhs81zem3EGpl/MmIRThmb+Fq9Z8ReFkvUMjxAOerA9BXnmo6Mmg3nllFkDkFVVc5Ne1hMTTnHlXxG05XtWg7NF/S7t0mCM6sYuAwP3hXb2s/mQfd3o4/EGvJL6C8tdWt54ojEWB3xdQR616J4RuN8flTvtzWeNoR5FNanVUksTQVePzG6zYSeUbiAEvGcsB1IqtbamkyIzqTMOma6hogGmDEjt+Fcvc2qadqKsoyN2RnpXJSnzx5ZdNiqUo1oOMt1sc74702/1ciW1C+a2N3HI+lVvCPh2505JZpmLMcZXnFenL9kmQSkbJMZPpUMs1pg7k4PBxVQxtRU/ZRWhxJQUr21Ods7bz7kyLwD29K7LV9Gi1Hwm3mn/AEmJN8bnqCOlcLqviG00lGEcsZdW+6TziujPj+1vPDx+zQ77grsVF7mscRQxE4xnBbM1nVbqQjDcZpt5JeaJbyTL+9UbHX1I71XnmYhAM4BwR0xWfpmoXFrpuyULvJLkDsTV20uhOg8yJdrfxDnmnKm4yk0tLkVKdpu21xz5EI3K289/aipmaIEHzQNvBDUVmr9hpNI5YaVC8aSpZ3Qc9SW4pLbQxFd+dNPcJnpubIBrvdS1Cz0yAPkNH/CBzmqwnj1GCOYeWATyCK2ji6rjdrRnasfVte2hz7+H5Jo3ktrpZJiMjI6/jVe20eaR83EeecVtTxTafMJo9vlP2z0rrdBs4r/TFlbG5Tg4oqYqVKN27pkPGSjG72PPNV0fbbnaoynJNYXhnVpba6kkjUBlbGa9U1+1hFowiXa5+U5rx7X9NawmkTeRHKcgrxzXdg5xxFNwl1OjDVPbwkt32Ol8cWMnjLRADNELuAbo8njPvXnWlmXT7ZbW6UGYHDY6fhXQ6VcrYgnM00u0hUXPJNa+geHRPP8Aa9XjCkZcI1dcGsPDkl8K2NcHT+rOVapHl8u5veG7ZI9NWRVwz4zmur0W8ggjneQgyxcxqTweK5l71LtdlqAEUYDqRtFY1y0glVrGbzJUPzIpzXnzw/t2+fQ55U1i7+9ZsvaZ451QeKBJI5aOSbyxB0A/CvYtV1GNdMaUg5C5YenFeReFI7C91E3T2flahGc5YHH1r0yCe2vLaaPdvkAw4rizKFP20XGFrbngVcJPDtwnucLq2tJdWEwhDAkEDFc/4Xv47JTHdbzJu6EdRXoFn4fgjaQbBg5IwKoPodk85LxDeO4FdEMRR5XBLQ7cHWjGm4VSrY60y6qstmuHA2jjgCtW91BoxturoiWQcc9DVa3sLeMmSLapB455rG1uGa6vdoiTGRtfPIojTp1J6K1icVWimvZo34rSaGETTyea3UAntVNo5k3TwSyb2OeDV4y+fbi3hDytGoUso4zSW6iG2KEMHA7jisoyaV3uaKpUWrRSj1S6KkKp8z3q9CrXFpvnOX64PWq1ucMrNgEHqBV/zAvKRySgDrjA/OnP+6gqSvpGNhskaxBZ2O1F/Wo7eG51O4XyUZ4w2VRjwvuay9Uu5ZZoojKPNdgEjXoK9J06yNnawGIDJAL471jiJewim93sTU/cRUnuzm9TsrjTgkk06shPz5GAo9qxtUns9Rt3t7GZpRt/1LcBx3I9a3/HVrcXsS2kJ/euDtXP3uOlcP4esr6S8gVrCa1ltZMyySDjaBjg962wqi6XtZS1RwV5zlyx7nEW0fna9iCxQ2yOECgZP4163BbSZEFukTKoGxV4A9asSaZptncSXVlbqb6Q9AOB6morMRwrJLJIyTNw2T0+lbYnF/WLOKtY2w1F0029yrqltEZPIkEbFB8wxkCqkcUNuSSyYH3SD+lTS2AuLotE7JA335G6t7CrY0W08smElvUNUqcYpJs7FOKVpM5nxf4kl0FPLtYd7yY5YZCZrP8ADfii51a8Flczq0Ug++ibRn0rp7jRtJ1SXZeWivjg8nP86zbnwvpumRM1mZYkBzxjiuqFWhyezcfe7nPKmpNtzt8irrFzb6XJGbcjzvMGGTk816KlgU0+2lUEkoC31ry2z0+K8vsW04WVDuKtzmvQP+Eqjt7WOC9jb5QBuXpj1rnxtOT5Y09WtxU6HIv3b5rlu9j8qIyMxDDtXMLNJ4l8UR2+5pNG0ORJpwfuz3mA0ae4jBDkf3mT+6at+LNeB0cHRlFzqFy621pCehlfoW/2VGWY/wB1TWz4Y0WLw/o1vp0TmUqC8szfemlY7nkb3ZiT+NeZU2UZLUqa6NG5II7ywYrgOnORXA63qkdpeOm07UGWYjgV1UkktnMNn3JO1YepafbaoXZLjyplPzYAzj3rbCqMJXlrE5505RXumRYa7Ffv9nAbr8jfwt7VHqIea9jZsPEnQDqK0LTTrOzkLI/mzDgORgCozb8kgEc9a7eaCk3TVjWjTdrzKWr6RBq9kw3SRTqMLKp5H+NQ6FptzpFjc21xKLgSjcjRjj8a6e12xopO3BPzDFU9SzY3Ecu4BJTkRj0pKtNr2fQ2vGMuZrVGZExjsz83zqOV9TWBY6tcf2xHE3mNvOHGPl/Cuimv7K8lc6eMyRnDqep9eKn02DTLgPd26KkwOCh6mtFPkT547/gRVXtV7SD0Egu7+wvcpdFI1GVXrya1/wDhIrs26tcGOZQfnAGDXMLI7aiyP06knvTbl5oZMFflNZSoxm1zJXDnVRc1j0vT2S7gEq8qwyh9PallVj0Ull7+tch4U1hrS5+yzS4hf/V56A16BFjYCSCNvWvJxNN0Z26GUrxepjY3FjjGetIynGDTnYea7DkZ7UiH5vXPSpKLdtAptmOOVPSqqwo05+Qrx07UT3It1ZVJGRyKltp1eNXbGCOKhqS94nuZGq66Le4GnrETI5AOB2rlvFektHfhpSVG35WzjBr020tLaVxcywo7A/KxHSsP4gfZDp0nmjdIoyuK6MPiFCoowXqOhJc/L3POdM0hzcSG5ImRlKhsdM96oaHNNBqM0bnhHKFvX0NbttqK2tukcsilcce31rHwYtXmiAXY/wC8GOte1Bzbkp7WPRwjVp0+h2kUi3cJYMAwwD6mq2r2kO7aylnAyD/SsHTtTQXBETYYZJyfStO01eG/kVVJEgPOTwcVxSoThK62IlTlSleOwoKpAU2kf7J7VXmKxxBYzkkZJx0puoantkmbaAVGAB3rz238YXUniJbeWNlh37SuOTXRQwk617CUOX357HnfiyDU77xuYY45PLLgdOCM17Zo+jLpukxRRqA4T5mPer15aQ290hWON95DK23ke1aP2WV0BlIwRkKDW2IxjqU4wWiQKnGnJyX2jHt0VoGWYbVPXPpWabxhKYNPJ8od/esm71bZrskNyxW3VsDFblkUvpfs1mqpbnlnA5pOnyLnlsz1VhlRXPNb6+RXlkmuZgEDtIowx7GiuptbWDTwsSkOx74orlliLP3Y6HLPGqLtFaGAIJWX944dQM4ai3ult4HcllhH6GorizuobvyMMy9C3tW7daZCdOa3EuCwB3dK6HOKspO9zXFVUqdo632IrPVrW+t2gkBU44YnIrofCutW2j2UjXUgMJORz0rhtE8MXk+oKU4t0yWkHSma3C+pNPpsCi3Cr/rAfvD1olh6NWTp393RvyPIfMoeze76HZ2fiex8Q6zItu4MSglV7sap6vpFpLcp/aM6w852NjArmfA2gXGlXS3M86H7OCIwByR70eMLXU9T1lby13MMfKuOG9c1UKEFXcacrRS/EcalbDwjKKszt47Kw0uxkW3SGeSRflk4OKy9PF48rG9CsrfKPYVneF7S5tLWR78+XEDvZWPArptD1G11N5YYUKyY3KCPvD1FZTTpqVtV3NXUs06j95kOseGrW28PzJYYSV8syK2CR7VxXhpI5NQtreyhkW6R8OCeo/rXS6vJfL4wsJY0d4FQxOCMrjPer9p4esrLV/7QEpRlYlYlGPz9q1hVdKk4zd21der6M82casqql5jL2/t7fVDbxRN5+QoK9QfStuOZ7F/MmiaEuBu96w5IIXvTcK2btmyoB4HvWxb+fcNvnzMy8AHoDXPVUbLsenOmmlzmnFrtonzZLk8EKDmob6K2uYzcS3n2busQ+81Qy2JkIaRwoxkolV0SCOYqIQxxkM3JFc6hBPmhuY8tOOsXqJKmlLZF4kuJZe7E7QKqQB7lw2nxxuY/vKWySPxqfVkuZ4LcxcRl8HC8fWs7SLeWDxFIMEIvUD0//XXVBLkcr6+Zm8VNT5UrrzOi0zUYkBSaJreQHBUrwTWl5ouYD5KoR33dqyry/wDKtppQiu3RQRnmsXT7uSS+MU27Dnb8gxtNYKhzpz2sROqueyLvi22uBpJOmyKs4I8w4+6vfHvXPeANZvbXxBPpV/M1zpNzGdlww4R8dK6WeG9t7aZHAvLdjyV4YD0PrVGyk0+K2aG0hKnklJOoNdNOSdGVJq9+vYU8PUqNTT2KUt1DY63brO6PIj4Qeo9a9K03W0uICseCQMcHpXz94lS+vtYUW8UnmoMZ6Aj2r1XwWbay06H7RdQ7woWRd3Q08ywkPZRm9WXiHUqzSlF2SNXUILm61FbqSRtkIwAOMU2eSWe2WMzsqsc8tyavXWpWhLLbSRlcc814bdarrdz8RRtWdbaOTaAUwgTnkGufCYeVdNy93lQuZrlXLu7Hq15qUVskkNvjzsbXk/uj1+tVdGubeaRghEj9y/P6VUSxM9kEJ2yOd+fU+9Q6bpzWF2Z5n6DGc9a05Kag1fUubkpcsdjoC5V3BXJ6AVErlGZJNqgrlTu6mq8N3vlZxwo6VxN4l3f66oR5w6vwV4xVUcPzt8ztYmSdPRo66RgLtnVgPUVU1+5jksnijLMSMkD+ldFYeGXZlmmOAyjcD3+lTXnhNJrciEnzF5XB61ksTRjNXextKdKWkmeXeF3WHUkeC2ljKty8h7V0OrNvknkcFomACha3F0K5gjImtCpHcntWXqAENq1tGo2uclj1HtXW68a0+aIqEI0nozCtLiSNg9rL5cmflUnn8a6CXxzDpwij1IbpmHCx9a4y5tp0Mhtox5hOd4OSKoxeHbrUXa5kvjFIowSy5rpeHo1Nar0/E6pv2qtJHqOm+I7XVpNsnyEcqCa0fscDyNIo+ZuuO9cR4M8KW0Exne8lnuAeBuwDXbNbSRttabaOAPevMxEaUJ8tJuxyuDhpcry2cascEKO2Kq+ZbqGjaUfNxluMGq/iGR7Qhlm3A8YHU1x9zqkj3ym6iEUI4Xdz+NbUMO6qvcmcuWHNe50balLFMYLfZMynrnjFOurdr/yriIyMU6oOSD6Uzw3YB45Z5EVInO1COpPqa0iRaA2sB+YjJaiclGVoboUf3kdUcPqurxWM4nkshBdITyGwT9a6bRtPn13SoNTt28pn/wCWeNpFYmoeHJNZ1COK5VBZo253Iya9K0vZBZpDAuIolCqB6VWLrRhTj7P4uv8AkKlKdO7Rw91b6nps7S3tjI8Q485BnFEN/byRGYur8YwTyD9K9TgnWSLbMoZG4wRWfq/gjRdWjZlh+zzn/lpCdprgjmEL2qxt5ot1aT+Ncr7rY8wklNyw2LwvIxXSaBq9xbOkc8jtE3BVj0qjc6PqOi30lm8KTxKNyOB8zD1HrSqscoSWMkk8H611zcKsbLVGjVo2buu56GkEX2XfGQSwz16VBDHl1Gc55rm9O1aW3t3a5+WHbkZHapPDnidNXl+SNokLbVJHJ/CvMeFqJSa1SOFy5dGdBNpy3bqFJVv4h61rWFlbxIqKuSvrzVdLy2luhscrJGMMQOtV7rWfKusWsJdRw5x1PtXI41J+6iZOT0N8KoXCgBR2HSvLPiVctDbp5zhY9/PuM9K7d9UjtrAMQSrclT1FedeN9YsdS8uCFUM+eFNdOXUZqqm1dG+DpSc9jjNXxLbi8iuUiA+VIj1c1btvPntlkRP9K8noeuaLLThdXZa4Vcxthcjv60kl40OoSrCThOBX0bfMuSPQ6sDSk6knHsZ9jbSPbMoVlvJG5GD8nrzXQWmmxWI2LMJJCMkHjFXYLuW8iUMiQ8cuByai1CCERrLG2G75PNc9StKT5XobwcoXje5KZZZECRCBGHdlyazLjTi8omaOESKeHVBnNTy6guIEMZPYtitOEblBTnd0ArBuVPWw5SnTs2tDMuLp3t0iuFCshyJAO9cL4h1q903UyGndSXDIMnGK9Kvbbz7faVAYmuZ8QW+nxhU1CNHkXlC47VthqkVL4b+RjUUcRC17NFODR4det01KQmMyD5hjvXRaPHBYIsFuufVm71Ws7g/ZYlgjAt8fKU6Yq/a+SHVty9fuseayryk7xe3RG8qtZ0lCbukJ4g1Cz0+FJL2XDMflRfvUVw3jtL6fWsmNjC6hU2ciiujDYSnKmpSe55zqzTsegajeMr5fapbjBrHvL0W81vEyu7yuAQOgyah8QTv5ccgQvjrXS/Dvw7Nf3aXt9GViUBgH5zXNL2eHo+0n93mdPP7KF+p29zaHTfCUsdqgEjx54HJrwuVNbfWPtZh2QKu3b3b617h4y1aOytWSMkyEYUelebWRkuLgzSs2FzlfWssrlKnRlKS+IzwtBzk68iHR7+U7x5ZVwMEGn2V/Ib6EjIIfBAGQRWLe6y1tcXNvCESRgTvbjH0rktH1HWV1rdbyHAPzBxgEe1ezHCOUJSdkb4ipBNJ7ntOsWbXFtmDLLnOzHUU3wZpk0GprqNzAVht0IUkYzmrWgSyy2kbuRvYZ2nrTfiTcXUejWVvC7QwTj96V6j0ryYznUf1Xo+vl1PNxEFTnzbluRBeTS3NvgMWOcdKgRIoCzyMxYVgfDczCS5jkeQwADHmeua667tBdrIoGFJ+bHp7UqiVKo6cnojaNeTh8iFIbWeNLrB+VhkL1qaSQxyTLCVCcEKDzTbeygj06a2sZWNwoJTP8XtXl2kavdya+8TtIJhJtZOeOe9aUcP7dSkn8PcxlXknGMj0qa7P323AAYxWWdUjhnTIcnpnGa09WI+xxtCAezU7TdMi+12rTgOkncDpWcXCMeaSO+nGCjeZbGsWsNjGZCUi6kkVhDXFa5kMEZZScbh3FejjQtOmszFLaq8fZTWPLoayxPDa20cQQ8YHUVy0sTRu9PvMadShd3TOWkv7cqkTAhScnjpV1jYRYaGQB3Oc+9Pvbe2DGBIlZwMMR2qpa6fGl5ExU4J4BrrvFxvqjR0qUtdjdsxIYnHPA3exqALbTRkmNTLzzirWpzJbQsIzgMOcdqw9NuEnZzG+McVhTi3Fz2MIRl8SLM+k28kKOp2yd8isfWRaaTaAiJPM6724A966hWiVQrfnnrWT4m05L+2VfkPGfn6YrahVfOlN6BKtVatFmd4duLPVrV8x+VcL0dTwR61HqMtyk/wBglAcD50cDqKl0GygtopTG2SowzdFx6CrMV7Z3NwqpIN8fQnv7Vs5fvJOKuvyHCTjaNZ6k9lubDZGAucis/WJTLcxxlyg6A1s6faRizuHR8ujlfbHamzWcd88Yxhl68VjGpGM2zWnUUKl5GppXh8fZFYSJKGFaVt4YtYJFmQfvh1PaoNJuv7PmjhuFAQ8KwPFdRHIkgyjBh7GvKxFarF76M469ad99Cm0i/wASspXjAHFOs48neF2r2HrVzA9KK5ObSyOZy0sQ3cCzxlT17GvO9bs/s9/LHKmWYZUjpXpRGQRXN+I4Imt5CR++jGQfaurBVnCVu5rQk72PL1EkErStGVjU8kjg1LZ3lleStE0bISDg4wCafrAkl3xzHEbjoKxdI0yb7fAsyH7Mrbgd1fTRUZQcpaM9Oc56cqNyziuLS6j8olVB545NdNc2zz7JvO5x8oHas29vLZb+K2Rx9oIztNbkUXmhQ52gLkCuCtN6SasFSpzWkYl9plzdAuzEkDjFcE93Ob6aG+tImSE/xnbgdsmvWZJRHhQT6cVk6to1hqA/fRbmH3sfxD3rTDYrk0mtDnkrrQ5PR/EM95FInlLEkRyAvIx+FTW15LfXkqtwQM7geo71vQaNY2EBitk2Iwxt7msqHSk0eKbyGOw5wG5IBrb2tKTfIrdjSLatY3LK+s57ORI22uoA5FaGnYhTO75SM5PeuA0e9hiuvKkDJLnlGHBGetdSZxHECGJUHvXNWw/K+VbMJQtodNHOSBnrnite0vAi8nLAZ5rzTS/Ecd9ffZ1jkR1zjJ4atXXPt8+jyjTwfPPGCT0/CuWrg7NRnoc84pq5sanqtnqV+sayxmWMED5hkGucvdLEV6WRxBI3O4dG+tc/p2gXzXiAROgcgvKTwD/Ous1pAsCQkltuBu7muj2cKMlCnK5WHnJaLYyvEVtcTaSyQfLKCMuvOB64rJ8MS3UE8lxcSbgmFUYxn3xXSl5hZo8Tj5BghuuKpxSwXMRCmMS87kyP0rSM2oOFrol0U587LMOtOb+Od2MaZwT6irOp6pGLuOa2kMNv13HncfpXKvpk/wBoY+eTBw3lnsKt3a5sWRRuViAvsaUqNK6cTaFNN3ZuXmuQz2Qiikzg/MQOprgdcsnh1KO6igYEDJYGuisNO8my2ufmJyDjvUWpCaK3/eup3naPU1rRcaU7QM2pKVqT3Kolae2ijtQDcTDL4/gXuTVXRtLae4lkY5Td371t29vFpXh6W4X/AI+pzjnrz0FT2Vr5drHuXtkkGiVflUuU9CFT2dPlj1K1+v8AZy7mI2EfKcVzZuJrxi54UcCumdI9VuPs3mBkU447VorpEEUe2PaAoKkkdfes4140viWrNYVYUI+8veOQScDYj4yRXQ+H2XPzKVB7+tV9a0yNoA8G1gvp1FXdJgmitY5CQGH97tSrVYzp3ROJqRnTui5rhh061M8zFFxnNcZrSw6npiXEbgsDgfSofjFLcxw2rEu1s6ZbGcZrG8CafcXlgZmZzHnMYY9avDUFGh7dy1v/AEjyIVG58vQ6DTNOeOxEfzKTyOe1cB4x8H6xqGtxXemzXMkY+Vo0k2nr2r1uOJoF+dWyvf19qrTedBci5B2A87RRTxUo1OeJ2K04Okxuk+CdXsfDttLNd+dcYyYpfmKjtz60Vz/ibxpqFrqkcMU0qps+RcZBainChi6n7zTXXYcI1Ka5ZJM7Xwrpseo3QaYKLdByWOMmu+nuIdIsi7hUQDC46V4Z4uvdSsLWGK2tpnUgbVTu3c1Hpd5rd1YRx6vPJNCvIj3ZZfYmuetlrq8tWU9H0M3GeJrOCVorqdrcltbupp/MIVc7SeBiuIl8XW1nqD2YgZtrbSy9a6S1aeRUWF2hhH8K/wBTUNxoOnGRrm5ijyOXcDk110XTheNRX7JdDqqXhopWS6GdrGsWcWoWJbSVntGALTMuc12L22iavZxzxpCs6jCKOMDHes7QZrC+Q2vlAKFzFk56VsS+G7GSOOVN0cjfxKelZ1qkYyUXeLWnqYQdCfvNvcZpEq2pQsu4K2Bius1a0S8tY5ZVWSJgNoI4Fc7ZabdQShA6TRD+M8EV2VwQLGGJdgG0cHivOxEkppwIxUo3TiznJrOOBE2ARofuhV4qSDEEEkrruCqcn1+lahMBQW1xl27E9qz7e4+yuUkQyRs20Y9KlSclqYXbVihbytBEkpQDLZBB5FTR22lTXUt61rHHcP8AfdV5PvTbqPKyrBg7H3Y9qoiVrqdba1QtLJw3tXSo8ybvYuMOd3LUen+bOhjOI88AnrW3bR/ZJAJkwAeKfY+H57W3DO4aReQCelSaosy26+djnuK5p1lUfKndBKopPlTujoU+aFGHUjjFULvU47O7hidCxlOBipdLuA9sgJAVR1rL1hkmvoHyNikgmuKnTvJqRyxj7zTHXGk2qXsrQj53G7aTU1vp0TXEZEY+Ucg9ql8sytFcRZ3L8pB9KvRgo+8jjHUU51JJWuDnJLc4bxFaeTfNFGTl+1YS6VeWVx5tuwMbfeFdXr8UtxqckyAjYvy+9Ysd45TyWBEpPzEjpXrUKkuRW+Z6NGpJU1b5nOatq14soARWXOMHgfnStqc8ltskYk5wFXmug1HQAtqZmQuh+Y9smsnT9Nee5DIgSFOAAK7Y1aUoXS2Hh6cIzdVvQ2INJI0MohPmSDJFcpYaNOur+Ztl2Dhgfugeprd8T6xNpZEdujFVAyB1NTRanJJZwNc5VJSNw74qKbrRhfpI4n/tFW/UtWqFbqRYXKxkAk9iav4O7kHOaz7eVRe3LFhnPyg+lWZLpI4988gRByX7CuWcW2bVW+Zkgure5uTbNMiTL0Rjgn6V02gk7mBXacc+9eFanc3fifxHatoUk6RpMEllTg7Qete16aWtdQt0EjSqy7CWPJ9zUY/D+yio31avbsccZucWuh0pIAyegoBBGR0prAnAH406vCMAJwKy9UhzIXZMo67WrUpkwDRMCM5FVCXLK5cJcrueR+IrKSK/YRcqOnfioI8x7FdMPtOH6c10fiSI72Eb5ZT0HasGVJWj+dfmU5JPWvpKNRygrnr06nNFGdpWmyxagby8wxHTJzk114vUZxlwrAYxXP3179ktQ2P3g+6GHFZwm1G/1SIyKjw7SzOg+76VtOm63vz6EPkhaD6nXSXcakEsD2x6Uvn7iSuNvrWRYywuzrImWA9P1qtqGqraMRGSxI5VRmudUG3yxQ6kVDc22wwbnNUJx58oR2yM9KqafqPnyx5cksvzDHStRDlCSoLKf0puLpvUUJJ6ozb2xSO4ZTGChH3gOar6hqC2OkyuVV/LBwG7mtxZVLNIFXcRgg1Rlhtb12txHHKOrA84pwnf41ohuV1Y8+8O31xa6uJhEHSXA255XNewaVeRRhQWPmdSKy7PRYbdStvBFGpO4kLzmtVbP93gd+4oxmIhXeisYxikrNjry4iBM0RO7+6en5VQNtLdBRIjFSMiqXjjxBaeEtBN1Koe5bKxjrzXHfDn4iarqurst8+61KE8pgD0FRRwlWdJ1oLRd+voEZ2doRudL4n0u5TS52tnkEu3+E9a8/0a+lctLKAky8NGeuR6V7j/AGrY3kDxyIqtjtXmniDTbSG8a4tYo8qc8963wWIbTp1I6nRTiq+ktGjoNNVZ4IhcHarruV89PY1NNYRR53yoyg5xntXN2utLcwqpj3kcfK3Spbi+iuJ447d2QkhWBPNTKhPn7Gjw00zak1W2FqptIWuIByXX29Kgjhku1Go3kISNvkt4ieV/2jWvBoGUQRDCEZFR39s9wv2GM7J4SGbn7wrmVSCdo79WYxdOD93fuYmsOJdRggfaEi59iRUpuBFYTPGPnxT9XtHSRJGjK/w5zVe0KBhGVG08HPetdHFGra919Ec3Y389jePNFES0gx9K7LRNUtrqIJdFhNjByOtQixgib5VDv/D7VOLONtzLEit/FRXqU6i2+ZpiK9Kt0s+5HfiO2jLB9yM4Bx6GrLokYVC25SMjPSqi26zM6tJtUcgHvUUF08qeUFLuhwRjtWDhp6HPKLkrI04ra31O3lt7uFZQoJRT0zWEbY2pGzbFGDtRVGBWtHqEkQZILZtyjJ46CsO11y2uL8Qsnzk/dfpmlThUu7bEwoT1aWiDVNXmhiVEG5h3I4ogkinSNpmO+T0HSuxktIBbB5YI3OOmOBWNHGGmdCqww4JUY6mpjWi1ZK1jKMrvTQ53UtPilffFGjFOVL96K4vxlfX8eprLaxvmN+FRqK9ehhJzgmpIHjpQdrXOvn1H7Y0ZgyAwz+FXoLfzlHljYo5PH3qydIsVheOAyqZ+rrnkD0rqyyxTYA/d4A4rmqSUElE9GrP2aUYg0J+zrgKoz06EVjXenXaajPblmaCWPOT0Ga071JtRufKjJTA+92FdHp9nPHZRCeMXBjXDMPSsVW9gr9WclWFopt7nC+E9Gu7PVDLcncqAgE8cGs2LXb2DxFcxxlvlc5Dk7QPavQ5pYftcaDAkHVGOKzr3QNOuL17h8rMeSoPFdMMTGUpSrR3RxTpNKPKbOjXv2mKGQrgMMmma01xI6LGrFMYGD0qGAx20QaVxHFEOg70/T7+G6kk2yZP91u9cSi4tzitCpxUvdkbWnyqYYvtC7pNu3cOtSW8hgunWRF4G7pnisuaaWBkkVDtJ64qvd66tpfCdgHiyFkJ/hPvWSoSnflVxSSirm1DDaT3qtG+yWcZHpmofDWivDqdzcS/6xGOBUFzNCjW08LIEdgwxXYWtxG8Alyu8jHHesK1SdOFo7MbqShGy66EkzZAU8E9c1l6woaNVzu71fkyYzJkb161QkQtA8h6EdTXNSVncyp6O5n2y7QRuO09hVm8iimtCBxgZH1qtARwD68Zq48auEjU+5x2rpk9bm8tya3uYxDF5u5dq4PvVyxvo7gYjBAUc5FZduSk7RSbSByvrTPOMN2xj6Z5FYypqVzN01Is6qnlvvQH3rlfmj1CT7QnDHINdrlL+3IRh5i9azNctoG03ZsH2jOA3cGtaFXlfJL0KhNJcrMS5vDeL9itXLLgliT92m6Xi1SS3uZEj2jOTxmtXw/aQRlleH95t+YnvVbxFpUF3ZMeQ6/MPb2roVSHN7LZG0Zxb9m9EZ1za2monzGG4pxn1qve2sUc1mgGV3crWT4f1CXz5ICdqjgZ56VoarfQ6fAt9ezJFb2+ZJJZDhUUdya63GVOXK3obqj7CrZlTxTqunaEDd6vPDa2qxKWeRtoJHYep9upq54d1C11XRYboQsIJ18xEmXDFT0JHbI55555wa+fYPBniTxd8ULG88ayX0+hPuureS6QRCSEMdkYjBxGWwCV4O3k819BWoVJ3dnUKPXisac5VY3aslt5nI25y5mrI1dOs7W1d/sVqkPmcuUHWtmygUTwsxJAcGsuyuUKny5I2XPQGthJUW1Bz+8LjaQOlc1bmvqS/I6IdKKzrW9cyrFNgluhFaNeZKLjozklFxeoUjsEUsxwByTQxxjPSsnxJfx2emzGU7QVOCTThBzkorqOEHNpI4q9vor3Wbv7M37vPXsaoX8kltOpkjzG/U5rn/D91u1CY7825JxXYefaS2yQ3Dr5hb5d+OlfSSp+xkla6PYqUvZtJCWmnRXQE0qlouMBhVpraSCBxbohy2QvQ1K24afJFbOHUAkEEHkV4l8RL3VYdUS6sri7aJQFdQ5XafbHWjC0JYqbjzWOarVad7XPR9WWa01SOaX5d+NwUdKr3Tme+ChYsv91Nwyai+Gt5e63o4/toq8qjEbnqw7VyHj7RdSsNcs7+yeQwGYeYVPMbDv8ATFdVKmnVdGbtJfiaVavPBNrVHcG3lghZzGI8HnA6VY0293FoZDvYjNVYtcivlSBt4kcYZ2GFY+1XYNOWAF4SWlPzH2FYT0VqisyYpOzix+oSm20yWVMB8Y9TWZ4LsLhryS7dn8gAqpYY3Zrd0yITlnlXcOmCMitdYZsEL5ccIGBjrWE6/soOmt2E1qWbOJmZgcbFHGKvvatLYyiIYYrgD0qpb3dpEFVpxnPzZqS98Q2tqpWJkA/vE15041JS91GMlK/uo8n8dadJcWMtnfxlwc7W9DWf4U0hdO0mA7SoBJJxyTXb6jexX7OXKMhOaqvJB5JTgD+EV7ca81SVOx6MZyS1M9Zn+aRI2AHU1j+I7qaTS7j7OuHYdAea2LhsKQn3WPOKox6bJNcsSSqkcVcOWL5mVypK8tDzfwzPcQaynmIxZ2+YZIC/WvQpII2uFfo+c7lp6aJELgM0YYk4JHU10C6REYsonlkLgLnNa4nFxk00ZxqRprc6LRPEIhsUSUZZBxkZzWNFrMcuoTSgbbidj5eenHasuSJrS0Yo7E9D3PNc94dttVm8Ws93mOwtl+Q7eHJrhhhafv1EcNa0J+71Oq8SmWSD57kCQ8lSQPyqvoEq3xCuwWSM/MP61yPxLhmOoCVrh440QFQBxmrvhu01mLTrLVVUPGP9dGfvGP1rdUIrDqTkk3sVh6/tm6MtH0f6Gz408RW+h3C29tG8ly4zgdAPWjwrrjasXWSMxyDowOQ1WPir4Yl16LS9R0pArGPBIOMj3rP8HaSdIcGeVTLnBAPC1jS9hLC3+3+NzJOcn5Gxcb21AQgZJHU9qv2MX2WXZcSCMueJQKqSyA61CVKnqCan8SJczWiwxhVI6HrXLLXlj3O6Su1Ha5u6vaK9rtM6yFhw6DBIryLXtPk0/VFeNiUJzn0Nd7pct3DZFJmV3jHyk1ymt39vqYkCSqHBwV/umtMFGdKbS1Rrgqjo1OVvRnTWutwT6Uu6U71TDD3rPsLozZDN3+83pWJpFtJD8siHa4/OtqJoY4vL2Z559SKdSjCDajrcmtSjBvlJJLKyeRn8gPKACG9DRSyXSW8bPCc4HQjtRWaU3sc8aUp6xRzdtDPa2wkIZ72Vt0kg/lXT6W7uAsrYXHU+tUkQHGcEZ6irMsUsgRUGBXRVl7Tc6pv2sm2dz4d05Zo3k2jaeDk9a1bWEW0xVYwqng56GqPhW5aLTxE3Uevetd9t5OiKSAvzNXg1Jy5pKWx5tVvnaexn694VttReO5iJhuIzncD1rm/EukQ2MCzQvI0pOGyeK9HH3eRgdKoXdna3SCK4XIetMPi5xa5ndImliJxaTeiOA/smK60wgzAy/eOW4PtUWlaaunSvc3MkbcevyqKva/pkumX8ccbk28vb0qr4m0z7V4fxEXkJYFkBwWr1ac+dKDl7si6qS/erW5r22vaVqLtb2Nyklwg5HY/SotV063l0u6kdMSMOB6n3rivCmjXCXySiBreOP5jv4Nd6l6LnT7wIQ7Rg7gRg1FamqFRKi7pWM6V2vfRz1s63NgEj3KYeCM9KvWcsoh3WszSALg/N3rg31aZdRubLO0zggYOAPxrb8LQXmnx3AvJdxmXCrnJHvXbWw/JC7fojtxUJUqqjbR6nWeGtSu5biS3upWJP3WJ/SuhaQvEUdsDOM1wUnnxW/nW5IZTx6mtbSNTudQjaO7KqQMjHrXn1sPd+0jsTUpc37xaHT21mkgLFsKvf1qVYhHIc5b3FR6ZNHJGI2fds5GasO/zlgcAdq8+TlzNM5W3fUo6hDLKzTW3yuq4J9aqIksoVPXqcc10Dsn2XPQkVhpqCQTETLxnGR3rSnKTVkti4SbVkjQtUW2YiJk3KM/Wqut3aQvbXIj3qWxICOlTBot4lSRSGHGDVG5vI5JWiIDwkYYAd/WinC87tXJguaWpbtrqH5pUm25+6GFPnuoHhkW4GxOpYHFYMqkp5SJgqMq3rVI3M0LiNlDiTgh+a6FhlJ3TNFRb2MWe6sNKubi/eWOG0iBeSaQ4VF7k1jxWt34tmi1XV4Xt9FhYSadp8q7WmYfdnmX9VQ9Op5wBck8M3niDWHu9USGLR7KXNpYo4bznH/LaXHHX7qdup5xjoXR2IikJIPQ10uSqSTeyN3N1JLm6GfcWt3d3VvNcNuKLkY6io9SUvaC5CSPHG+JVXqPf6Vh6hd3FvqF5M4kWaCUrgngqOnFdDaXcm2GRoyEnUMydfxrunGUOVkuX1qFlpYwtCvlluTLAkqZk2qpGA49cV6h4fuYpGeGYHa/QHtXBeJfOtGjk0qFEyCWcLn9Kd4V1K6FoZroOjgkgnrmssVS+sU/aR0/M5aUbP2TPSZgYrsFGz757VdtdQBfZclVP8LdjXn93rMzgM0meMue9VLfWJLhydzCFB19BXnfUZTjeRs8Np7x6LqeuW1mp+cM3XaOSa8O+J3inUNR1VbfDQ2IGfTIrcl8Q21zLCy72idzGHx0I9ayvHFkmoxRRwyASpyT7V34DCRw1ROcdfyN8v9mql4q5zuj67BDshX7zdDV3Vv7Qv71GaGSe3RMhUXODVHRtDYXCSTAOEPy8V3atc2dgzQKBI4+8RwK9SrONOadNXZ6GJkuSTkUfBpvoLt5ZUkgtzGQEYYy30pb+GF2jOoWzG4hbC4/iH071s+Hr29vbWRNQjTMZ4I9Kv2epWtnqRiaMSbh8jMM49a8+dWSnJpa+X+Z406cKkE47mTpdnDpWhSTziSyaSXdAncj6dhVfxFDqF6sVzaCOWULwjfdc/0NVfG2sM+vRwvHvhiXcuTx+VP0ye6jvbeOFZShTzVdzwfbFaRhNRVZ7vUxo17y9lLYzLe1v2mgS9g8gofMd1Pyk+1dtZSKY96yAEJjBqcwQ6jaSTECJgmSP7prmbGyKE+ZNLMIwfmc4LGsZ1Pbr3tLHo0oJprax0ljePZxSSyRq0OMgd6hfUtU1aNlsrcxQjozCmxW7PHFH5saxydecn6V0tpqWl28YtRPHEyjZuPQGuSpJQd4xuyalSFN3tdnnOppfWU6zSz3DozfdhTcV+o7Crd3pq3EaShpptwBwlb80e+9do2WQA53g8EVUtr0rdmDjJb5HFbqtUlqh/WKk17plLpSRcbWVTyST0qRoLe2VZHw+e+c12/wBnaciOUh1cc5WudOgKmqSB8lEGWUHiso4nmupMVOvz/GxbdLV4AwjXb1GRWL4lv10+IFItzSZAJPSuug0GOYLskbkdB2rP1XwxJ56RGUOkhwNw6UqVekp+8zK8Zuykc94auVuLFp5AdyZ5IqLSPFFhqd7cQJKEmhb7pPLfhUmvpqGjWgsNPtRPezHaknREB7muf8M+AbbwxNJqt5dy3OpXLEzyMcBQeuBXX+6knOXX4bf1sRNNtRhrY6l76G9uCtufuHD1VvtWi0W35QySs+IkPAP1rSsdMt2jeWHPluc7zwTWLruit4iVrS3uVhuYTlGYcGoXspS5ZfD1FLm9m+XdHS+GDpfi6MJf2yGeL7yDkY7HNbU+kpY3P7pMxSjYR7VkfDbQm0uR1nuEe8KYdl4HHTFbnxHS7TwxdTaeCLhF5ZeoHfFeZiHB4lQpP3enZXOWE5wT5tytqVvKmiNBbMcQNkr/ALJrzq91FY9SPkg4RfmHvSfCrVrpddeOa5kuLSaL94GbO01qeItPj067uWdfkcb1f2r0Y0fq1Z0p631OrB1oz95o5pNTuJZXnKEMp7Diu7t7lbqwVpm8s7ATk8ZrhPD3iXTry7SylhKO7bUc45/CtHxrLc22i3JtATs+8o9K2xNJylGm48rO3EYqnWj7i2OihmjnJjWUHPAAPevP/EXh28tNY+126t5Eh+cDsap+Cr66kvIywYeYuRz0Ir0Ge8+26eY3UrMvXNOUJ4Kp7uq6nFTn7S0loZmmzypGlvcDG0fK+P50+8jmRTsGVPJK9ahEpjlXeCwC4OelPe/cbVVSUI5bsKycW5c0TtjCTRZht2urfZI3lKgy2fSiiOSGK2jRJjM8h6Dv9aKi87uzsileCtF6CQZEC5G361dsfMkk2qG46H0rHeWW4vVAXKDv2ru9BsY1jJK5cjO7vWdeapR13Lq2pQu+pa08taOjzAmN+DgfdrpNNmDXL/KApHykd6xru6S1t9r4Jbpgc1e8PzB2CygI5G4DPWvIqpyjztHlTXMmzbmfaAeTngCmyDaNzYGKkBGcUy7G6HGea5YvWxzo5/xfAzW8dwCMIwrnbi4ZXBI8sepNdV4phMmjsdwHljO3OM4rhUuRqcG7+NeCK9nCLmpXfQ7qK5oX7Fq5mMllK6GRieAV64pvhyKeC3uXuFZCyELv6uPU0+2URqv7wIEOSQauW2oWt6z2gkXzf4Gx1rZtqLiloZSjFSu2ec6/oc2o3e7TiTcp8/1x2rb0XVotQgSKTEV/F8ksb8EYrZ0mM22rzKRkhSKx/HGnRtAdTtIfK1C2YEleN69813+0VWSpS+T/AK6HuurGvy0anyf+fkaGqaxb2mlSKpUyp0OeM1m+G9XnuMtLF5bLzn+9UnhnQ7XW3S4mdvKlw3lg9GrQ1exg0K52SSqHbpk44qX7GN6MdZHitVIVXGpoWrXUprHUPOD5gkGNmOlbsmqrKhaNwrAcg1w95qG1oQPnDHkgfdq8sMk1yPLchSBmsKmGi7SkdCUKj10sdHNrNx9nVI1Vhjl6zUujNcIk+FJPB9atPbCOFgG7cjFVoUhEoE/IQZBrKCgk7IzjKMb6GnPawxlisjKOuBVm0ihFplMZqubhJrAyJnaPl5702wG2La+V3HisWm1qzC8iB3aR22MAV6VSurd9oJLFu2KeLO6NzK8SkLnJz0qad3t4vndfOPvXQnyv3WdifK1ZkFkr7X8vKleo9amtpJPtCKQASw6iq8Ms0DEqQd3PPTNSC9mkv4TcIEfI4A60pJtuxDTlM2PEvhWxvruK+kV1m2gOqdHA9a5K+Z7W8dlTamNqr6AV2l1qErgoidupPSuf1qENEkrgeaOc+tRhJzVo1HddAwy5dH1M29eWbQ55IRiQJkCuU0W5uTqMAaUvbyZJz1z6YrprnXtOS4jtJpkV5eoB6VCdOt7S7a6gDuZcY7gfSvSpy5IOM477GdWjJ1VJFz7OhkJHcdKItLK20yR4BkBDKf6VNDLGqhjGxftxSR6gzOwDoo6Fz1H4Vz3n0NZRnU0ZgXluLSyECRrDEvO3HLN61QWK5uLgRKMb/vMecCtu9sxezh5ZZZgv3MnitfTraCBAm0lurN6VvKtyRvuzooKGDg3u2O8PeH1txvkLNuHpWpq1pGbdbcKRGRwcc5rA8a6teWa29vYuYZXXKSKOCfep9A12bUrOe21Abr22UN5irgOvf9a4p060kq7eh51TF+1qWkP060FoJIonLFuWJ/lR/ZomvY9x+Tggd1NCSM2prGmChXd6c/WpLzVbW2cpPLtX1A5NO9Tm03ZMmtOljH8R+Go9VbczYmXgMCR36irvhPSJLNXt72c3Eyg7Sf4RWgL+C7tM2jJKQMPjqtYNrdSwaqhRpAqttbcOoNaqVWdN027WK9yck7akt3Oz3c9tG+HT7wU/eA70y9PmR2ttbKVklOGc9h3P5VyPia8bTfFEN7Ezxtv2lTyrqetdlZ2zXEzSM5VlHykdBkVvUp+yjGXRr8TqhVc6TsrNEWqyQWlnm3U4T5UJYliR1PFYdlCt7fh79nKuuxY+RufsRXa2enQWFswdQ7SfxtzijwvpUQ1iSf5ndeV3cgfQVhHEwhCVvvOGNGai3zGXZaZqtlZGGRc45bJ5A9KksrdobyGWZTnPAHSu4u7Rri2Z0YntiqVvaA2gt3A3K2cnjBrk+uOSba16nVCqlGyJ5rryvL8iN3lfgKegpVtZI7kKz7nmUl/8KbpsDwb5GctuJzk5q7bw7tQV5JskjCgdq4ZSUdEcstNhbaCS0kTyACGGCG7Vj+J/Eui6Be6fDq12G1O6kEVrZQ/PNMzHA2r6ZP3jgDuRR8VtXl0bwZdw6VfyWuu3o+z6aIohNLLOeioh4PAOSeFGWPSvH/2dvhvrFj4o1rxZ4/juJNZidra2+1OZHZiMPNu7jHyqc9C3tXN7RvVGPOz3LXII5LYPGQrqOpHIrhpLcySyS3hYsflUHoBXeyTxzTtGyfu8YBPrWFr9hJJBPHEh8zadtd2Gq8nus7KFXkVupkW1zbMvk20obyx+8A6Vzc+uQWetpjCvuwynupPWquiJJo+kXiTq/wBqDHJYc8+lY2lafLqM080g8yVWysrjBx6V7dPDwTk27xIhOUZpNb7+h7faQw29okwP7yQbi/oKtW+q2ssws5ZA0jr0YcMKwPDl5/aOhRxPkyxr5bD0xVW4tZPPgjXO+Bg27djjNeG6Kc5Qmc1VShK3Ut3EelaHeOpjigErcFUAPNZfi+ze90ho4yrxlT5cme3pVzxRpLarItzbuCQNrL1/Gp47M2mhR2lz8+MsCBgDPpWkJKMYzcryvsXSm4z20PEPCvhu6j14+ZCVit23GVv6V6RdQC7hnVxlJBgg/wAQomjklkMUaFsfwqcZFL9lnjjy/mrAqklm7e1eliK8q0lJs7Y0Iw2ZhaVpVtpLu4+UD7oY9K2oY1u4/ORhtPAAHU1Hptpa6tcLEhdthyzOcA11ccen2exIJYmmj9/0xWWIrWl713Iu9Omko7hpnh60eBJLiJmOOFrH8Q+HJbbzXhH+j44AFbt/4w0/SbAyXTAYHCjvXLz+Nl1lTHZLyw2lSfWuKjHFTn7RLQzg6rkrrQydNjS2UEJlyfyorSMBji/eKdw460V01JKcm2aVJ80rmbp00dzGPK4rV0nWry1uCP8Alip78/hXDa/rMXhe7FraKZpSAxycAV03hOeXVtOknmQRjrgd66a9DlhzyXuvY0hXhK8XqdLNqSXIadnK84AxwKt6brULXUaQlkkVSM1ylohWaRSCVU5APatBZYkuoyAiueTg9K5Z0I6xKqQhH3T0W1vGMqvdZUkZz7VJqerwiSOC1IkmJzweAK5nUNdWy02EbDKzcMT2FDXthbWwu4J0cvjp1HtXBHDXak1vscXsH8VjT8SQtf2D8sox820965yxgitUEaqFz0PrWrFrqXLKp2g9hnrVS4MKTvI4CxDk5PT6V1UuaMfZsum5RXI9iGa08xXRe/b1rAazmsLzz2cRqvzMd3OB7VqPqUhV5VbZGD8v0rI1O7iuIniutyM6/IB95q9ChGa917dTVYNzabKvh/xxGPFklpdWZMNwcC4B5T6j0roNd1CyeO6gEyl5h6cY9M1ymj+G7Kwme7jgY3DjlmYmtl7C3uNjSIC/TFbVYUFV54XS0/A1hDklzVZa+R1vhuBNP8H+dCBv6jA+6a8g8SNq2pawxk3yzb+Nx/hr2/w/EP7FmtQAMDgde1cFqipbagVcYkB4OK58vr8lWo7XZxzisRVk3uV9JsgqRm5LCQLyM8Vs/aPIdWTDEdqgV0liG0ZeknRY0XapZn6gdq0k+d+8dlOkupt2N00syrLtKOOV9Ky/GkVzYaP9ps5ipL4xjkCn2O4EIcgjkGtK8jhlGHzJFIBnPQGsIyVOqpdOxyVoa2iQeHb9LzwrGzoWuVXe+OhIqn4S1G41DUJ47vc0R5VgOEOelatpFBbxrFbMoQcFcU8OlozxwqI9xyQo61m5RtNJb7eRg4O6dzSurpIQVQ5YevevPPE32+fWY/JiYw9SynBH0rV8Ta3Do6rLKhdm55OKXRNbtdXhMiqUlTkoxHStsPTnQj7XlumVeLfKnqWrXz2tInnCLJ6scHFcr408Qaho17ZCytlkkbkyPwoHt610T3aXFxGojOwHDmqni/U5LS6gU2MUsajKPIvA9q0w6tUtKN730Nq0ZUqau7Mt+HLzUboi+uo/LilX7p7Gt0eXKdkpIycqSK4fx3Dq2r+F9NbR3EDbt80KtgsPam+Crq6hijTVS/m42gvknH8qmeHc4e1TSfZdLGcK13ypGV408MTxamtxZQ/aY5X+8T9w13OmwLZaRbxzEsVX5s81znj281a0vY106UpZvHuQxruDN6N6U7wvdXmq6NPcBXaSI/OrKRn35roqe0qUISm1Zf1qa0cRTnN027M6CREZU6kZppsbcPvKZb+6O9SWUiyWKTIwcgcr6VOG3SQFRkE8muNya0R1tuN7DFtHiZCQNueoPSpNXiWK2a4G4MnQA9au3FwglRFAIH3h6Vn6qjX0BjjOG6qSayhJuSbOLENzWplRNb+IdMe0uCVvITuR/SpfDOitpc87zEs0w24zxiqGiaPd6XdyzXVxkyvwpx+mKwo/EV5bfEiayluDNaKnzKxC+X+fWu3klPnhSl7tr/8ADHGoqKU5LU9Bfac5UKU6H1rn9Xjt7pGVHZZCMEjjP0ro8pMIwhDo46jmuSltZo9QkjdJnSIloiehz2/CsMNve9mi6r2XcpaDpl3p+olrZdsbnLsc5P19a7aD7KPMymS5wT3qC3V2iUuOQvI96r5EMmG4DfN9KdWo6zu9zSFJLSJFqeh2F6n2TUIlZs74JO49qdY+XFO0bsPlUDHrir8rCe1JTBdBlfUn0rlY77/S5NgyytyrdhSgp1YuLex6FKLnGT69Tr85iOQBxwOtXPCbOfOkYYUErmudjnmuk2WC7gv3ye3tW7oc7QOtvMuwv0PvXNVg1TaMXH92zqtMcneJRsXPAPpWbdTRNqV0sfOeAR0zV+QH7MQWOG+WoYbSKKMrCmW7e5rzU7SbOFOzbIZLWaOJCH47gdTWd4i8QWnhrS1ku45Jr+d/Ks7SAZluZT0RB+pJ4AyTgCtC6uLmK1mmit3uZoo2KQIwUyMBwoJ4GemTxXM+FdIm+2ya/wCJnS48QXCmMKnMVjEefJiz+G5+rH0AADfM1ZilqbHhDw3c/aW8R+KnjufENwmxVQ5isIjz5MOfw3P1Y+gAA2tRIMiorbQeoHep7QOPnLP5RHANQX8Y8xGKEDPBrGCtIlKzGIiMY4wfmJwB6VoylGjVXjyelVY7dBOpZjkdKn3HaW3Z5wDRJ3YjzrxLGPttzuhGDx7Vgacx8yKKIiKInDKo616b4g0mS+fehXLLwuK4S2s5La7lLphkONuK9jC14ypcvVHbSqJxfcsafdNo2r/uBuik6g9BXn3jLxRqp1+WRzdRmNyI1t+QPQkd69AaFpt6uvz4yKrRrFBcI1zbo5H8RHIrpw86dOftJRu7GVei66VnZot3Xi628P8Ahu0udXDm8nQEoBgnjqfSpdP8Vwa/pZngVowh2sjdRWB480rT/EMcE63nkyxjYwYZBH0qLSNKTTLGO0tpTO0r4MmOpPSpWHoTpc7T52/kjGnTqOqk9jtdGEFtZSX1wVVZTtQ+1Q6nsa1mjaXaX5WqHjFXt7CO1SRUSGNQQ3rWfcasqpHHCRKQqjp3xXPCi5/vF1f4LY2pOVackloc74hnu/D9rHLDKDJNkZHGBXP+F9Xkn12NrltoAYZzkAV3OsWxvbQNfIroOSnoKxX0i0eDfY+XG3UovUe/vXqUq0PZtTWr6nZTpUormk7FzWGtdRjNuib2YcnGar+GtPg0i5AkDIrcktVBtQh0+6jhaceYvzMiY3Y/Gu1VBe2kE7Rb4CM7sdRWFVujBR+yxLGRnemtirqN7F5kgTcTjKn+8aK53xRrGlaVqMFhcTtDLL80RPQUVnTw/PFSSdg5YS1UrF/xF4Vsrt4r643SW/3YrhOh9mFR212+mOsERAiAwvpWvo+oWEWm3CRu8ljIxPlPySfUe1Y+qWsMvlvp3n+W+cxSJnb9DVwlKf7urstF/XR/gGHhzLmmrNixatG91LGR8xHODWSHuP7VhQK7c8Edq5G2vPEcXiBrddJaOMvhWIyMZ65r2DT9LR4Y5I9Qga62jcmznP1rqr8uE0et16/kJx51du3yZWnkmkk2SglTgEVGNJG8qkhCdSKuavcf2WqLqCxqz8h0OeKp2ms2LyM1s0k7dlVcgn3rlhzqN4LQ6aMqlrU/w1MvWXksbpHhZo0hAbe3AA9zXRW7Ta4IHhytowDZPG71P0pJdK/tiNRqMKtE5GIR0x7+taGvp9k0+307TmEcsw2HaP8AVoOtOdVT5YrddSKcPZzve7f4HN3l+019Ja6fGZkiO0ykfKD/AFrQ0+xijXzLgmW4PVjz+VXFso7S3S2jAVQvAHUn1Nc7ZvdQ6osQ3Sxu2CD2rRP2kXyaW/EqpiW9Ka07nRPGzOGjBKjgn0qF1ePP1q3v+yHYxPzdqNUQRwpKuCzdBWMXqkZxXvW7nSeGJ2iTe4G3GPc1heMreCSVryMjYv3s1Z0u8uPLWPbtBAxU+vaakFrJPknzQAytyDXLTSp1uZ9TnlCUKl1ucpp88cyYiycd62bKG4YAxoHbNc7aBbSSTaeWP4L7CuksbySNcKBhl4auuvdP3TplzqF5blC5uvLeQt+7KtzuOAK2dEu4NTRo4pY5AF5KngGuG8R211q9pd2sR/ft74z+NQ/CjSL7Rb24+37o4OhXOdx9a0q4eDoOfN7y6HJUcuZK2h6FBKkCzDCPIMgY7e9UWuVckuc9s5qzrdukSGSFnUP2H+NYRhYKCjA9yM9a5aUVL3jWnBSVyTXNOtddsvJlJEicxyYzj61T0TQHsHG6VWmYYwB2qW8vY9L06W/uSViQcKByx9MVn+Dtdm8VM8qWr21qhIEpbO8egrsiqipOz9xCUKcannubOl6fP/bEhibMGeC33QaqeIddRb/yHZJVjbHlOOtdUjKgTBVI06ZrmtT0G2udSec3KeXIcnPUH2rCjUjOfNU7GeInUq25DbtZLe5tbe4it9m/jYR0NZlzqbpcxxmKJSWIB2CnHUo7ZEhhjIji4yR1pJPs93ObkDAI5A6ZqYQs7yWnQqdCrypmtCLS+gVZIzGGPOw4wfWp9KJsPtNrKu61b7rMMP8AU+1Q6fJBIvyjkcYqa6KLIGUksRjBrmne/J0Id07SM13tdJvJvlzBINysOQfWpPPElvHcxAiNulYvikz6fFFMgDW2fnT0J7+1M0W6nRJLeZt1tIPNRuoB9K7FR5oKonc1jVvPlZ0VqoIfdyTyabKp5xlB2qOOZoZNqqdjqMmrchWSAlucVzvRimmpMytrTrHuPO7apPas7xL4Ti1gxGRlt7tWKyuEBLjGBXRWMQlDdNmc5I6V18+nQz2sTupMrLgYqZYt4eacdBV3FxUWcHolrBoVjDYLNJN5K43sck/Wr51C2kkAWJyw4zjrVjxY+leE7C0uNTkMUF1crbNcP9yNmBKlz/CpIC57FhnjJFyz01oLuKR1GW5xWP1inUbk9yY+ysZb3BEJJhdeeARWFqQkfzNzY3DIwK77UkRm2NFw3GcVx2sRJFMQmGC1rhqik9jehKN9EQaJMJofLkbaycfWsPxZatZ6jFdxKTA5/eACrmnusF8C3Ct6dqu6zdRXVqUCFhHyWI6+1dqbp1bpaM6Yy9lVv0ZY8M3EMsbGH5RjjB4P1rYvZh9kMmwhgchh2rk7G2fR9PN1uRrYncoHoe1atzrFslgskr/LIvyKvU1zVKfNPmhqjnrwUJc62OusNTinsrVs75M4Y1qG4QEkDGBnPrXl2ja0bJzNC++EtypH3TXcjxBa6lbxLGSD/E2ORXHiMJKEtFoclalZ3jqmdFp0KCPzRyW9e1WFt4QTiNcnnpWNpeoQ28LI0m7B71fl1ARAMyjaetebOE+ZnLyybLVwQkBIIAFZ67p5CznKqM0jTm727MKhp0T4baew5x0NCi477lRVkRySmRkKDJFWSdoBC8kdD2qNJEU5xjHtUEs6O5Cnbnqc1Vr6WHa5bjkBG1j+865Hauc1uyaCWS42b4SMlh1zWtDIFySCccZ9qtKrXSlCMQ45JGc1cZOm7jg+R+R5xLJly8J3KPQ81T1KYRWrSMM56Z6g1ueJrBdMvvtFqMQvwyjpWVqMUd9apIhCY4FerSlGXLJbHXayUonF299596gnBKhsFQMZrrfDt1HLrUMZQJHDlivrVGy0i2td1wzebID1PU0+1mW2uhMq7mbvjt6V3VZRqpqHY0prmT5tyD4t6xOl1EloY043tvGQ1VPBtwuoWW6VAJQ3zEDrXU+J9Ds9S8NJc3RIcDKsP4fasrwfaQ2tusSfdHO48E1lSqU1heSO8WTSvGLtsaOqWE1zpM6WhzKRwPX2ri9DtL+61uKKaznhMEgy23A2n3r0WXUrTT5Vkup0hRvlXce/tW1bXHmorSN5kbDcpTkGuWGMnh4v3bpnBVXtZWucNq/gWxv9aW5ETidBwy8f/rrrdI0mW209LRVO0Z+91FUNZ1poL2HMY4bA9QK6SHU4jGJO+OVxXNXr13SjGWqLlQlBqdtzx/4mfDyXxQUmjnSC9tjgbuA6+lFej6pdRs5k8sFcclu1FdWHzbFYeChBaehcqPO+axwGploNPc222N8jB28Vd8FXU72dxFKudhDDjv7Va1K3eG0ZUj3Z/vCpNOlg+wiJSsTkgkdDW85qVHlt1N5UpTftFqjbhIfaQoMgPdRUGqW1vKCzRCOcH5SODUa3UcUm2IGQhcrisSTVpprjbeIyKeFyOa56VGbd0a06VRvmj0K3iu2mvbSMhHmlhGwOvdfcVhaRax3DpHaRSQXOfLdQpHB7k13dhL5g/d45GOOn1qyLGGcNLbv5Nyv8Q/i+td0MW6cPZtf15mLpQ5+dXi/wOC8DeI77wh4vuNG1+Vrqwkf92X+9GD0Oe4rtrqN7nUZ7+I/u2O1PYVS1rTrTWLqNtRtgNSt1+Vx0dR6VYtXeOzRUOFPP/wBaprOE5e2grSaV10v3XqaUqcqabk7t/kTTWzvbvM+QwX73aq/h6yuZFaYAlVP3iKvQ3q3UkdpGd244Irpns5LayeCJwkWM4x3rmnWdNcj3f5GntHSjytbnN6lYOAJXkOCM1ZsdHNxp5kmnL5GU9qta7bTtYwlQSm3kismz1ma2gFsAvloeSeopqU5wThuVFynD3Ny5pcbSEgY3R8VqawFe1RZG56kVi2Uc4glndtgc8Y61rRQfatjZztHzE1lUsp8zexhVfvXucnqUcMMqvGCAf51Pb3KugQDnGcmsXXvENqdcm0zaCYm27xxz6VbtJY2HJ+TGMdOK73TkormRcU5wujFu/FWnwasttakyvu2u69BW3b3M/wBoRgQUB61yF34Njsta+1wy4tXbzNh6g+lbBu0sH866YLGOhJ4rpq06bt7LXQulFuF5Hc6zHdXGlRXVu3mRD7yryRXPQLLNNGAv7rufSn6d4kS3hM9lcKyn70Z5De1Zem6pctrMlxGD9klbmEjo3t7Vy0qFSMZabBSUo+7bc2NX0qDVjHbzIWhBB2j+dXbWC3sglnZRrFFEMKEHH41b0q6jinkeUq0jff4wF9qz7icw38jW8Ybd3HSs+aU/ceyMmnOVkUvEbutxBErsFzluatW2nS708udXXIJz0AqvcwyzTLJPz2ArodJsJbsDy49ipgZPGadSfJTWp1SqezppIuaj4dt2ii8o7ixAOB1q8vg+zS12xuVOOa2bGxNtbbZHJPY+lWIbYq2XkZuOnavGliqmylseZLEztZSPO77wxNpe67trw7FPOabrck9l4eN0pH2o/db0z3rofiE7WOhqYVJXfzWfbQrqGjqJRlQPmXHau+lWc4RqVNVc1qVJVaSk9+55N4eludY1jyGklaZnKuXB+Zf5YroPD2n3cd/qOkNFujt2MschPBHcA12NhpNraF2tI1jmb7znripXBgIlhC8DDFec13VccptxgtP1OalTtu9Tn9OneWaVGbaRhFBrRuJHtIQGI3L94A9RWVEoGtv0CzDcoHY1dv5C+QQM46kc1nON5I9OUL1E+9jotEtTPDFJENqynnPcV2UMIjCg87RgGuJ8HahJJbyW8oBKYKbe1dhHdM4VVTn+InoK8bGKfO0zz8TGSk0cZ8ZNC/4Sn4ceJNMCh5WtWkgXuZI/nQD6soH415z+yrqvirUNIutH8UQEWWnRxtaSXTFLkI4+VdhGWjwDtY46EDI+77lcMvzgsNpHHvXHeMDJo11Z+LNPgdm05DFfRoMtcWTHL4HdoziRfowH3q5+V2ujFp2ujurqFTbSBgCACV46V5xPbrLcMZCeW5Fek2lzDd20U0EiSxSqHR1OQ6kZBB7jFct4igjs7tpgoCmujB1HGTj3NcNNxbR5z4mf+z1eOEYkYgZPXFS6Q5ntthUHcuDVDxfPHd3sjAElFz1rm9H8QTW+sLalW2gZJ7Yr6anRlUpabnp1qkFSV9ztbiG5vdN/sUvsKNlWxnIJ6VzWsWV/pd41pMjMu0CMryVNd/oFwkGt2N06gRy/IwbnGehrB8dxjVfG2owveizjt4lMJBx5rY9fasaFZqr7NrSzb9TjrVYw5nL4ZJfeZPh2xvobKRtRGZZWyEHQD396uavLcaJAk9q2zccEGtXwjcYsYRqPzlgQWbqGFZnxHtL298hbKPfjoO2KtVOevyzWn4GTm6MHyO6ZPpevtexMk5bchBLDjNddpOrx3reTcS8AYAJ5IrzjwxZzRxf6ZKpkbgIcAn2xUuuSLpbROXxIfuoDjHuazr4WFSfJH5FQs4pzdj1mCzkMubKdlTGQCeM1eQXLSITCd6jLEHg15P4W8UG7Vow8kbJ1XJwfpXfaVrjTbYTLlJDg56ivKxOEq03ZkyWl46m01wkr4ceS4ODk1DNZ+bBNNDMu5OuDms/VLOKUH7TcfKucBTg1fsDYppzxW1wrSMnzfNzn3rl5VGKlEjmSWhhQeIjEShVQU4O7vW1o2vtcxOsiLnOFK9K4HUdOuFuJ45PmJOQy1JocdwLuJdsiAHbx3r0KmEpShzITXNqzutfUTWxXaHXILEVxctgyiRreUbM52Z6V6NeWOdEeGPhiMk9815vDuaeZBmNwSpB9a58HO6ai9jqw8rxduhWLlo5In+XeOo9ax7q92SbWDKFGOK29QjjsreWSUlyBnA6n6Vxq68l/fLGIQq52sCPm/WvWoQ57yirpDVeEJ2ZJ4i8Qaj/Ywso5GVHO+Ns4yO4rV8AX0lzaO11w8a7WJ6UT6ZHeWggcKULblJHK0ujac+lw3kCSBmJGMDgitKjpujKCVmXySlUbj8LOf+ItnfXN7BcoJDaBflKgkK2fQV6v8J0uIvB6teglmkYop5OK5q6a7txCijdGe2Mg11Hhe4u/tGJU8tcZ244rz8ZUlPCeyVrJ7nl1IL2rkiXxV4c+3eTLA4SRW3EdqmWIRwKuASoAJFdAy7xmTn2Hase5QI0gXg+lePCrKUVBvY6Y1ZSSi+hlXrIiHzQAT2NFPvYQYi8nzMBminKpy2N42aLOnQw37iWVMgDj0q7deHbC6w6xBGHUrxVuG3WKKMIoCN19q1AAVwBxilKvKMrwZzSqtO8XY5w6JFbRlrRf3g5Gec1S1zSob7T1e6VYpcYBUYrrLnEcLFOp4rnNbkaJUjkzsIyR3rehVm5p31NKdWcpXvqef29vNpc8m2cFVPTPaui0i4V0M2AQRyO1VdY05Li2ke3RiwUncO/1rO8JSvPbyRSHLxtgrXsTtVp8/wB56Fb99TdTqtzc1uYi2iuIsebCQ3A7elR6Tewi3IuUXYB1Part5Dv064XIH7skZrAsFgubbe0mFYdPSpgozpWfRmNNJ09ejOj8H29pJqVzcQoHkH3MnpXTalJmBmnHHTaK4HR5H0S8FwxLW7cN7iur1bU7e4sx9nYHK8GuTEUpSrJrVPqRiIOVROOqNhmFxp5jAAYDCgeleeapZi1v2z8xJya6XRJjbxhnkbzCeeap6pA82qFwS2Blj608NelNx6Cw8vZVGjL025uJdRAYN9mHXjgCujlzbQia2lV3b+HtXOZ23DhWaGM9VxitPRiJLWUOG2j7u7v9K2rxWj6dhSo8nvXPIfHVg6ePIbyLdtnYFwOme9bOr3EsNjLJEpLKvyqvU11Hi3S1Nqt4E+eNgM47Vy8uqWtsyRznJfhTXrU6vtowaV7afcdUOT2TSMjwLqt5qct1a3zPJARuVnHKGuh1jRBqOmvFFKRKOVz0NSWsUUTl7JI4933yg5at7SbUsrmT7pBIqa1blqe1hp5GdOi6cOWbOH8MaHc28MpviFjz93HU+tdpo2nx2dsZpg3mN/q1PYVMFjup1GMQxcA/3zVm4nEa+U+PmGBx0rCviJVXbuN+5FQhuVY3LTNEnO7qKja1nhG+PJx1Gah0+98jUEAUE5xu9a6FreY6htUfITnFYzk6bsXL93ZFPT457+5hi8nygCCxI616PHbxRxRogG0enrWPaWy283lIpYtyAOxrbSExoMn8K8bF1vaNW0R51epzPTYW4k2qOMiltJllT5ePY9aY9u0oAY7V7gd6f9nSNg0eVOMcd65Hy2sc+lrFfXLJdR02a3Zd24cV57pWpyafqTabeAxsvA3DqK9RB45rkPiBYwiCK/8ALHmRsAWA5xXZgqqv7GS0f5m2Hmv4ctn+ZjeNLuTTtJNzagfvcKGAziuH8M6vcXEsTATK7NtKOfvc9celegalBBqehwRv88LAfKexrN0zT7DTnMhYNIvAL9QPQV6uHrQhRcXG8jJ05OXNfRGRdl4NVQkYCvnOKuX08HmNF5o8wdADUHiJoysxyCrLlT6GuXE85t45ooibmQgZPTFdMKftEpbHp1ZyhCNVLTY7fwxcS2Vy4ZTgj5j6Cuzs5GnBWIkq3Oc1xtoGjWBpBhigLCtrS7yeC7AhG+J+Nmcba8vEx57yW5lWaqvmW50lwQIlXGHzgEiq9tuImExyuMAEcCopZzPIu8MjRt0qSS4QyMIwSBxn1rhSaVjn5dLGD4FP/COavP4TnOLXa15o7E9bfI3wD3iYjA/uOn901X+MF9dWunRpZR7nILE4rb1TSYNTn02WZmWaxuBdQSRttZGAIIz6MrMpHcE+xE/i22TUdFcHacLgkjmnhWqdeM5K6uZqPvI+d9M1Vr6YfaMd1YHita10S3kuIpxNmPOQB/Kta18CwrMbiNiCGyEzwa1ZtAuLDT5JiAIOpx1FfU1cXTv+7lY9OgouPLN6iXlwsdum5thXCqM+9Zvi/wAOW+tWSyvPIt1ncjq+3af61Qubt7qRbRiqhhuRj/FXQadciZEjlYMIxyD7Vz2lRtOL1OydFU4K6v5EWiL5dra2t9MC8OQjAY3H1JrqV0C61hUjhuYreNerfeP4VxF5I9tdu7qptyTyD29a6XwtrgggWR5AVDYwT1WssTGoo+0g9Tz6jurRSVjoIPhxpsNs7O8kt8OY5ycFT9K8v+IFuDM0F5Gkd7ENpDHAbHcH0Ne72er215ErW7gqxxknoa4P4qaZ/aluiQXKRshy7DG7H1rhy/GVfrCVZ/8AAOeFR1XyV7teW6PLvCdqIp5JRNuwMmMHIWu00q4ZZiY8kDqcdKp+E9Ihg0+QqD85wrt1fHet2JVtoSioN2OQB1r0sVWU5s6asadKTp01oaGqTia0UxLE7oMnn71YdvZm2Y31sXWORcGNhnBqWzn2kxMrHPTir889wUC+UpjHGB6etcavT91dTOVG3uogj1IbVc/Mw+8vvXY+G5LG9w8a4kIyykd65FdMe5zs2nPIGOtdX4P0ySxV3nUozcAVzYvk9m2nZnHUXLodPIF8lg3CkYrzbVoLeO8byzmZidzZ7V6NcQi4hKFiue4rzrxhAthqMQUjLjn1JriwDXPy33NMLu0jE1q1kuYRGkjKcgpIB9361nx+F3udRW9naKSRQBmPjNcv4z8b32kPJFp0AmMYw3mDqfQVveBPFf8AaKrHcW3kzuobjoT7V9CqOIpUeeK0Jnyc9up0Nzai0lRJCNrDt2qiEcNL82IkGAWON1WtQ1KNtQCyclfQZzVRtPmZpZZ2AR+QCcAVzRbUbzZ6UbwgubQqap4pi0y7W2+zm6wgaXacbB7V2vhy+E+nRXUBLwzqGTcMN9K4TWPBo1GdbuyvRA7RhX5zux3Br0fwfosVnpNpbMxk8oZLn+I1jjHh1QTi/e6nlNyVR32NJLx0H71eSMjHNVpWSaUnBBPTPatW9gjMRAGAO4rLkARQAWC148JJu6Li09UUdRLNaSKqguo5xRTNXfZp1y6g8JyB1orOrujeF7aHUylYoSQuQozinWtytzbrJHxnjHpWNB4ksrmTyi3lg93rJ1rUmN0bPSJQS/JK9q1hh5S916MxhRk3Zo64p5sgaV/lQ+vBNYHi2KFZorh5wMdQDWfp8N/l4Lm53Kw455BrntcklsZnS9DyJ/CTzXdhcP8AvNJG9Kj76SZ0tvqdvMvlwuuSMMMcYrm54F0jVPOjGUm4IH1p+hRSNEtwU2KxwDjHFP1/fJeQxxryD+dd9OKhNwT0e5vGKp1HBPR7nQWriW3bIXkEYNcA8x0q5lWVgIg5XJ4AxXcaf5cLoswLJ/dBrF8SaLb61BqESHa6YlTHrV4WcYzcZ/C7E0p8nNFK9ynpOtwatE8UeXUdiOnvU1s7WuVcZXPGam0DRorfS1FquWI+ZxxUj4yUOM9M1rJwUpKGw6NZxvGQtpIPMd/MYr1Bz0qWaK7nuRPaux/2QaiiVVULGNy9wBWrYCSO4MkGRtTIHr7VlOXK+ZEYhKauipqMgdlO0F8bWHvVLWtRms9EuJLdD5kcZIA9abqutWUUwMrLHdseVHQVaidbiMOyhkfr6GnCPJyuUdCW+eFkc38LvFV5q19c6PrY82OZTtkcYKmsTxj4YlOpOts+2SJ8EHpjPauuuI7SynaW2gVZjwSvWs26knvLyKaSNypGH/oa7qU+WtKtRXLFrbzLw9Bxj7+xlW2s21leQ2tywVsAMe1egTlY7CGFJYx5i5dweQvoK8hvtNmu9TlmmiItw4Ab1+ldnPFNaxxLIGcog4HPHpVYrDxvHlZpiMSndrp+J0qASFdmAAMDFYt7cySXD7QWI+UYrUt1b+yI3IKTFeAetR2DRpexJ5RkP3j/APXrhg+W77F4ZqzmyvZ6RdMq3DoQuM8V1WnSMwt3csONvvUkmpx3CLbi3kiY9GHQVd07TVEXmS7wxORg9K461dyXvqxjWquWs9DW0Xl5XbqT361pAiRu+BWVYwsirufLlj+VakQ2SMozgCvIq25mzzqm9yaiiisTIKrahaR31pJBMMq4qzRTTcXdDTad0cBcqumGbTzho0GVPoK5PUbWRtSikgdyuMAdq6/xeDp+rLdSJvhmG08VTC25XES4YjKNXu0KrjFTXU7muaKfcwNc05n0J33Eyx/O30rKs9Ths7IOyb9rYUhc7a6xgJY5Y5GGWBU5rktNjaKaeEeWJEYqFbo2On512UJqcGpdzrgnLDygt1qWYdXaa6DMr8/Md3pXb6JguGyMcMK4aHTLie686WTyUDZYdePQV0dhdJp97Av3lY4UGscXCLVoHHDnqOzR24jPmM4GPc+lJIiws5j4NTCNpI1LuueuFOaZLGSwU8g8mvDUrmdzOvDjGVZeeCDRaSh5khlDEE/dPQiqlxO7XZjlRkjByrVH9qb7XGS3yno2eldKp3VjTkui7fWEaTKyOqRE4wO1OFxplzp1zYXBJ+Uq5781G8UoQszZDcjNef32vfZfE+xoh9nJ2SMR3rWjh5VtL7G2HoSr3Ud1qQjQhpyMI4vPgVjslJyVFSxmOMbyBnvxXYWCKIDiMPA3OfY1zniOxkWYC1UogG7GM7q7oV3VlySNpYtt2kc/qd7HHGrSLuiPoOcUWscN7aqI8rG4ypPGKtNYXFzEu6wmdPYcU5g1vIsT4hKj5cjgCuvnSVo7nRP2bppQWvU2fh/eS6bdvb3TqYJDt+bt70vjC1bUPEKWVqzGI/NK4PAHpWReK4iMlu2Gx17Vq+GXf7S6XRLSMgctnrmuSceWbxC3sYQjGmnWjv2LF9d22nIkO3cVGAi9gO9MtbiO8j82Nsjp9KzNflmTWpB9mH2V1P7/APu8dKqeGluI3uEuoyc8hh90g9DQqK9nz9TzY1XKVjodPRA0pI6HnNXXAEW6MjYeCtZm77PCxCM5xnA7iodJ1yK+llgliMEiDjPespU5STklojrVGo4uolojf0+fyLhducHmu5s5vOgUkV55ZlpCrcYHGc122mXMEcKI8g3dK8/Gx0T6nJW11NMnjk8V5h42mF3dZj+d43616VM37mTGOFNeTP5j6lLJMwEe4gVOXxXO59i8IrNy7HA+J/Dmp3dw17pccU+8bZLeQ4/EGtPwT4ZvNGgN3qgWLYpKR5ziuslhjnkCxuyMDg9qz9fnh023EU0uI2+8zHoveve+uVJ0/Yrr99hqhGpVUrFTRo5by4ur3aflBMQI+9XO+LbvWtb0i4sFQ71YkeQSGI9K7/Qp4dSskuLEBYj90g4GKx/FLN4ftJLqxGyWZ/mkb5gvuKzp1l7azjr0T6DxlR1JN7JHG/DxtV07SZIp4rgBH+RZiS2O/WvafAPiKPVrFonTy5oW2sp4ryu214X2hXt5es5awXzGkhBy65HOPxroPBjXj6kuqEMljIo25GA1GYRhXU/aJKS1/r1OCN3bl1R61LJvyq8Ac5rNnkVtygY9jVtZ0lRHXuKzL4HeZScdgPWvmoLWx000ZHiRtmhaiQdjiI8/3eaKZrUckmm38e0OGhYAdcjiisMW+WSsr6HdS5UtSWeC1nAEkaEHoQegrKAg0u8L28ZZCfvVwvhrULxNQi/1j7zjaxJ4r0UyRRwM02xV6ncwr6GrSlQlySd0zCnUbVl9xpWV/byNmaJkZvuknipb6CC4i+cxuoPO7nNc/BfaVkB7nzJM4XbzirWoRLFbpNEWw3JGaxVO0tNCnTcWr6Dp827KkLDye6gcCqksiW8qSyKXc8gin+c99ajEfliM43Z60slklzGh3kMOD710wai/e+YqnNFWW5etmWUBgMZ5qKMuviQCM/ehAIPQ1atbcQIqhWKgckDmqCyodblKZzGgAPvUwd+a3Yqim2/Qs3cUlhDK9qwCMfmi9D6isCaWUyKAMk+ldQ6Qvb7tzPO3JzWBcPHazedJHgA4AHQ10UJXT7mkHF6y3LKr5AjLHkj7tXdL1GOK9RZMFe4qrPFHcRbmby8DORVCGJoh5kUqMA3U0OMakdSlGE9L6nMeONElHiG5niLNbyfPGwPArV0m6aKK3jaTlVCnNb1zp19Np07gK7N8yDtVDTfD+oXsIc2oUjhieOfauv6xGdJKo1poTRjSp3TYfaYLicxhl8zHIPem6fcWV/fNBbyB3iB3lOn51xl3FdW/jSOylG1Fk+YqeStehaZpFppVtOLVQZrs4T1x6mnXhCjFa6tKw5TclaGxVURXM6LceXDDC37uPPMjetaMsduw82XkL3Neea61xBqKQoHDxtjuec9a6lpJXt7ZZz+82guPelWoSjytPRnPQtWlydEXftL6hcosKN5adOO1bcFumn2VxOqlnI646fjWZpTLGmdwXYRnPHFaxum1aUwWw2WaDJz1c1wVXrype6jpqNrRaRRds1jksQZR+8dc+9X7G4kWUK8ZZcfKfWqUDhYzjBIGNpqSW6xbkwvhwPkNcUo8za7nI3zXOltUjdVde3b0q1ivPPD2sX8Imef5k34YE/yru7GYz2yydj0rixFCVKWphVpuOvQsUUUVzmIUUmR6ige3NAHK/Ea5SDQirAbnYBSe1cFpNxLZTRTNIXUjBHWvQ/HGnJe6d5kp+WPnFeaN/o1sxY5XOFxXvYDllQ5T18HyypOJ0N3NArrL5saZPO44rnPFFjJbXa3sI+SQDJX19a56U3s2qFJt5gY4AAJJruodOf8A4Q8wzs7NH8yM/UV3Ol9WcXe9zLC13TrcrWmwjX9vdabFJFFh9oV2PSmzmO6SAlhuiOeO9ccl9PLFJAHWKFOWPWtjwzIy27zTfJGT8gY8n3onh/Zq9y53pVeW2x6Vo00peJxtEJXG08VvbF2HI5Pc1yFtqDyW8ScYBGMd63I7yWOIeXG8ki9FNeDWpSuctWLepFr+yGJGdljQcH3rnTbTS6ink/6gDOexqfVbxRcA3kDSzNkhB2rZ8OotzEkzLhR27VtFujTuXGXs43HSR3BiUSqc4457Vx95YwXd3N5ix4DdT1r0i9eMW0hIwMYzXnttZyfa3eH94C5HIOBRhajd3sVh5tXktDUtLeeG18mOLeB0JPQVp6HbZBluVBlDfKD/AAiti1iihhVWx5jrz+VIsCRRs4BJA7VzzxHNdGMqnNcw/MYXUqSRM1vvBO3gqao+JtPtLi2diFKuNykDkGukskj2MyDlyc7uaqa9a79GmYL88fIwOtVTqKNRW0LhU5Zq2h5nb2EhjPzZXoM1Hpjy2OvRJMw2FduT+laNk21WBHOfWqOu27vsmVgJByo9TXtRlzScZdT0VK83CWzOh1S1+2sFeNQp59BVO6CwxGFIyhPBAqn4F1a61O1lg1ON1njY9VIBA6YNXbhB57SbsyDj6CsHGVKXs5dDzeRxkSWWPs5ySdvbvWHfMkss0FjD5kycuy9vrW7DFLswoDZ71zVrZwWGr3krzy2l+53IxP7uYehz0NXRs222aVMTOlG8S34c1GYb7e4ieKZTyG6N7g10dnLNKWUHO05xnFczMS3iCGC0lMu1N80h5UZ7A10ViWtJpJVKvHxgjvU4lL4kt0ZRk66u9zpbjUpE0hg4BcLjrzivOru6MbGSQhYyTy3rXQajcM245Y5H4CuI8VIZtKe2+Z1c8EdVPY1jg6K5vVm1vY03Y2NOlS6jLrJu+bkDg1y3iSx1DVrme5tY2liiYR7N2Bjvk0uh+Zpz27PLtITaQTw1EUt19ojtYZ/LDSs4bPy5J4zXqxpulUbhqZxcqmHnPYrIb/T9IhtJJFMYcspibAHtn1r0DRCmueGYU1C3LhgVYt/Ouc0NUlv59Kv4Q5/1pO07Se5WuyjZYoPLt49qxjAA6AVx4+rokl7173MY07vm6MztJ0m10Vm+yo539zzx6Yq/dTxQxAOyIOyk4zWLqHiGa3aMCEMrnb5Y+8x9c1S8QWkl5atcxtIfMjzGF6g1zeynUkpVXv1CLjFWijq9O1CXYwX5cc47VSu/FdibwW13vZh1ZR8q1zfhe8ubewji1LepB2rI38Y96xvGnhi6urSdtFdluJMlZCcbRVLB01Xcajsuj/4JpPmjFSitz08SRm1vrgNuiEJKEHr0or5609vHGjaXfwahqDDToIGZ1YZLcjgGivMzPLJxqpKSasbUIOquZo9NttCv/tG+7dLFW/hTkj8etPudItzlYnuLlh/E7nFakk7XUzTuwJb+E9BWrpGm/amEjviIHovevZniZU/fk/6/M7lV9kr7eS/q5l+G/DyRL9oaMZByBjjNdFdWSzhXVyHI5U9OKv3FuIUZYzggfL2qo8u9PnwsqjqO9cDxE6sudnDUryrS52zhtZ1C4S+WCMFIx1PT9K2Le9c6UZGOGHU46ii6sbe9QmX/AFqNkOo6VpW2n2/lLGTujI5r0KlWnaOmxhyy9673M7SvELp50Nyx8pkJST1qjo+oxkvO7bmlYscHgVZ1/RltRFAkgd5zsiA/hU1NYaDZ2dusO3fKD989zWn7hRco9Tpoc0KWvX8jWur5bHTRcmPc54Hp+NZ1pqcGpR/Z72KNZj8yFDx9K277Tk1DSnscbXAyp9TXKWmj3UdyqCARLF1kPU1lQVOVNu9pI4pOTqeRkanrdxb6vJpkMRYum5SetXfDs7XuoR2LRsXaNt3HGcUl9pkt3rEF9BES8Rw5HcV1OmahD9redIo1AX53KbSMdea669SMafuR1a/EqpGcZp3Os8Izw3OkpCyqJoSUdT14q5repWul2Mm6RFfaQqA8k/SuA0u6j1WW6udIu9kYO0+Wcc+9SosNvme4kM8/QvKc/lXkSwa9o2312NXSjKXNf5GdFbRTTyajfokUknPI5I7Cq97riabKjLIkszDPqAvpSa5NLqCTbQFUDEYHauftdBmv4sPMYXAwGx1/CvZp04SXNVenY2rTn8MUddZyW+pWpvkVTnhsrypqK1g+3XRAz8vUVd8J6cmlWklu8jTeYcsx6ZqxpsJinu2TYQGOB3NckqnK5KPTYqhLlTfUglRI2x5YY4wQK39Hj2Qp5SqIsde9ZaMhlkzgSY+YZrRs4FNqSs7Io6jNc9Z3jZhVfNGzGzEu+y2QEEne56irFpErRhTggcEmpYrLyoHcuWLc06B0MiqCPNIBHpXPKV17phzaWRl+IrUWMHmA4jPYd66Hwjfx3GkJlxlDg5pmtw293pkqXRHC5B9DXL6TcR2iFCrfMuCD/OlyfWKNuqZVlVpW6pnowlRsYYHPNeeeIvFGoPc3EWkcRJlTJjPPtT11dredvKlJiPy4J+7WLEDHK2NrRljt2mrw2DVOTlNXLoYeMLymrh8M9X1m41yeHWhKY/4ZJOAa9UeZYARwV7YNeeWrEXCZOEPAFaF1dzWm1ocSAHmjFUI1qvNFW8jnlS5pWubHiLUFksGh24LHvXAXNqZikaoWAOW9q3byT7QVuZXIA52g9KpGKZ5/MgIaNhwyt1FbYePsY2R1UbUkUbGIyaiY8FY0A6DnNdLO7T2bWz7QjDafU1zF/MlleLsuMSfxLjNaVvNPKPkUt3JHetKsOa0xVJKT5onN22nw6drpDDckgwyv09qtr9neWVXHQ8Y6Cn6ugkvY5ZOMdMdapCaH7PcefN+8j6IvDAetdd3USlfUeKq2jGfyNTSr46ffBrpGkgCnYB/CfWu/0u+hltVmgkyHHU9a8rtr+1vLZUXcHY/LvGDiuv8ACzgzsJysUUaZUdMmuHG0E1zPRoVRRq0+dbk+orJLLNKQVGcAnuK2tHeKwsRCX2yMNy85FVr+S2aJUZvkfoMdap27fY7eXyIstngHkgVyNe0gonNKyjqaOq3jeQIgQzOclR6VcsY4jaoUAUN1X0rnrGWee5kS4hG/b8rY61rRTPbhVQbkAzn+lZzp8q5VuJ/CrGp9oEMo8yJjIRtBHYU2ORgjkZ6/lTre78y23IgZj1UnkVVhniWaQSNsYg8HpmuVLfQlLyJUiMQX7O2d3VTVLxCZo9KmeOTAUHIPfir3mjCeUgJ2/M3pVLxLLFFpFxxlyuMetaU23NaFQ+JXPN9PlMkeWYDLfnVmaMOis/DH7p7VWs/ujYAue3TBpNRvodMslNx87bsj0Ne403O0UdteajK7LWmPN9vVN4aJ88g8KferskhKO0gUMpxx3rnfBOrw3t3K8Me2LPzRse+e1dZqdk29GETeXuySvpWeIXs6nLJWMKkffvfRnldz4ljuvE8mn3H21ZVbMckOQkfp9a7bSrj+1dIMepxJOYmKMSOT71m614cZtVa50m4WJnG1iw5X3Fa+l2Q020W1e4aWU/M7H+M+tdVaVKVOPs9/xOejCbm77EdtZW1goS2LCNskJnJNVo9RMcr25WRY93Ru1EkrT62YpR5flrmNwenvVTxHfQrJBaWrBycb2U4JPriojBzfvatlOvKhV5LaF+8uZMERuzE9AKsNbK1k0hA5IAQ96z9O3QzCR1JXbkt6VtssUtqZI1OD+VY1PcskddWqpJJI828bQ3kssMFjAwDHGUFbVr4bmsNBtLq6maO5J6kZAPau88G2v2rUA21XCnJ3CovGbjW9UOlWrJFaQLm5lXseyj3rR46ScaCVktW/IdOVqnJtG2pkaTcRJEslxGZr3bgFPuqKgudXu7YkiAvGTyRmreiWy2ymBFGFO0N3I9TWhNAVDgFdo9egFc85RU3dXJ54QbUY6HE6nO80gluLOZYx8wZG/wDr1HPrMjFUszs2DjzDwKXxcjyaRcCBN0SnI75NcpoLXF3JEJrZoyzYfcOor0aNNVIXeyKjiKVKa9zc9D0aBfEdm8cF5F50Y+YZyc+wpl9aavpsptvNRlAByRkmudtdGez1E3Wm74pU+YhOMj3r0jw7djWSkkihwflJx3rkrv2Xvx1j2tsdE6zjeWjieceOrW9bwhqk1w7qBbsRxweRxRXoHxai0/T/AIfa+shAkNqdqnuciivIxGL9q00tC6GI543tYzNN00zSBiSVjOdvY10VgbjzsEFYxxgdAKt2NpHaQKsI3lfvE96sMwSItuVEPJ46VvWr+06eh5Veq6k009EaM/NoBkM5HUjnFc9cP5c7KWAY8ZIrct3Etqphbdjr71z09tJc6iUYbD23Vjh0tU9kTT3aZVhVWJBHy54atR3jitZGmBxjIPSoDGtqT5uF29qytakk1D9zCx8kDLMPSu1Q9rJX2OiEOd+RHZTHUrxr2ckeWNsKHsO5rZtmEQnurp18tV3D/ZFcv4ckJubieY7YSfLRT3A9K7C7tItT0aVNvltjaQO4reulCfI9FovQWIquULxXoc7aeMbW4vkhSOaN3b90z8b/AMK6uVpb2LDFY0A+dyK4fSPC8trqSXuozKUhz5Sgd+mfyre+Iv2qw8O2MummSSN3xIVHr3orUqUq8adF79Tz/aShDmnubttawxqRbOrn+KsLxYqrpojhIjmuG8sE8Y9TVbwx50l7AilgqJiRvX61b8U2sd1q9o0od4rTMgVehJ45qacXTrpN36lRqOcXJmb4bhXw54fnjncNdzt8u0Y3D1rJvLh5GRQ3ysRkZqLW7ia6ujczqYnwUjjz0FYNpcTm6AicF1PevTp0W26kt3uexl+Gfs7vc7i4tPLtFkJ4AqtFO6LlB9aI7ue7t1QZZF+8AKuW6RqVABz6EVz35V7xOkG+YfBeXLRtFAhG7+Kr0OlSRxLPJMVY8kCpILmxE4gMyrcf3a1b6RRYbVwSeMDnFck6r5lFK1zD6zraCKmn6YZUE8rZDHjPetC5skt4PMhBVx1B6VPpCI+nxozHCc0usybbeRmPyKvB9a5XVlKpy3MXVlKdiGO7f7N5eSeBwO1Rxus23apikXjI5NZmkzW4VDNIw3DJJPf0rVRokkDwsrIB8xB5q5Q5HZGklyuyRga/qVw8nkPu2qM+341T06+E8blxuKcZ9a05bU6ncyu77Vz8pAps9kba1aFI1HHzEV1RlBRUOptKcVFRW5xmsawEkdzItvbrxnrWro0IuojLDPzjcCOhrm9S0wzTywXkTSW7Nldn8XtXVeH9Meys1jUELjAU/wAIrvrqEKa5XqclKvUUmmySeWe2nQMPkPcdjViW9JQjJYMMEVbkjV0IkweMHnn61RS1LZib5QBlTXEnGS1NHIiiEl03kx7ljHrW1asLWNU2njjjtVNESB1UBlcjIq2C7YBBORyazm76dBuXMkjmde0e6n1AyQqcMchwelZupXl1YJ5yTmJoSBuPT6V2JlU/MZSsfTrWHqFzpRlaCfypGJzhz978K6qNbmspK9jH6vN6QLRZ9U0+Cfy1EmAw2nIY1kOsVzLLPbeX9pX5WUHJ/wA5rftrc6hYXUNifsziIrHt7ZGMivNvCaala61fWa2Uv22z+c71IEy9+fU9auhC6k4vbp5P9Dp5o3WHqddvU6bTdJvT5skm0cZUe1btqXUbUJfnJHrVTSNS/taWcWTNE0QxLbyYDof8PpVVXntzJvQxyqSFfdwfT86ifPUbUrJky/2V8klZnZCVZSh6kDueg9KVNQS3JYnOOAM9a5i31QLZMdgaU8EE9TTtKvjdps8tV2Mc5Oc1yPDtJto0Sj1N6TXJFlMiICvrjoPSpmv2uWCwbhDjDAdQazljn8lo4/LweQT1FVpF1GxtmaBVeReTj+Ko9jF/DuVKFPlvHc6jTbbbOXSRifXNZ3iwwwWjvLK6k8ZzirWi6gyJC9zG29k+YYxXJeMLtNVm8hmxAD61lSpSlW16E4WMp1Fcs+FPFjJE8bS/aYVOOP4RW/rurQT2yLA2Vflh3Fef+HtIi0+e4ltnbyZeShHQ+oq5eIRIfJDknqBXbPC0nVvE6nQjKfM9GW7LD3xXGVU5WofGGktqVgRCwjkHTNSaHbvDOzSuST0A7Vo6h+6WQSIyr0B9TTcnCqnF7HNXUZS5TlvB+hzaPJJcTFRleimur0/XppW3E7gDtZSO3qKzY42kgdYmLuvzYPBApkl1Z6XDHeSB1K/eXsaut+/k3NXbMatJ2ST2NO88xNV2xAM7/Nk9hT0/02Yo42zRnqKybTxLZX94JoZM5OxgBwK0HuY47qW5K+RCi5ZweGzWDpygkmrMwjUnTqWGXlpFNJg4BHQjrUyeHLTzBcMwyyYIx8wPrUGj3lnql6620hfYfnUjBHvW7KkcQVYH3A9M9RWdSpOnaF2mVKXPLmRmWlvJDL9ncI8Dc78UyWF5XeztCFweWPataTZDCHZT5h6c9KoaDcLcazIGILRjLnIGahSbvK2xpTTs59hZdQHhzSvs9n8+pXLbFJ7ccsfauYRmiBgjuCx3b5Gz989zVmV/7S1XUb3cShbyIu4AHX9agFi/NukQMrDO/PSuilTjG7lu9X/XkdE4v4E9ev8AXkXY7zyJAVIkY9MVNqK6lfWrraxMN4xvJxitPw3oKJb77r/j4/hz0NdfY2cXkiMbdqdveuPEYqFKWmrRhUqRhpFXZ5Nb2U9vov2PVU2zFiQT0cViIq6aEmQOfMfAHUH2Fet6vpUV/e7JwWiUZAHY1xupaVBaX8pjO5Y/mji6gGuzD4yNS7e71sZr3rJblPUHdZwsAZE2gu1Z/h3xKfD+qTxyxNLbMcjb2ap5b2SaQbtvlNxn+lZk0KTa2kKr8uNx4renTTi4VFpY7qDhO8Jaos/E29kvvBuu3l8MO1q2xf7oyMCiqnxM3D4da95n/PDgg57iivn8baM1FbWI9rynsthqFoqBQCG9DV5DZz/NIij69DRRRWpqL0ZwVaai9COOS2huA0DII+4HQVV16/tFSPkCR+/QgUUVVCmpVNWVGmnJJnJ6xqUVwwlVcRIMEE9a4vxD4lkCrb2jiFZOGwOfpRRX0uX0IOSTW3+R24mPsqF490jVsIJruygPl7cAMpz+tegW0QtNNFxeTxwQKvzSOcAmiivOxUnKcYdLnDiZuMXJGF4n1KG20ManaSLdQRNxsPBJqr4J8enVJXsL+BSANygDIx6UUV1QwtOphJTktYt2foc0ZOVRRex3MAt93l2USKj/ADHaMZ+tZsRf7ZqDhBhFKnJ6CiivIi7Np67fmb00lexxN9ZCUlmO5zkgnvWNFYSRyvgAE9MUUV7tKo7Hq4epKMWkbekeZaAnqGHNa/2m3Rd0zFP9o0UVjJc8tTmru7bZlpoUt5qIvLKVSpbls9BXd2lmEgVcb+PnbqaKK4cVXnN2fTQ41psM0y9SGeS0cYOcoT6ZqPxDdfaH8m2fKnhvaiikqcVU5vI6YwXMpBY6dZhdspD56ZHNW7G3tYLoCFApORhj+tFFZVJSd7szcpNtNlO4MtpdPFKgVCcrIOhqhd6giELnO79aKK3oxU0mzWEVKzZzeswhZPMid0B5BB6GqESX06BUupyc4IU4AH1oor0qUvcuzupO0LnRaZpgUQ5leRT1YtmpL+SGxId5SByMdaKK5qcnUqWkc8P3s0pGYfEUXneYSHfpgiraa284IgjZmAzwOKKK6p4eEdbHdLC04q6RmahNdTQNGAsfmDjA6GuUtvDV0+rGXU5xvJ4APAFFFVTrSpq0NLnLUavsdVc3Ufh6NZkncleMk8VtWmvJqVoiykJIeVlXkt7GiiolRjKmqj3OeMnVqOMuhzHxJ0ya0trbXdOLRXQ+SVl43L7+tc3aa891DFFrEEiqrBvPTofc0UV14BKrRXNuna/U9/B0KeLwvLWV7NpPqbcZhuJRFHLiORSUbd1NO8PJ/Z8kgiLylGO/JzRRUS6w6HzVaPJXcV0Nu/8AEccJQxbY3PG09a07HXjIn7/YOMDj71FFc08LT5L2J5ncs6fr9ndObOSQJc9VXHUVgeLNLeKSO4XKxMRyD3oormUFQqpR6l4SvOM7oijuUtYgr7ulWoJ4WhLFlCnnNFFbuCtc7nJydmQz6hZpKn70sV+bCd8VyXiTxVd6rcx/Y2aC3QjlRliPaiiu7C4aDld6nLi37Fe6ejeE7N/7Ct/tuTOy7iWPOPeuO8UarNY6bcPFbrc+Ux+Vu4zRRXFhkqleXN3MqdRppGd4E8Vadq8bxW+nCznLZY4+VzXbapZtf+Fpkix56OGCDjcBRRWmZwVCqnDuga56epx/hU3lv4nheKG5QrlZTKuFI/OvRrho0WR5G2uMlQaKKwzHWpH0MsJBWscrBrk810EZCV3FTg9K8f8AE3ivVLTxxJZWLsiM+HIPrRRXp5fRg6lrdDuhrHl7yR7R4ajeHSbeJmGMbmPqTzk1b0mTb4gaGUBxsyCKKK8aesp38zSWs538zv7JY5okRF2xLxubqTTrlBFI2cquOCh5/GiivAl8fKeW/iK7hZQqIWV88sepqKfToljkxCGbHLHrRRT5nHZg201Y871G0itbyUIMLklR6VlXV0tvK0kamSYx4X5ec0UV9Bh/3kY8x1w0vbsed/Eqe5XwhqC+fKrMn7wHo4z0ooorzs2/ix9P1Zwyuj//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph in recovery phase of acute tubular necrosis showing multiple mitoses (arrows) indicative of regenerating tubular cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_58_19366=[""].join("\n");
var outline_f18_58_19366=null;
var title_f18_58_19367="Treatment of venous thromboembolism in patients with malignancy";
var content_f18_58_19367=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of venous thromboembolism in patients with malignancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/58/19367/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/58/19367/contributors\">",
"     Kenneth A Bauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/58/19367/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/58/19367/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/58/19367/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/58/19367/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/58/19367/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/58/19367/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with malignancy are in a hypercoagulable state. The spectrum of hemostatic abnormalities ranges from abnormal coagulation tests in the absence of clinical manifestations to massive, fatal venous thromboembolism (VTE).",
"   </p>",
"   <p>",
"    The treatment of VTE in patients with malignancy will be discussed here [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/1\">",
"     1",
"    </a>",
"    ]. Prevention of VTE in patients with malignancy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link&amp;anchor=H10#H10\">",
"     \"Hypercoagulable disorders associated with malignancy\", section on 'Prevention of VTE'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of VTE with anticoagulants in cancer patients is associated with both benefit and a high rate of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/2-9\">",
"     2-9",
"    </a>",
"    ]. This was illustrated in a retrospective analysis of 1303 patients (264 with malignancy) in two randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/4\">",
"     4",
"    </a>",
"    ]. The study evaluated the incidence of recurrent VTE and major bleeding with respect to the presence of malignancy and the achieved level of anticoagulation during a three-month period of treatment with oral anticoagulation. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The overall incidence of recurrent VTE was three times higher, and that of major bleeding 6.5 times higher, among those with malignancy.",
"     </li>",
"     <li>",
"      In the patients with malignancy, the incidence of recurrent VTE was 2.8 times higher in patients who were not adequately anticoagulated (ie, INR &lt;2.0).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar conclusions were reached in two prospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In one, 842 patients with symptomatic DVT were treated with conventional anticoagulation; 21 percent had underlying malignancy. The incidences of recurrent thromboembolism and major bleeding during anticoagulant therapy were significantly higher in the patients with cancer, with relative risks of 3.2 and 2.2, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/5\">",
"     5",
"    </a>",
"    ]. Recurrence of DVT and bleeding were both directly related to the stage of the malignancy, occurred predominantly during the first month of treatment, and could not be explained by over- or under-anticoagulation.",
"   </p>",
"   <p>",
"    In a study of 3805 cancer patients receiving anticoagulation for an index VTE event, 156 (4.1 percent) had major bleeding during the first three months of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/10\">",
"     10",
"    </a>",
"    ]. On multivariate analysis, significant risk factors for bleeding included immobilization, presence of metastases, recent bleeding, and creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LMW HEPARIN VERSUS WARFARIN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to anticoagulate a patient with cancer, VTE, and a limited life expectancy can be difficult because of the need for close laboratory monitoring if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is used, as well as the high risks of recurrent VTE, bleeding, and death.",
"   </p>",
"   <p>",
"    There are a number of theoretical reasons why",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -containing products might be more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for this complication, which may or may not be associated with the anticoagulant properties of the heparins [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link&amp;anchor=H3#H3\">",
"     \"Hypercoagulable disorders associated with malignancy\", section on 'Mucin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Only one major randomized clinical trial (the CLOT trial) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/13\">",
"     13",
"    </a>",
"    ] has convincingly shown that the use of long-term LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in reducing the incidence of recurrent VTE in cancer patients without significantly increasing the risk of bleeding. Some of these studies are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H513254\">",
"    <span class=\"h2\">",
"     CLOT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multicenter, international, randomized clinical trial (CLOT trial) compared six months of treatment with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    (200 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    SQ once per day for the first month, followed by 150 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    for the remaining five months) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (target INR 2.0 to 3.0) in 672 patients with cancer and acute symptomatic VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/13\">",
"     13",
"    </a>",
"    ]. Dalteparin therapy was associated with a significant reduction in the cumulative rate of recurrent VTE at six months (9 versus 17 percent, hazard ratio 0.48, 95% CI 0.30-0.77).",
"   </p>",
"   <p>",
"    Most of the recurrent thromboembolic events occurred during the first two months of therapy in both treatment groups. There were no significant differences in the rates of major bleeding (6 versus 4 percent), any bleeding (14 versus 19 percent), or overall mortality at six months (39 versus 41 percent) between the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    arms, respectively.",
"   </p>",
"   <p>",
"    Based on the results of the CLOT trial,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    (Fragmin&reg;) was approved to reduce the recurrence of symptomatic VTE in patients with cancer. The recommended dose regimen is 200 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    <span class=\"nowrap\">",
"     once/day",
"    </span>",
"    SQ for the first month followed by 150 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    SQ",
"    <span class=\"nowrap\">",
"     once/day",
"    </span>",
"    for the subsequent five months, not to exceed a daily dose of 18,000 international units. No monitoring of blood anticoagulation tests is recommended or required for this usage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H513284\">",
"    <span class=\"h2\">",
"     Other trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CANTHANOX trial compared three months of therapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or the LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    &nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    in cancer patients with proximal DVT, PE, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/16\">",
"     16",
"    </a>",
"    ]. All patients received initial treatment with therapeutic doses of enoxaparin (1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once daily for at least four days) and were randomly assigned to either continue enoxaparin at the same dose or to receive warfarin therapy. After 147 patients were accrued, the study was terminated early because of poor recruitment. Approximately one-half of the study patients had metastatic malignancy at randomization; these patients were equally distributed between the two treatment arms.",
"   </p>",
"   <p>",
"    At three months, 15 of 75 patients (20 percent) in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    arm had reached a primary endpoint of treatment failure (ie, symptomatic, recurrent VTE",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    major bleeding) compared with 7 of the 71 patients (10 percent) assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    , a difference that did not reach statistical significance. The majority of the primary outcome events were major bleeding, reported in 12 and five patients, respectively. Of these bleeding events, six were fatal; all occurred in the warfarin treatment arm. The number of patients with recurrent VTE was similar in the enoxaparin and warfarin arms. The investigators concluded that warfarin was associated with a high bleeding risk in cancer patients with VTE and that prolonged treatment with LMWH may be as effective as and safer than oral anticoagulant therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of meta-analyses have explored the effect of anticoagulation on VTE occurrence or recurrence, survival, and side effects (eg, bleeding, thrombocytopenia) in cancer patients with or without a prior episode of VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/17-22\">",
"     17-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2008 Cochrane review of results in six randomized controlled trials in cancer patients receiving long-term treatment for VTE found no statistically significant survival benefit for LMW",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      over oral anticoagulation (vitamin K antagonists), a statistically significant reduction in VTE, and no significant difference in bleeding outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EFFECT ON SURVIVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary analysis of the data from the CLOT trial of cancer patients with idiopathic VTE showed no difference in survival with chronic LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/13\">",
"     13",
"    </a>",
"    ]. A post-hoc analysis of the data indicated that, in patients with metastatic disease at initial presentation, there was no observable difference in mortality between the two treatment groups (72 versus 69 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/23\">",
"     23",
"    </a>",
"    ]. However, treatment with LMW heparin, as compared with warfarin, significantly reduced mortality at 12 months in the subgroup of patients without observable metastatic disease at initial presentation (20 versus 36 percent, hazard ratio 0.50, 95% CI 0.27-0.95).",
"   </p>",
"   <p>",
"    This latter observation is consistent with results in three other trials (including the FAMOUS trial), in which the use of LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in patients",
"    <strong>",
"     without",
"    </strong>",
"    venous thromboembolism was associated with improved survival in those with a relatively good prognosis, and no improvement in survival in those with a poor prognosis or advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. The survival benefit in these trials persisted beyond the time of administration of LMW heparin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/23-25\">",
"     23-25",
"    </a>",
"    ], suggesting that LMW heparin may have a beneficial effect on tumor biology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RECURRENT VTE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5120738\">",
"    <span class=\"h2\">",
"     Recurrence risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the risk of VTE recurrence is higher than normal in patients with malignancy. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Overview'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the CLOT trial, 9 or 17 percent of cancer patients developed recurrent VTE over six months of follow-up, despite treatment with LMW",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or a vitamin K antagonist (VKA) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a population-based cohort study, the six-month cumulative incidence of recurrent VTE was 4 percent for those with idiopathic VTE compared with 16 percent after active cancer-related incident VTE [",
"      <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/27\">",
"       27",
"      </a>",
"      ]. While multivariate analysis confirmed that increasing proportions of time on adequate",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy were associated with significant reductions in VTE recurrence, the hazard of VTE recurrence in cancer patients receiving such therapy was increased approximately threefold.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5120748\">",
"    <span class=\"h3\">",
"     Clinical prediction rule",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical prediction rule for determining the risk of VTE recurrence in cancer patients has been developed using data from a retrospective cohort study (derivation set) and two randomized trials (the CLOT and CANTHANOX trials, validation set) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/28\">",
"     28",
"    </a>",
"    ]. Factors in the final model included breast cancer (-1 point), TNM stage I or II (-1 point), female sex (1 point), lung cancer (1 point), and prior VTE (1 point), for a final score ranging from -2 to +3. Those in the low- (score &lt;0, 19 percent of the population studied), intermediate- (score zero, 42 percent of patients), and high- (score &ge;1, 38 percent of patients) risk groups had recurrence rates of 5.1, 9.8, and 15.8 percent, respectively. This model, if independently verified, may be useful in identifying those at greatest recurrence risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5120731\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of these patients is problematic, with suggested options including insertion of an inferior vena cava filter, switching anticoagulation from a VKA to LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , or increasing the intensity of anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective study evaluated the effectiveness of escalating the dose of LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in patients with active cancer who developed an objectively documented episode of recurrent VTE while already receiving anticoagulation. Results included [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Forty-seven patients were receiving LMW",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      . Of these, 15, 24, and 8 were receiving therapeutic dose (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"       dalteparin",
"      </a>",
"      200",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      once daily,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/44/21191?source=see_link\">",
"       tinzaparin",
"      </a>",
"      175",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      once daily,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily, or enoxaparin 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once daily), maintenance dose (75 to 80 percent of the therapeutic dose), or low dose (&lt;75 percent of the therapeutic dose) therapy, respectively.",
"      <br/>",
"      <br/>",
"      Thirty-two of the 47 patients had their LMW heparin increased to a therapeutic dose; the 15 patients who had already been receiving a therapeutic dose received 120 percent of a therapeutic dose.",
"     </li>",
"     <li>",
"      Twenty-three patients were receiving a VKA. Of these, 11 and 8 had therapeutic (eg, INR &gt;2.0) or subtherapeutic INR levels, respectively. The INR was not known for four patients. All of these patients were subsequently given a therapeutic dose of LMW",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Six patients (8.6 percent) had a",
"      <strong>",
"       second",
"      </strong>",
"      recurrent episode of VTE during the three-month follow-up period, at an event rate of",
"      <span class=\"nowrap\">",
"       9.9/100",
"      </span>",
"      patient-years and a median time between the index and the second recurrent episode of 1.9 months (range: 0.6 to 3 months).",
"      <br/>",
"      <br/>",
"      All six were treated by increasing the weight-adjusted dose of LMW",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      by 20 to 25 percent for at least four weeks, and one also had an IVC filter placed. None of these patients had a further recurrent VTE event during the three-month follow-up period.",
"     </li>",
"     <li>",
"      Three patients had bleeding complications after their index episode of recurrent VTE. One patient with a malignant brain tumor had an intracranial bleed after the LMW",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      was increased to a therapeutic dose. Two had a minor bleeding episode while receiving therapeutic LMW heparin. Deaths on this study were not related to either recurrent VTE or bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Larger, prospective studies with longer follow-up are required before the safety and efficacy of dose escalation with LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    for cancer patients with recurrent VTE can be adequately assessed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     FUTURE STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many questions remain regarding optimal anticoagulant therapy for patients with malignancy. More studies are required to investigate the optimal",
"    <span class=\"nowrap\">",
"     dose/schedule",
"    </span>",
"    of LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and duration of treatment in this population, including the use of anticoagulation in hospice settings [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Values and preferences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the above-noted questions, as well as the fact that the cost of long-term prophylaxis for recurrent VTE with LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    exceeds that of the vitamin K antagonists, the use of LMW heparin, as suggested below, should not be generalized to all patients with malignancy. Given the many issues involved in this decision (",
"    <a class=\"graphic graphic_table graphicRef81646 \" href=\"UTD.htm?16/24/16780\">",
"     table 1",
"    </a>",
"    ), including patient values and preferences, possible out-of-pocket expenses, and potential side effects,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is a reasonable choice for selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/14,32-34\">",
"     14,32-34",
"    </a>",
"    ]. The CLOT trial included primarily ambulatory cancer patients with symptomatic VTE in the absence of other risk factors (eg, recent surgery, hospitalization, clots in association with central venous catheters); the presence of such concurrent risk factors could lead to a lower on-treatment recurrence risk with warfarin than was observed in the CLOT trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations are generally consistent with the",
"    <span class=\"nowrap\">",
"     2007/2008",
"    </span>",
"    <span class=\"nowrap\">",
"     guidelines/statements",
"    </span>",
"    from the American Society of Clinical Oncology (ASCO), the 2007 clinical practice guidelines of the American College of Physicians and the American Academy of Family Physicians, the 2012 NCCN Guidelines, the 2012 American College of Chest Physicians (ACCP) Guidelines, and the 2013 International Practice Guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/14,21,29,32,33,35-46\">",
"     14,21,29,32,33,35-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anticoagulation for prophylaxis against recurrent VTE should generally be avoided if there is active bleeding",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      there are other contraindications to anticoagulant use (eg, recent surgery, pre-existing bleeding diathesis, platelet count",
"      <span class=\"nowrap\">",
"       &lt;50,000/microL,",
"      </span>",
"      coagulopathy) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/58/19367/abstract/29,33\">",
"       29,33",
"      </a>",
"      ]. When anticoagulation is contraindicated, one treatment option is insertion of an inferior vena cava filter. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H20#H20\">",
"       \"Treatment of lower extremity deep vein thrombosis\", section on 'Inferior vena cava filter'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with malignancy, a reasonable quality of life and life expectancy, and venous thromboembolism, we suggest",
"      <strong>",
"       initial",
"      </strong>",
"      treatment with LMW",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      over the use of vitamin K antagonists (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This was down-graded to a Grade 2B suggestion since such patients may place a higher value on avoiding daily injections, and would thus prefer oral anticoagulation. For long-term oral anticoagulation, we suggest the use of vitamin K antagonists over the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Values and preferences'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Accordingly, a reasonable plan is to initiate treatment with LMW heparin for the first three months. Because the risk of recurrent VTE is unacceptably high in patients with active cancer who stop anticoagulant therapy, we recommend extended anticoagulant therapy rather than three months of therapy if the risk of bleeding is not high (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ) and suggest extended anticoagulant therapy rather than three months of therapy if the risk of bleeding is high (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      It is advisable to frequently re-evaluate the risk-benefit ratio of ongoing anticoagulant therapy in individual patients, taking into consideration the overall clinical status of the patient, including the quality of life and life expectancy.",
"     </li>",
"     <li>",
"      Anticoagulation for VTE in patients with primary or secondary brain tumors is controversial and is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/39/30327?source=see_link\">",
"       \"Anticoagulant and antiplatelet therapy in patients with brain tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of catheter-induced upper extremity venous thrombosis is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=see_link&amp;anchor=H22#H22\">",
"       \"Catheter-induced upper extremity venous thrombosis\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/1\">",
"      Siegal DM, Garcia D. Anticoagulants in Cancer. J Thromb Haemost 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/2\">",
"      Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol 2002; 3:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/3\">",
"      Sallah S, Husain A, Sigounas V, et al. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clin Cancer Res 2004; 10:7238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/4\">",
"      Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18:3078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/5\">",
"      Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100:3484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/6\">",
"      Douketis JD, Crowther MA, Foster GA, Ginsberg JS. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis? Am J Med 2001; 110:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/7\">",
"      Luk C, Wells PS, Anderson D, Kovacs MJ. Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med 2001; 111:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/8\">",
"      Lee AY. Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol 2005; 128:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/9\">",
"      Monreal M, Falg&aacute; C, Vald&eacute;s M, et al. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2006; 4:1950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/10\">",
"      Trujillo-Santos J, Nieto JA, Tiberio G, et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/11\">",
"      Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007; 110:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/12\">",
"      Solari V, Jesudason EC, Turnbull JE, Yates EA. Determining the anti-coagulant-independent anti-cancer effects of heparin. Br J Cancer 2010; 103:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/13\">",
"      Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/14\">",
"      Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.",
"     </a>",
"    </li>",
"    <li>",
"     Information available on the United States FDA website at: &lt;www.fda.gov/cder/foi/label/2007/020287s035lbl.pdf&gt;. Accessed on May 2, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/16\">",
"      Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/17\">",
"      Akl EA, van Doormaal FF, Barba M, et al. Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. Cochrane Database Syst Rev 2007; :CD006652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/18\">",
"      Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 2007; 110:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/19\">",
"      Akl EA, Barba M, Rohilla S, et al. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2008; :CD006650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/20\">",
"      Akl EA, Rohilla S, Barba M, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2008; :CD006649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/21\">",
"      Noble SI, Shelley MD, Coles B, et al. Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol 2008; 9:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/22\">",
"      Le Ma&icirc;tre A, Ding K, Shepherd FA, et al. Anticoagulation and bleeding: a pooled analysis of lung cancer trials of the NCIC Clinical Trials Group. J Thorac Oncol 2009; 4:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/23\">",
"      Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005; 23:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/24\">",
"      Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/25\">",
"      Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23:2130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/26\">",
"      Sideras K, Schaefer PL, Okuno SH, et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 2006; 81:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/27\">",
"      Heit JA, Lahr BD, Petterson TM, et al. Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study. Blood 2011; 118:4992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/28\">",
"      Louzada ML, Carrier M, Lazo-Langner A, et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 2012; 126:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/29\">",
"      Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25:5490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/30\">",
"      Carrier M, Le Gal G, Cho R, et al. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost 2009; 7:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/31\">",
"      Holmes HM, Bain KT, Zalpour A, et al. Predictors of anticoagulation in hospice patients with lung cancer. Cancer 2010; 116:4817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/32\">",
"      Prandoni P. How I treat venous thromboembolism in patients with cancer. Blood 2005; 106:4027.",
"     </a>",
"    </li>",
"    <li>",
"     Streiff MB, Chair. Venous thromboembolic disease, version 2.2011. National Comprehensive Cancer Network (NCCN) guidelines are available online at www.nccn.org. Accessed March 14,2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/34\">",
"      Wittkowsky AK. Barriers to the long-term use of low-molecular weight heparins for treatment of cancer-associated thrombosis. J Thromb Haemost 2006; 4:2090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/35\">",
"      Bick RL. Cancer-associated thrombosis. N Engl J Med 2003; 349:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/36\">",
"      Lee AY. The role of low-molecular-weight heparins in the prevention and treatment of venous thromboembolism in cancer patients. Curr Opin Pulm Med 2003; 9:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/37\">",
"      Segal JB, Streiff MB, Hofmann LV, et al. Management of venous thromboembolism: a systematic review for a practice guideline. Ann Intern Med 2007; 146:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/38\">",
"      Snow V, Qaseem A, Barry P, et al. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2007; 146:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/39\">",
"      Engman CA, Zacharski LR. Low molecular weight heparins as extended prophylaxis against recurrent thrombosis in cancer patients. J Natl Compr Canc Netw 2008; 6:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/40\">",
"      Carrier M, Lee AY. Prophylactic and therapeutic anticoagulation for thrombosis: major issues in oncology. Nat Clin Pract Oncol 2009; 6:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/41\">",
"      Lee AY. Anticoagulation in the treatment of established venous thromboembolism in patients with cancer. J Clin Oncol 2009; 27:4895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/42\">",
"      Khorana AA. Cancer and thrombosis: implications of published guidelines for clinical practice. Ann Oncol 2009; 20:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/43\">",
"      Djulbegovic B. Management of venous Thromboembolism in cancer: a brief review of risk-benefit approaches and guidelines' recommendations. J Support Oncol 2010; 8:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/44\">",
"      Panova-Noeva M, Falanga A. Treatment of thromboembolism in cancer patients. Expert Opin Pharmacother 2010; 11:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/45\">",
"      Khorana AA, Streiff MB, Farge D, et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009; 27:4919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19367/abstract/46\">",
"      Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013; 11:56.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1340 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-211.167.112.14-E421669322-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_58_19367=[""].join("\n");
var outline_f18_58_19367=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LMW HEPARIN VERSUS WARFARIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H513254\">",
"      CLOT trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H513284\">",
"      Other trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EFFECT ON SURVIVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RECURRENT VTE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5120738\">",
"      Recurrence risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5120748\">",
"      - Clinical prediction rule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5120731\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      FUTURE STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Values and preferences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1340\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1340|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/24/16780\" title=\"table 1\">",
"      Issues anticoag for malignancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/39/30327?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27050?source=related_link\">",
"      Catheter-induced upper extremity venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_58_19368="Infection with less common Campylobacter species and related bacteria";
var content_f18_58_19368=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Infection with less common Campylobacter species and related bacteria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/58/19368/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/58/19368/contributors\">",
"     Ban M Allos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/58/19368/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/58/19368/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/58/19368/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/58/19368/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/58/19368/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Campylobacter infection usually consists of acute enteritis caused by Campylobacter jejuni or Campylobacter coli. The genus Campylobacter comprises 20 species isolated from humans and many more isolated from animals. New species are identified regularly [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/1\">",
"     1",
"    </a>",
"    ]. These organisms can cause a variety of infections including intestinal, systemic,",
"    <span class=\"nowrap\">",
"     fetal/placental",
"    </span>",
"    (abortion, stillbirth), and oral (periodontitis). Certain closely related species of Arcobacter and Helicobacter also cause human infection and may be provisionally identified as campylobacters in clinical laboratories.",
"   </p>",
"   <p>",
"    The clinical relevance of less common Campylobacter infections will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/2\">",
"     2",
"    </a>",
"    ]. Issues related to C. jejuni and C. coli are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5065?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of Campylobacter infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/19/19769?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of Campylobacter infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTESTINAL AND SYSTEMIC INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections with the less common Campylobacter species and related organisms are observed more frequently among individuals in resource limited-settings than among individuals in developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/2\">",
"     2",
"    </a>",
"    ]. Bacteremia has been observed in the setting of malnourished children with diarrhea and patients with immunodeficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Campylobacter upsaliensis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Campylobacter upsaliensis is the most important Campylobacter species after C. jejuni and C. coli [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/3\">",
"     3",
"    </a>",
"    ]. It is commonly found in younger dogs and cats, which are likely sources of human infection. Interestingly, dogs fed homemade cooked food appear to have a higher risk of carrying this organism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Considerable variation in isolation rates has been reported, which may be partly due to methodologic differences rather than differences in prevalence. The selective culture media used for C. jejuni and C. coli are unsuitable for C. upsaliensis, which requires filtration on nonselective agar or a special selective medium.",
"   </p>",
"   <p>",
"    In Europe, C. upsaliensis comprises about 1 to 2 percent of clinical Campylobacter isolates. One Belgian survey noted C. upsaliensis comprised about 13 percent of isolates, which was likely attributable to immigrant children from Morocco and Turkey [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/5\">",
"     5",
"    </a>",
"    ]. In Cape Town, C. upsaliensis has been observed in 23 percent of isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    C. upsaliensis infection typically causes watery diarrhea and abdominal pain, usually without fever. It is probably less pathogenic than C. jejuni. An outbreak among 44 children in day care centers in Brussels has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/6\">",
"     6",
"    </a>",
"    ]. In an Australian study, C. upsaliensis was associated with prolonged diarrhea of mild to moderate severity in HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Campylobacter jejuni subspecies doylei",
"    </span>",
"    &nbsp;&mdash;&nbsp;Campylobacter jejuni subspecies doylei is a slower growing, more fastidious organism that is phylogenetically distinct from C. jejuni subspecies jejuni (referred to as C. jejuni) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/8\">",
"     8",
"    </a>",
"    ]. It requires the special filtration method for its isolation from feces and an incubation temperature of 37&ordm;C rather than 42 to 43&ordm;C.",
"   </p>",
"   <p>",
"    Subspecies doylei is generally observed among children living in resource-limited settings and is a cause of systemic infection. It was first isolated from Australian aboriginal children and has also been identified in South African children [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/2\">",
"     2",
"    </a>",
"    ]. In Australian aboriginal children, subspecies doylei accounted for 85 percent of all campylobacters isolated from blood in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/9\">",
"     9",
"    </a>",
"    ]. In South African children, this organism accounted for 24 percent of blood isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/2\">",
"     2",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Most C. doylei strains are susceptible to both nalidixic acid and cephalothin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Campylobacter lari",
"    </span>",
"    &nbsp;&mdash;&nbsp;Campylobacter lari shares many of the features of C. jejuni and C. coli, including the ability to grow freely at 43&ordm;C and on conventional campylobacter-selective agars. C. lari is found in abundance in natural water and is a normal inhabitant of the intestinal tract of seagulls (genus Larus), other birds, and shellfish [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    C. lari accounts for less than 1 percent of campylobacters isolated from humans. It was implicated in a water-borne outbreak of diarrhea in Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/12\">",
"     12",
"    </a>",
"    ] and occasionally is isolated from blood cultures, but many strains are clearly nonpathogenic. C. lari has been reported as a cause of a permanent pacemaker infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/13\">",
"     13",
"    </a>",
"    ] and prosthetic joint infection, sepsis, and death in a healthy elderly person [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with diarrheal illness may not require antimicrobial therapy. The organism is generally susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , aminoglycosides, and imipenem. Some isolates are susceptible to fluoroquinolones, but the rate of resistance is growing. A few reports have suggested C. lari is resistant to all cephalosporins, penicillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Campylobacter hyointestinalis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Campylobacter hyointestinalis is normally found in the gut of pigs. It has occasionally been isolated from patients with diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/17\">",
"     17",
"    </a>",
"    ], including a patient with infection acquired from a pig [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/18\">",
"     18",
"    </a>",
"    ]. In one series of stool isolates from South African children, it accounted for 1.3 percent of campylobacters isolated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/3\">",
"     3",
"    </a>",
"    ]. C. hyointestinalis also has been detected in gastric biopsy specimens of patients with gastritis but associated with less inflammation than H. pylori [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of hydrogen is essential for culture. In vitro and animal studies have shown that C. hyointestinalis is susceptible to many antimicrobial agents including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The organism may be resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/24/43396?source=see_link\">",
"     lincomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Campylobacter concisus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Campylobacter concisus has been isolated from the stool of about 10 percent of children and adults with and without diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/2,22,23\">",
"     2,22,23",
"    </a>",
"    ]. The organism is isolated with high frequency from patients with enteric illness, but in the absence of a control group, no conclusion about its pathogenicity may be made [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. C. concisus may be associated with Crohn&rsquo;s disease. Studies using PCR assays identified the organism more frequently in the stool samples of children recently diagnosed with Crohn&rsquo;s than in samples from controls [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Campylobacter concisus is a part of oral flora; it may contribute to the development of periodontal disease. Additionally, the organism has been identified in a brain abscess in a patient with chronic sinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/29\">",
"     29",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Most C. concisus isolates are susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    ; susceptibility to cephalosporins is variable [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Arcobacter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arcobacter species, including A. butzleri and A. cryaerophilus (formerly A. cryaerophila), are occasionally isolated from humans. Both organisms cause intestinal infection; persistent watery diarrhea appears to be the main symptom [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. A. butzleri has been reported in 2.4 percent of children with diarrhea in Thailand [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/33\">",
"     33",
"    </a>",
"    ]. It has also been isolated from the peritoneal fluid of several patients with acute appendicitis, and occasional cases of bacteremia have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/31\">",
"     31",
"    </a>",
"    ]. One outbreak, attributed to a single strain (Lior serogroup 1) of A. butzleri, affected 10 children in an Italian primary school. None of the children had diarrhea, but all suffered from intermittent abdominal cramps lasting for 5 to 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/34\">",
"     34",
"    </a>",
"    ]. In a study of 1380 persons with diarrhea in New Zealand, A. butzleri was isolated from seven (0.5 percent) and A. cryaerophilus was isolated from five (0.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/35\">",
"     35",
"    </a>",
"    ]. In another study of 201 travelers with diarrhea, Arcobacter species were isolated from the stool of 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/36\">",
"     36",
"    </a>",
"    ]. Nevertheless, the pathogenic role of Arcobacter species in such studies cannot be established because they lacked an appropriate control group.",
"   </p>",
"   <p>",
"    Arcobacter species have also been isolated from the peritoneal fluid of several patients with acute appendicitis, and occasional cases of bacteremia have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Patients with gastrointestinal infection typically have self-limited disease and do not require antimicrobial therapy. However, for more severe and invasive infections when antimicrobial treatment is warranted, fluoroquinolones, aminoglycosides, or tetracyclines may be used, as most in vitro studies show the organisms are susceptible to such agents [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/30,37\">",
"     30,37",
"    </a>",
"    ]. More than 20 percent of Arcobacter isolates are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/30,37\">",
"     30,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Helicobacter cinaedi and Helicobacter fennelliae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formerly classified as campylobacters, these two species have been isolated from up to 8 percent of homosexual men with diarrhea or proctitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/38\">",
"     38",
"    </a>",
"    ]. They have also been found in South African children with diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/2\">",
"     2",
"    </a>",
"    ]. In the latter group, Helicobacter fennelliae accounted for 7 percent and Helicobacter cinaedi 0.8 percent of campylobacters isolated. Both species have caused bacteremia in immunocompromised patients, particularly those with hematologic malignancies or HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/8,39,40\">",
"     8,39,40",
"    </a>",
"    ]. Some have speculated that this organism too may play a role in triggering inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These organisms are not associated with fatal illness, but clinical response to antimicrobial therapy is often slow. In vitro studies show the organisms are susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    , nalidixic acid,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/42\">",
"     42",
"    </a>",
"    ]. Many isolates are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    . The best choice for treatment may be oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other Helicobacters",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several newly described intestinal helicobacter species that have been isolated from patients with diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/2\">",
"     2",
"    </a>",
"    ]. Their status as pathogens is difficult to assess, since routine methods of detection are unsuitable for most of them. Helicobacter westmeadii was isolated from the blood of two AIDS patients with diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/44\">",
"     44",
"    </a>",
"    ]. H. pullorum, a species found in poultry, has been isolated from several patients with diarrhea. H. canis, found in dogs and similar to H. fennelliae, was isolated from a boy with diarrhea.",
"   </p>",
"   <p>",
"    Helicobacter bilis (formerly \"Flexispira rappini\", then Helicobacter rappini) has been isolated from patients with chronic diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/45\">",
"     45",
"    </a>",
"    ]; it has also been isolated from the blood of a child with pneumonia and the blood of a man undergoing hemodialysis. Most recently it was implicated as a cause of pyoderma gangrenosum in a boy with x-linked agammaglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/46\">",
"     46",
"    </a>",
"    ]. This organism has a striking morphology consisting of a large fusiform body encased in spirally wound periplasmic fibers with bipolar tufts of sheathed flagella.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Campylobacter fetus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Campylobacter fetus is the species most frequently associated with systemic campylobacteriosis, which generally occurs among patients with immune deficiency or other underlying disease. Systemic campylobacteriosis can also be associated with focal infection such as cellulitis or septic arthritis.",
"   </p>",
"   <p>",
"    C. fetus is an important cause of abortion in sheep and cattle. There are two subspecies, C. fetus subspecies fetus and C. fetus subspecies venerealis. Cows are infected venereally from carrier bulls with C. fetus subspecies venerealis. In this form of infection, embryos are destroyed early in gestation before pregnancy is apparent; it is known as bovine infectious infertility. Human infection with C. fetus subspecies venerealis is limited to a small number of case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    C. fetus subspecies fetus is the subspecies usually found in human infection (referred to as C. fetus). C. fetus is found in various animals and animal products, which are probably the main source of human infection. Infection following consumption of raw milk and raw liver has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/47\">",
"     47",
"    </a>",
"    ]. Primary colonization takes place in the intestine, but in normal individuals this seldom causes disease; in such cases enteritis is the primary manifestation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/3,48,49\">",
"     3,48,49",
"    </a>",
"    ]. Human infection is uncommon and generally limited to patients with immune deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/50\">",
"     50",
"    </a>",
"    ]. Predisposing factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Liver disease (particularly alcoholic cirrhosis)",
"     </li>",
"     <li>",
"      Malignancy, leukemia, and other blood dyscrasias",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      AIDS and other immune deficiency states",
"     </li>",
"     <li>",
"      Elderly subjects",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    C. fetus possesses a surface layer protein (SLP) that functions as a capsule and protects the bacterium from the bactericidal action of normal serum [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/51\">",
"     51",
"    </a>",
"    ]. The SLPs are critical in virulence and undergo high-frequency phenotypic switching by recombination, resulting in antigenic variation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/52\">",
"     52",
"    </a>",
"    ]. The antigenic variation is thought to be responsible for the ability of the organism to persist in animal and human hosts and may account for relapsing human infection despite seemingly effective antibiotic therapies. Most other campylobacters (including C. jejuni and C. coli) do not possess SLP and are readily eliminated from the bloodstream.",
"   </p>",
"   <p>",
"    Patients usually present with a nonspecific febrile illness. Localizing signs are usually absent, and the first indication of the nature of the illness is isolation of C. fetus from the blood. C. fetus has a tropism for endovascular tissue, so endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/50\">",
"     50",
"    </a>",
"    ], infected aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/53\">",
"     53",
"    </a>",
"    ], or septic thrombophlebitis may be observed. Other forms of focal infection can occur; these include meningoencephalitis, osteomyelitis, empyema, cholecystitis, pericarditis, myocarditis, peritonitis, and salpingitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/2,54\">",
"     2,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Healthy persons who develop C. fetus gastroenteritis will usually recover without antibiotic therapy. However, immunocompromised persons or those with bacteremia or other extra-intestinal infection may require a prolonged course of antimicrobial treatment. The organism is generally susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    , third-generation cephalosporins, aminoglycosides, imipenem, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    ; these agents have been used effectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. As an example, in a small series of patients with C. fetus bacteremia, all of six patients treated with imipenem and 7 of 11 treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    had favorable outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/55\">",
"     55",
"    </a>",
"    ]. In contrast, use of fluoroquinolones was associated with death in a separate series of 94 cases of C. fetus bacteremia, among which the fluoroquinolone resistance rate was 33 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/49\">",
"     49",
"    </a>",
"    ]. Because many isolates are resistant,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    should not be used [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no therapeutic trials on which to base treatment duration recommendations. Endovascular infections should probably be treated for at least four weeks. Infection of the central nervous system should be treated for at least two to three weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     FETAL/PLACENTAL INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Campylobacter enteritis during pregnancy occurs with relative frequency; a very small proportion of fetuses are affected. Approximately 30 instances of Campylobacter abortion, stillbirth, or congenital infection have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/58\">",
"     58",
"    </a>",
"    ]; roughly half are due to C. fetus, half to C. jejuni, and one each to C. coli and C. upsaliensis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/59\">",
"     59",
"    </a>",
"    ]. The stage of gestation ranged from 10 weeks to full term (average 19 weeks for C. jejuni, 28 weeks for C. fetus). It is probable that many gestational infections go undetected.",
"   </p>",
"   <p>",
"    Infected pregnant women typically present with fever, with or without vaginal bleeding. Abortion can also occur without antecedent symptoms. Abdominal pain with or without diarrhea is present in at least half of patients with C. jejuni. Hematogenous spread from the gut is probably the main route of placental infection. Inflammation of the placenta with necrosis is almost always present. Campylobacter organisms can be isolated from blood cultures and from placental and fetal tissues. Ascending genital tract infection may occur in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of C. fetus infection, the fetal outcome is frequently death; survival is possible if the agent is C. jejuni and infection is at or near term [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/58\">",
"     58",
"    </a>",
"    ]. Intrauterine infection at term may be difficult to distinguish from perinatal infection acquired during delivery from a mother with stool shedding of organisms. In such cases, the prognosis is relatively good with appropriate treatment, even in the setting of meningitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PERIODONTAL INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Six species of Campylobacter are part of the human oral flora: C. sputorum, C. concisus, C. rectus, C. curvus, C. showae, and C. gracilis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/61\">",
"     61",
"    </a>",
"    ]. C. rectus (formerly Wolinella recta) has a particularly strong association with periodontal infection, and has a protective surface S-layer protein (as described above for C. fetus) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/62\">",
"     62",
"    </a>",
"    ]. Patients with periodontitis have a higher titer of IgG antibody to this protein than controls [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/63\">",
"     63",
"    </a>",
"    ]. Cytotoxin production by C. rectus has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19368/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Campylobacter fetus'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4591708\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The genus Campylobacter comprises 20 species isolated from humans. These organisms can cause a variety of infections including intestinal, systemic,",
"      <span class=\"nowrap\">",
"       fetal/placental",
"      </span>",
"      (abortion, stillbirth) and oral (periodontitis). Certain closely related species of Arcobacter and Helicobacter also cause human infection and may be provisionally identified as campylobacters in clinical laboratories. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infections with the less common Campylobacter species and related organisms are observed more frequently among individuals in resource-limited settings than among individuals in developed countries. Campylobacter upsaliensis is the most prevalent Campylobacter species after C. jejuni and C. coli. C. jejuni subspecies doylei is a slower growing, more fastidious organism than C. jejuni subspecies jejuni (referred to as C. jejuni). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Intestinal and systemic infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Campylobacter fetus is the species most frequently associated with systemic campylobacteriosis, which generally occurs among patients with immune deficiency or other underlying disease. C. fetus is found in various animals and animal products, which are probably the main source of human infection. Patients usually present with a nonspecific febrile illness. C. fetus has a tropism for endovascular tissue, so endocarditis, infected aneurysms, or septic thrombophlebitis may be observed. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Campylobacter fetus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 30 instances of Campylobacter abortion, stillbirth, or congenital infection have been described. Infected pregnant women typically present with fever, with or without vaginal bleeding. Abortion can also occur without antecedent symptoms. Hematogenous spread from the gut is probably the main route of placental infection. Campylobacter organisms can be isolated from blood cultures and from placental and fetal tissues. In the setting of C. fetus infection, the fetal outcome is frequently death; survival is possible if the agent is C. jejuni and infection is at or near term. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Fetal/placental infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Six species of Campylobacter are part of the human oral flora: C. sputorum, C. concisus, C. rectus, C. curvus, C. showae, and C. gracilis. C. rectus (formerly Wolinella recta) has a particularly strong association with periodontal infection. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Periodontal infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enteric infections due to Campylobacter and related species do not necessarily warrant antimicrobial therapy. For patients with severe or systemic infection, antimicrobial therapy should be tailored to antibiotic susceptibility testing. The typical susceptibility profile varies by species. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Intestinal and systemic infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Lastovica A J, Allos BM. Clinical significance of Campylobacter and related species other than Campylobacter jejuni and Campylobacter coli. In: Campylobacter, 3rd Ed, Nachamkin I, Szymanski CM, Blaser MJ.  (Eds), American Society for Microbiology, Washington, DC 2008. p.123.",
"    </li>",
"    <li>",
"     Lastovica AJ, Engel ME, Blaser MJ. Atypical campylobacters and related microorganisms. In: Infections of the Gastrointestinal Tract, 2nd Ed, Blaser MJ, Smith PD, Ravdin JI, et al (Eds), Lippincott Williams and Wilkins, Philadelphia 2002. p.741.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/3\">",
"      Bourke B, Chan VL, Sherman P. Campylobacter upsaliensis: waiting in the wings. Clin Microbiol Rev 1998; 11:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/4\">",
"      Leonard EK, Pearl DL, Janecko N, et al. Factors related to Campylobacter spp. carriage in client-owned dogs visiting veterinary clinics in a region of Ontario, Canada. Epidemiol Infect 2011; 139:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/5\">",
"      Goossens H, Vlaes L, De Boeck M, et al. Is \"Campylobacter upsaliensis\" an unrecognised cause of human diarrhoea? Lancet 1990; 335:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/6\">",
"      Goossens H, Giesendorf BA, Vandamme P, et al. Investigation of an outbreak of Campylobacter upsaliensis in day care centers in Brussels: analysis of relationships among isolates by phenotypic and genotypic typing methods. J Infect Dis 1995; 172:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/7\">",
"      Jenkin GA, Tee W. Campylobacter upsaliensis-associated diarrhea in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 27:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/8\">",
"      Parker CT, Miller WG, Horn ST, Lastovica AJ. Common genomic features of Campylobacter jejuni subsp. doylei strains distinguish them from C. jejuni subsp. jejuni. BMC Microbiol 2007; 7:50.",
"     </a>",
"    </li>",
"    <li>",
"     Morey F. Five years of Campylobacter bacteraemia in central Australia. In: Campylobacters, Helicobacters, and Related Organisms, Newell DG, Ketley JM, Feldman RA.  (Eds), Plenum Press, New York 1996. p.491.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/10\">",
"      Lastovica AJ, Le Roux E. Prevalence and distribution of Campylobacter spp. in the diarrhoeic stools and blood cultures of pediatric patients. Acta Gastroenterol Belg 1993; 56:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/11\">",
"      Keller JI, Shriver WG, Waldenstr&ouml;m J, et al. Prevalence of Campylobacter in wild birds of the mid-Atlantic region, USA. J Wildl Dis 2011; 47:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/12\">",
"      Broczyk A, Thompson S, Smith D, Lior H. Water-borne outbreak of Campylobacter laridis-associated gastroenteritis. Lancet 1987; 1:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/13\">",
"      Morris CN, Scully B, Garvey GJ. Campylobacter lari associated with permanent pacemaker infection and bacteremia. Clin Infect Dis 1998; 27:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/14\">",
"      Werno AM, Klena JD, Shaw GM, Murdoch DR. Fatal case of Campylobacter lari prosthetic joint infection and bacteremia in an immunocompetent patient. J Clin Microbiol 2002; 40:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/15\">",
"      Evans TG, Riley D. Campylobacter laridis colitis in a human immunodeficiency virus-positive patient treated with a quinolone. Clin Infect Dis 1992; 15:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/16\">",
"      Simor AE, Wilcox L. Enteritis associated with Campylobacter laridis. J Clin Microbiol 1987; 25:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/17\">",
"      Edmonds P, Patton CM, Griffin PM, et al. Campylobacter hyointestinalis associated with human gastrointestinal disease in the United States. J Clin Microbiol 1987; 25:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/18\">",
"      Gorkiewicz G, Feierl G, Zechner R, Zechner EL. Transmission of Campylobacter hyointestinalis from a pig to a human. J Clin Microbiol 2002; 40:2601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/19\">",
"      Seo TH, Lee SY, Uchida T, et al. The origin of non-H. pylori-related positive Giemsa staining in human gastric biopsy specimens: A prospective study. Dig Liver Dis 2011; 43:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/20\">",
"      Laatu M, Rautelin H, H&auml;nninen ML. Susceptibility of Campylobacter hyointestinalis subsp. hyointestinalis to antimicrobial agents and characterization of quinolone-resistant strains. J Antimicrob Chemother 2005; 55:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/21\">",
"      Inglis GD, McAllister TA, Busz HW, et al. Effects of subtherapeutic administration of antimicrobial agents to beef cattle on the prevalence of antimicrobial resistance in Campylobacter jejuni and Campylobacter hyointestinalis. Appl Environ Microbiol 2005; 71:3872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/22\">",
"      Van Etterijck R, Breynaert J, Revets H, et al. Isolation of Campylobacter concisus from feces of children with and without diarrhea. J Clin Microbiol 1996; 34:2304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/23\">",
"      Engberg J, On SL, Harrington CS, Gerner-Smidt P. Prevalence of Campylobacter, Arcobacter, Helicobacter, and Sutterella spp. in human fecal samples as estimated by a reevaluation of isolation methods for Campylobacters. J Clin Microbiol 2000; 38:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/24\">",
"      Aabenhus R, Permin H, On SL, Andersen LP. Prevalence of Campylobacter concisus in diarrhoea of immunocompromised patients. Scand J Infect Dis 2002; 34:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/25\">",
"      Hess DL, Pettersson AM, Rijnsburger MC, et al. Gastroenteritis caused by Campylobacter concisus. J Med Microbiol 2012; 61:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/26\">",
"      Man SM, Zhang L, Day AS, et al. Campylobacter concisus and other Campylobacter species in children with newly diagnosed Crohn's disease. Inflamm Bowel Dis 2010; 16:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/27\">",
"      Zhang L, Man SM, Day AS, et al. Detection and isolation of Campylobacter species other than C. jejuni from children with Crohn's disease. J Clin Microbiol 2009; 47:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/28\">",
"      Lastovica AJ. Clinical relevance of Campylobacter concisus isolated from pediatric patients. J Clin Microbiol 2009; 47:2360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/29\">",
"      de Vries JJ, Arents NL, Manson WL. Campylobacter species isolated from extra-oro-intestinal abscesses: a report of four cases and literature review. Eur J Clin Microbiol Infect Dis 2008; 27:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/30\">",
"      Vandenberg O, Houf K, Douat N, et al. Antimicrobial susceptibility of clinical isolates of non-jejuni/coli campylobacters and arcobacters from Belgium. J Antimicrob Chemother 2006; 57:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/31\">",
"      Mansfield LP, Forsythe SJ. Arcobacter butzleri, A. skirrowii and A. cryaerophilus--potential emerging human pathogens. Rev Med Microbiol 2000; 11:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/32\">",
"      Collado L, Figueras MJ. Taxonomy, epidemiology, and clinical relevance of the genus Arcobacter. Clin Microbiol Rev 2011; 24:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/33\">",
"      Taylor DN, Kiehlbauch JA, Tee W, et al. Isolation of group 2 aerotolerant Campylobacter species from Thai children with diarrhea. J Infect Dis 1991; 163:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/34\">",
"      Vandamme P, Pugina P, Benzi G, et al. Outbreak of recurrent abdominal cramps associated with Arcobacter butzleri in an Italian school. J Clin Microbiol 1992; 30:2335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/35\">",
"      Mandisodza O, Burrows E, Nulsen M. Arcobacter species in diarrhoeal faeces from humans in New Zealand. N Z Med J 2012; 125:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/36\">",
"      Jiang ZD, Dupont HL, Brown EL, et al. Microbial etiology of travelers' diarrhea in Mexico, Guatemala, and India: importance of enterotoxigenic Bacteroides fragilis and Arcobacter species. J Clin Microbiol 2010; 48:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/37\">",
"      Kabeya H, Maruyama S, Morita Y, et al. Prevalence of Arcobacter species in retail meats and antimicrobial susceptibility of the isolates in Japan. Int J Food Microbiol 2004; 90:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/38\">",
"      Laughon BE, Vernon AA, Druckman DA, et al. Recovery of Campylobacter species from homosexual men. J Infect Dis 1988; 158:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/39\">",
"      Tee W, Street AC, Spelman D, et al. Helicobacter cinaedi bacteraemia: varied clinical manifestations in three homosexual males. Scand J Infect Dis 1996; 28:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/40\">",
"      Minauchi K, Takahashi S, Sakai T, et al. The nosocomial transmission of Helicobacter cinaedi infections in immunocompromised patients. Intern Med 2010; 49:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/41\">",
"      Hansen R, Thomson JM, Fox JG, et al. Could Helicobacter organisms cause inflammatory bowel disease? FEMS Immunol Med Microbiol 2011; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/42\">",
"      Moore JE, Barton MD, Blair IS, et al. The epidemiology of antibiotic resistance in Campylobacter. Microbes Infect 2006; 8:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/43\">",
"      Burman WJ, Cohn DL, Reves RR, Wilson ML. Multifocal cellulitis and monoarticular arthritis as manifestations of Helicobacter cinaedi bacteremia. Clin Infect Dis 1995; 20:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/44\">",
"      Trivett-Moore NL, Rawlinson WD, Yuen M, Gilbert GL. Helicobacter westmeadii sp. nov., a new species isolated from blood cultures of two AIDS patients. J Clin Microbiol 1997; 35:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/45\">",
"      Romero S, Archer JR, Hamacher ME, et al. Case report of an unclassified microaerophilic bacterium associated with gastroenteritis. J Clin Microbiol 1988; 26:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/46\">",
"      Murray PR, Jain A, Uzel G, et al. Pyoderma gangrenosum-like ulcer in a patient with X-linked agammaglobulinemia: identification of Helicobacter bilis by mass spectrometry analysis. Arch Dermatol 2010; 146:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/47\">",
"      Centers for Disease Control (CDC). Campylobacter sepsis associated with \"nutritional therapy\"--California. MMWR Morb Mortal Wkly Rep 1981; 30:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/48\">",
"      Rennie RP, Strong D, Taylor DE, et al. Campylobacter fetus diarrhea in a Hutterite colony: epidemiological observations and typing of the causative organism. J Clin Microbiol 1994; 32:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/49\">",
"      Pacanowski J, Lalande V, Lacombe K, et al. Campylobacter bacteremia: clinical features and factors associated with fatal outcome. Clin Infect Dis 2008; 47:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/50\">",
"      Farrugia DC, Eykyn SJ, Smyth EG. Campylobacter fetus endocarditis: two case reports and review. Clin Infect Dis 1994; 18:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/51\">",
"      Blaser MJ, Smith PF, Repine JE, Joiner KA. Pathogenesis of Campylobacter fetus infections. Failure of encapsulated Campylobacter fetus to bind C3b explains serum and phagocytosis resistance. J Clin Invest 1988; 81:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/52\">",
"      Tu ZC, Gaudreau C, Blaser MJ. Mechanisms underlying Campylobacter fetus pathogenesis in humans: surface-layer protein variation in relapsing infections. J Infect Dis 2005; 191:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/53\">",
"      Montero A, Corbella X, L&oacute;pez JA, et al. Campylobacter fetus-associated aneurysms: report of a case involving the popliteal artery and review of the literature. Clin Infect Dis 1997; 24:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/54\">",
"      Uzoigwe C. Campylobacter infections of the pericardium and myocardium. Clin Microbiol Infect 2005; 11:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/55\">",
"      Gazaigne L, Legrand P, Renaud B, et al. Campylobacter fetus bloodstream infection: risk factors and clinical features. Eur J Clin Microbiol Infect Dis 2008; 27:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/56\">",
"      Tremblay C, Gaudreau C, Lorange M. Epidemiology and antimicrobial susceptibilities of 111 Campylobacter fetus subsp. fetus strains isolated in Qu&eacute;bec, Canada, from 1983 to 2000. J Clin Microbiol 2003; 41:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/57\">",
"      Fujihara N, Takakura S, Saito T, et al. A case of perinatal sepsis by Campylobacter fetus subsp. fetus infection successfully treated with carbapenem--case report and literature review. J Infect 2006; 53:e199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/58\">",
"      Wong SN, Tam AY, Yuen KY. Campylobacter infection in the neonate: case report and review of the literature. Pediatr Infect Dis J 1990; 9:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/59\">",
"      Gurgan T, Diker KS. Abortion associated with Campylobacter upsaliensis. J Clin Microbiol 1994; 32:3093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/60\">",
"      Simor AE, Karmali MA, Jadavji T, Roscoe M. Abortion and perinatal sepsis associated with campylobacter infection. Rev Infect Dis 1986; 8:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/61\">",
"      Williams RC. Periodontal disease. N Engl J Med 1990; 322:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/62\">",
"      Rams TE, Feik D, Slots J. Campylobacter rectus in human periodontitis. Oral Microbiol Immunol 1993; 8:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/63\">",
"      Kokeguchi S, Kato K, Kurihara H, Murayama Y. Cell surface protein antigen from Wolinella recta ATCC 33238T. J Clin Microbiol 1989; 27:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19368/abstract/64\">",
"      Gillespie J, De Nardin E, Radel S, et al. Production of an extracellular toxin by the oral pathogen Campylobacter rectus. Microb Pathog 1992; 12:69.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2716 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-118.195.65.248-47B75F185E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_58_19368=[""].join("\n");
var outline_f18_58_19368=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4591708\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTESTINAL AND SYSTEMIC INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Campylobacter upsaliensis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Campylobacter jejuni subspecies doylei",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Campylobacter lari",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Campylobacter hyointestinalis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Campylobacter concisus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Arcobacter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Helicobacter cinaedi and Helicobacter fennelliae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other Helicobacters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Campylobacter fetus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      FETAL/PLACENTAL INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PERIODONTAL INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4591708\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/19/19769?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of Campylobacter infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5065?source=related_link\">",
"      Microbiology, pathogenesis, and epidemiology of Campylobacter infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_58_19369="Plasmacytoma variants";
var content_f18_58_19369=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F57085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F57085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Plasmacytoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure illustrates two variants of plasmacytoma. The tumor on the left is the plasmacytic variant, showing collection of mature-looking plasma cells with eccentric round nuclei, condensed, coarsely clumped \"clock-face\" chromatin, basophilic cytoplasm, and a prominent, pale Golgi zone. The tumor on the right is the plasmablastic variant, with cells showing striking variation in size. Their blastic nature is apparent from the coarsely clumped chromatin and basophilic cytoplasm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_58_19369=[""].join("\n");
var outline_f18_58_19369=null;
var title_f18_58_19370="Treatment of chronic lower extremity critical limb ischemia";
var content_f18_58_19370=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of chronic lower extremity critical limb ischemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/58/19370/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/58/19370/contributors\">",
"     David G Neschis, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/58/19370/contributors\">",
"     Michael A Golden, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/58/19370/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/58/19370/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/58/19370/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/58/19370/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/58/19370/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/58/19370/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H554865745\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eight to ten million Americans suffer from arterial occlusive disease, with approximately 500 to 1,000 new cases of chronic limb ischemia per million per year [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with critical ischemia present with rest pain, which is pain across the base of the metatarsal heads at rest relieved by dependency, or with tissue loss, which can be ulceration, dry gangrene or wet gangrene, occurring in the lower extremities due to atherosclerotic occlusive disease of the iliac, femoral or popliteal arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/1\">",
"     1",
"    </a>",
"    ]. Signs of critical limb ischemia on noninvasive testing include an ankle-brachial index less than 0.4, a flat waveform on pulse volume recording, and low or absent pedal flow on duplex ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The different therapies for critical limb ischemia will be reviewed here, according to the site of the vascular lesion and the specific clinical setting. The clinical manifestations and diagnosis of this disorder and acute limb ischemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14486?source=see_link\">",
"     \"Clinical manifestations and evaluation of chronic critical limb ischemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=see_link\">",
"     \"Acute arterial occlusion of the lower extremities (acute limb ischemia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limb-threatening ischemia occurs in 1 to 2 percent of patients with PAD who are 50 years of age or older [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/2\">",
"     2",
"    </a>",
"    ]. The natural history of critical limb ischemia usually involves inexorable progression to amputation unless there is an intervention that results in the improvement of arterial perfusion. This is in contrast to the often benign natural history of mild and moderate claudication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link\">",
"     \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    practice guidelines suggested the following distribution of outcomes at one year in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alive with two limbs &ndash; 50 percent",
"     </li>",
"     <li>",
"      Amputation &ndash; 25 percent",
"     </li>",
"     <li>",
"      Cardiovascular mortality &ndash; 25 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines also identified a number of factors that increase the rate of limb loss in patients with limb-threatening ischemia. These include factors that reduce microvascular flow (diabetes, severe renal failure or heart failure, smoking, prolonged cold exposure, Raynaud's phenomenon) and disorders that require increased microvascular flow (infection, such as cellulitis or osteomyelitis, and skin breakdown).",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines summarized the general principles of the treatment and prevention of limb-threatening ischemia (now called critical limb ischemia) (",
"    <a class=\"graphic graphic_table graphicRef61050 \" href=\"UTD.htm?12/7/12413\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56143 \" href=\"UTD.htm?31/63/32763\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. These guidelines are consistent with recommendations made in the 2007 TASC II consensus document on the management of PAD [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H909632825\">",
"    <span class=\"h2\">",
"     TASC classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The guideline from the Inter-Society Consensus for the management of peripheral artery diseases (TASC II) presents a scheme that classifies arterial lesions as type A, B, C, or D based upon overall success rates of treating iliac, femoral, and popliteal lesions using endovascular or surgical means [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/1\">",
"     1",
"    </a>",
"    ]. There are no classifications referable to the tibial vessels. Type A lesions represent simple lesions while Type D lesions represent more complex lesions. Type B and Type C are intermediate lesions. Endovascular therapy is the treatment of choice for Type A lesions and is preferred for Type B lesions. Surgery is the treatment of choice for Type D lesions and is the preferred treatment for good-risk patients with Type C lesions. The details of the TASC classification are reviewed in detail elsewhere. These definitions are constantly evolving as a result of technological, pharmacological and surgical advances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1031?source=see_link&amp;anchor=H909629056#H909629056\">",
"     \"Classification of lower extremity peripheral artery disease\", section on 'TASC classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Depending upon the characterization of a given lesion, a patient with critical limb ischemia might benefit from a bypass-surgery-first or an angioplasty-first approach. The TASC classification, however, does not provide guidance for the treatment of tibial vessel disease and does not address multilevel disease which is typical for patients with critical limb ischemia.",
"   </p>",
"   <p>",
"    Surgical bypass has been the gold standard for revascularization in patients with chronic critical limb ischemia. However, increasing interest for percutaneous transluminal angioplasty (PTA) came from a trial that showed no significant difference in outcomes between PTA and bypass surgery after a median of four years in a group that included patients with rest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Bypass surgery first versus angioplasty first",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bypass versus angioplasty in severe ischemia of the leg (BASIL) trial was designed to determine whether patients with severe limb ischemia due to infrainguinal disease would benefit from a surgery-first versus angioplasty-first approach.",
"   </p>",
"   <p>",
"    The BASIL trial randomly assigned 450 patients with severe limb ischemia (rest pain, ulceration,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gangrene) due to infrainguinal disease amenable to either procedure to bypass surgery first or angioplasty first [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The patient population was highly selected and several thousand patients were screened to obtain the final group for randomization. Patients were required to be equally suitable for either procedure. As a result, the significant improvements in end-points identified in this study cannot be generalized to all patients with severe limb ischemia.",
"   </p>",
"   <p>",
"    The primary end-points in this trial were overall survival and amputation-free survival. Following the initial randomization, additional procedures were allowed. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 224 patients assigned to PTA, 217 underwent the procedure, immediate technical failure occurring in 43 (20 percent). Among 228 assigned to bypass surgery, 196 underwent the procedure.",
"     </li>",
"     <li>",
"      On intention-to-treat analysis, there was no difference in amputation-free survival at one year (54 versus 52 percent, respectively) or at the end of follow-up (38 versus 37 percent).",
"     </li>",
"     <li>",
"      At 30 days, there was no difference in overall survival between the two groups, but surgery was associated with significantly increased morbidity (57 versus 41 percent). Overall survival (47 versus 41 percent) was also similar at the end of a mean follow-up of 3.7 years.",
"     </li>",
"     <li>",
"      For patients surviving at two years from randomization, bypass-surgery-first was associated with decreased subsequent mortality, hazard ratio (HR) 0.61, (95% CI, 0.50-0.75).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the strength of these results, the updated",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines for the management of peripheral artery disease recommend the following [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients that have an estimated life expectancy of two years or less, or those who do not have autogenous vein available as a conduit, balloon angioplasty is reasonable as the initial procedure, in selected patients, to improve distal blood flow.",
"     </li>",
"     <li>",
"      For patients with an estimated life expectancy of more than two years, and who have available autogenous vein conduit, a bypass surgery is reasonable to perform as the initial treatment to improve distal blood flow.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Thrombolytic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter-based intraarterial thrombolytic therapy is an alternative to surgery or percutaneous intervention in the management of acute thrombosis superimposed on chronic stenosis or occlusion in patients with critical limb ischemia. The role of thrombolytic therapy in such patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=see_link&amp;anchor=H18#H18\">",
"     \"Acute arterial occlusion of the lower extremities (acute limb ischemia)\", section on 'Thrombolytic therapy versus surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SURGERY FOR INFLOW DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortoiliac disease is also called inflow disease. Among patients with inflow and outflow (infrainguinal) disease, the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommended that inflow lesions be addressed first, whether surgery or percutaneous intervention is performed (",
"    <a class=\"graphic graphic_table graphicRef61050 \" href=\"UTD.htm?12/7/12413\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. After this has been accomplished, revascularization of outflow disease is warranted if there is persistent infection, ischemic ulcers, or gangrenous lesions, and the ankle-brachial pressure index (ABI) is less than 0.8.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines made the following recommendations when surgery is performed for aortoiliac occlusive (inflow) disease producing limb-threatening ischemia (now called critical limb ischemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aortobifemoral bypass is recommended for hemodynamically significant aorto-bi-iliac disease.",
"     </li>",
"     <li>",
"      Iliac endarterectomy, patch angioplasty, or aortoiliac or iliofemoral bypass was recommended, if aortic inflow was acceptable, in patients with unilateral disease or, if the patient is not a candidate for aortobifemoral bypass, in conjunction with femorofemoral bypass for bilateral iliac artery disease.",
"     </li>",
"     <li>",
"      Axillofemoral-femoral bypass for extensive aortoiliac disease in patients who are not candidates for other types of intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Aortofemoral bypass graft",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortofemoral bypass grafting has become the preferred method of treatment of symptomatic aortoiliac occlusive disease in low-risk patients. The perioperative mortality rates are well under 5 percent.",
"   </p>",
"   <p>",
"    Most procedures are performed for severe claudication, but approximately 30 to 40 percent are done for limb salvage. Early studies revealed an overall patency rate in all patients of approximately 88 percent at five years and 75 percent at 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/8\">",
"     8",
"    </a>",
"    ]. A subsequent series of 285 patients followed for 19 years (median duration of follow-up of 50 months) observed that the cumulative secondary graft patency was 96 and 94.4 percent at 5 and 10 years, respectively; the amputation rate was 4.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/9\">",
"     9",
"    </a>",
"    ]. Another study of 1000 consecutive cases of aortofemoral bypass revealed that an important determinant of long-term patency was the initial severity of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/10\">",
"     10",
"    </a>",
"    ]. The five- and ten-year patency rates were higher in patients with rest pain than in those with gangrene or tissue loss (78 versus 63 percent and 63 versus 49 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H909633631\">",
"    <span class=\"h3\">",
"     In situ autogenous reconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of an autogenous femoral vein that usually can be fashioned to be of appropriate length and diameter is an option when there is infection of a previously-placed graft and the patient is unable to undergo extra-anatomic revascularization for technical reasons. Sequelae from venous harvest have been surprisingly minimal and the reconstructions durable [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Extra-anatomic reconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are circumstances in which standard aortobifemoral bypass grafting is not ideal, usually because of a high operative risk or the presence of infection in the operative field precluding the use of prosthetic material in that location.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Axillobifemoral bypass graft",
"    </span>",
"    &nbsp;&mdash;&nbsp;Axillobifemoral bypass grafting offers a reasonable alternative in",
"    <strong>",
"     high-risk",
"    </strong>",
"    patients. Since neither the thoracic nor the abdominal cavity is violated when performing an axillofemoral graft, the procedure usually does not interfere with the patient's ability to breathe, cough, or take oral feedings. In addition, it is possible to perform this procedure under local anesthesia, which is particularly important in patients who are poor candidates for major surgery. Additionally, this option is useful in the setting of an infected field such as following the removal of an infected aortobifemoral bypass graft.",
"   </p>",
"   <p>",
"    Cumulative graft patency of approximately 70 percent at five years has been obtained with this procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/12\">",
"     12",
"    </a>",
"    ]. These results are inferior to those for aortofemoral bypass. Thus, axillofemoral bypass grafting is usually reserved for high-risk patients with limb-threatening ischemia; it is not commonly performed for claudication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Femorofemoral bypass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Femoral bypass is a useful option in patients with unilateral iliac occlusive disease whose aorta and contralateral iliac artery are free of disease. Femorofemoral bypass can be performed under regional anesthesia, an important advantage in high-risk patients. Cumulative five-year patency rates of 70 to 80 percent have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H909633572\">",
"    <span class=\"h3\">",
"     Axillopopliteal bypass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Axillopopliteal bypass is generally used as a final attempt to prevent amputation. This procedure consists of a bypass from the axillary artery to the popliteal artery. It is typically performed when the usual options are not available because of groin infection with or without graft infection, extensive operative scarring, or extensive involvement of the iliac and femoral systems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H909633610\">",
"    <span class=\"h2\">",
"     Profundoplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Profundoplasty consists of endarterectomy of the origin and proximal portion of the deep femoral artery. It is most useful when combined with an inflow procedure such as an aortobifemoral bypass or axillofemoral bypass. On occasion, it is performed as an isolated procedure when there is no option for distal bypass. This typically follows graft failure, with a goal of limb salvage even though there is less than maximal improvement in limb perfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Minimally invasive operative alternatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic techniques to minimize the invasiveness of aortobifemoral bypass grafting have been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/14\">",
"     14",
"    </a>",
"    ]. Further data are required to determine their utility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Endovascular grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endovascular stent grafts, similar to those used in the treatment of abdominal aortic aneurysms, have been evaluated for the treatment of aortoiliac occlusive disease. In a series of 42 patients with limb-threatening ischemia followed for a median of 22 months, the four-year primary and secondary patency rates were 66 and 72 percent, respectively, and the limb salvage rate was 89 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/15\">",
"     15",
"    </a>",
"    ]. Although these rates are inferior to conventional open reconstruction, they suggest that endovascular reconstruction affords a reasonable alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SURGERY FOR INFRAINGUINAL DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infrainguinal disease is also called outflow disease. Among patients with both inflow (aortoiliac) and outflow disease, the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommend that inflow lesions be addressed first or simultaneously in selected patients with advanced ischemia manifesting as tissue loss (",
"    <a class=\"graphic graphic_table graphicRef61050 \" href=\"UTD.htm?12/7/12413\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. After this has been accomplished, revascularization of outflow disease is warranted if there is persistent infection, ischemic ulcers, or gangrenous lesions and the ABI is less than 0.8.",
"   </p>",
"   <p>",
"    The guidelines made the following recommendations when surgery is performed for infrainguinal occlusive disease with a clear preference for the use of autogenous vein for the bypass graft [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bypass to the above-knee or below-knee popliteal artery should use autogenous vein if possible.",
"     </li>",
"     <li>",
"      A distal bypass should originate at the most distal artery with continuous flow from above and without a greater than 20 percent stenosis. The tibial or pedal artery that can provide continuous and uncompromised flow to the foot should be the site of distal anastomosis.",
"     </li>",
"     <li>",
"      Femorotibial bypasses should use autogenous vein, such as the ipsilateral greater saphenous vein or, if this is not available, other sources from the leg or arm.",
"     </li>",
"     <li>",
"      When no other form of bypass with an autogenous vein is possible, both a composite sequential femoropopliteal-tibial bypass and bypass to an isolated popliteal artery segment with collateral outflow to the foot can be considered.",
"     </li>",
"     <li>",
"      When autogenous vein is truly unavailable and amputation is imminent, a prosthetic femorotibial bypass and possibly an adjunctive procedure, such as arteriovenous fistula or vein interposition or cuff, should be used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Femoropopliteal bypass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Femoropopliteal bypass is indicated when arteriography reveals that the superficial femoral artery or proximal popliteal artery is occluded and that the patent popliteal artery has luminal continuity with any of its three terminal branches. With a popliteal occlusion, bypass to an isolated segment of popliteal artery usually is effective if the segment is greater than 7 cm in length. If the isolated popliteal segment is less than 7 cm or there is severe gangrene of the foot, a sequential bypass to the popliteal and then to a more distal vessel should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/16\">",
"     16",
"    </a>",
"    ]. Femoropopliteal bypass grafts are categorized as either above-knee or below-knee as determined by the location of the distal graft to artery anastomosis.",
"   </p>",
"   <p>",
"    In order to better categorize outcome data, the following terminology is used [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A graft is considered to have primary patency if there has been uninterrupted patency without a procedure being necessary or performed to deal with stenosis or disease progression in the graft itself or adjacent native vessel, such as transluminal dilatation or proximal or distal extension to the graft [",
"      <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Assisted patency refers to grafts that undergo a revision (such as balloon angioplasty or bypass of a stenosis) prior to actual thrombosis of the graft.",
"     </li>",
"     <li>",
"      The term secondary patency is used if the graft has become occluded but patency has been restored with thrombectomy, thrombolysis, or transluminal angioplasty, or if there are problems with the graft itself or one of its anastomoses that requires revision or reconstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A review of studies published since 1981 found that primary above-knee femoropopliteal graft patency is 84 and 69 percent at one and four years when reverse saphenous vein is the conduit, and 79 and 60 percent at one and four years when polytetrafluoroethylene (PTFE) is used [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/18\">",
"     18",
"    </a>",
"    ]. With below-knee grafts, performed specifically for limb salvage, cumulative primary patency with reverse saphenous vein or PTFE is approximately 90 and 75 percent at one and four years. Secondary patency for PTFE grafts in the below-knee position for all indications is 68 and 40 percent at one and four years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/18\">",
"     18",
"    </a>",
"    ]. Based upon these data, prosthetic material is avoided whenever possible for below-knee bypass because the prosthetic graft crosses the knee joint and is subjected to bending.",
"   </p>",
"   <p>",
"    The use of PTFE is less risky in the above-knee position, and some consider it to be the technique of choice in this setting, citing studies demonstrating early patency rates similar to autologous vein grafting [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/19\">",
"     19",
"    </a>",
"    ]. The use of PTFE has the additional theoretical advantage of preserving the saphenous veins for future coronary bypass or more distal peripheral revision.",
"   </p>",
"   <p>",
"    Several retrospective studies have specifically addressed this issue:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report of a retrospective analysis of a 20-year experience, the need for secondary above-knee repair was only 7 percent with the use of a saphenous vein graft, a probability which did not support the routine use of PTFE when an adequate saphenous vein was available [",
"      <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second study found that the amputation rate following occlusion of vein grafts was lower than that with PTFE grafts (12 versus 26 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/21\">",
"       21",
"      </a>",
"      ]. Furthermore, when amputation was performed, above-knee amputation was much less likely to be required with vein grafts (20 versus 80 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two randomized trials have compared PTFE with other conduits for above-the-knee femoropopliteal grafting.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial compared PTFE with Dacron conduits in 240 patients, 37 percent of whom had limb-threatening ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/22\">",
"       22",
"      </a>",
"      ]. There were no differences in primary (43 versus 45 percent) or secondary patency rates (68 percent) at five years between the two materials. However, the risk for graft occlusion was significantly higher for patients younger than 65 and for grafts with a diameter less than 7 mm.",
"     </li>",
"     <li>",
"      A second trial compared the outcomes of PTFE, human umbilical vein, and saphenous vein bypass in 752 patients, 68 percent of whom had limb-threatening ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/23\">",
"       23",
"      </a>",
"      ]. The cumulative assisted primary patency rates were similar among the three conduit types at two years (69, 70, and 81 percent, respectively). However, at five years, the patency rate was significantly higher with the saphenous vein (73 versus 53 and 39 percent for umbilical vein and PTFE, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings have led to the recommendation that a saphenous vein graft is preferred for above-knee grafts. If a prosthetic bypass graft is used, the human umbilical vein should be considered before PTFE. The argument to preserve saphenous veins for possible coronary artery grafting does not appear justified, and many vascular surgeons prefer the use of autologous vein graft in any position.",
"   </p>",
"   <p>",
"    Despite the good outcome from autologous vein grafts, late occlusion due to progressive disease of arteries on either side of the bypass or deterioration of the graft itself remains a concern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Distal bypass",
"    </span>",
"    &nbsp;&mdash;&nbsp;A distal bypass to the infrapopliteal vessels should be performed only in situations of lower extremity ischemia in which femoropopliteal bypass is not feasible or does not allow graft flow into patent runoff vessels. A review of studies of infrapopliteal grafting published since 1981 noted primary patency rates with reversed saphenous vein graft for all indications of 77 percent and 62 percent at one and four years, and secondary patency rates with PTFE of 68 percent and 48 percent at one and four years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When performed specifically for limb salvage, cumulative patency rates were higher for reversed saphenous vein grafts compared with PTFE in the femoropopliteal position (85 versus 68 percent at one year, and 82 versus 48 percent at four years) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/18\">",
"     18",
"    </a>",
"    ]. Reported primary patency rates of PTFE grafts in the infrapopliteal position at three to five years have ranged from 12 to 41 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/19,24,25\">",
"     19,24,25",
"    </a>",
"    ]. Thus, most surgeons avoid, if at all possible, prosthetic material for bypass of infrapopliteal arteries.",
"   </p>",
"   <p>",
"    The most important factor in choosing an outflow vessel for the distal anastomosis of an infrapopliteal bypass is the overall quality of the vessel. If two vessels of excellent quality are available, the preference probably should go to the vessel with the greatest degree of direct continuity with the foot. If no other factors are involved, the generally accepted order of preference for the infrapopliteal anastomosis is the posterior tibial artery, the anterior tibial artery, and the peroneal artery. The peroneal artery may be less desirable because it is deeper and more difficult to expose and because it is not directly continuous with the pedal arteries, and therefore thought by some to produce an inferior result in the setting of foot gangrene.",
"   </p>",
"   <p>",
"    However, the possible lower efficacy of peroneal artery grafts has been questioned. One retrospective study evaluated 118 infrainguinal vein grafts; there was no difference in hemodynamic parameters among grafts to the peroneal, anterior tibial, posterior tibial, or popliteal arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PERCUTANEOUS INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous intervention (angioplasty, stent) is a less invasive alternative to surgery in patients with critical limb ischemia. The BASIL trial discussed above found less short-term morbidity with percutaneous transluminal angioplasty compared with surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/6\">",
"     6",
"    </a>",
"    ]. Long-term outcomes, however, appear to favor a bypass-surgery-first approach.",
"   </p>",
"   <p>",
"    As a result, the",
"    <span class=\"nowrap\">",
"     ACC/ACA",
"    </span>",
"    guidelines recommend that percutaneous transluminal angioplasty (PTA) be offered first to patients with significant comorbidities who are not expected to live more than one to two years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. For patients expected to live longer than two years and who are good surgical candidates with adequate autogenous vein, the reduced intervention rate and possible improved durability with bypass surgery could outweigh the short-term increase in morbidity. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Bypass surgery first versus angioplasty first'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Among patients with both inflow (aortoiliac) and outflow (infrainguinal) disease, the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommend that significant inflow lesions be addressed first, whether surgery or percutaneous intervention is performed (",
"    <a class=\"graphic graphic_table graphicRef61050 \" href=\"UTD.htm?12/7/12413\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. After this has been accomplished, revascularization of outflow disease is warranted if there is persistent infection or symptoms. If the hemodynamic significance of the inflow disease is unclear, intraarterial pressure measurements should be obtained across suprainguinal lesions before and after the administration of a vasodilator.",
"   </p>",
"   <p>",
"    Subintimal recanalization, also called percutaneous intentional extraluminal and subintimal angioplasty, is a technique for managing chronic occlusions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/27\">",
"     27",
"    </a>",
"    ]. This technique has been used primarily for femoropopliteal revascularization, but has been used in iliac and tibial vessels as well.",
"   </p>",
"   <p>",
"    Subintimal recanalization is performed by inserting a guidewire into the vessel above the occlusion and passing it into the subintimal space. The guidewire is advanced through the subintimal space distally and reenters the true vessel lumen beyond the occlusion. Balloon dilatation is then performed in the subintimal space to create a perfusion channel parallel to the occluded vessel segment.",
"   </p>",
"   <p>",
"    An early large series described 200 consecutive femoropopliteal occlusions treated with subintimal recanalization [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/28\">",
"     28",
"    </a>",
"    ]. The procedure was technically successful in 159 (80 percent). Among the successful procedures, the mean ankle brachial index improved from 0.61 to 0.90, and the new perfusion channel remained hemodynamically patent in 71 and 58 percent at 12 and 36 months, respectively.",
"   </p>",
"   <p>",
"    In another report, 39 patients with arterial occlusions, including 25 with gangrene and 14 with claudication or rest pain, underwent subintimal recanalization [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/29\">",
"     29",
"    </a>",
"    ]. Technical success was achieved in 34 (87 percent); all five failed procedures were due to inability to reenter the true lumen distally. Claudication or rest pain resolved in all 14 patients with these symptoms, and gangrene healed in 21 of 25 cases. The cumulative patency rate among patients with successful procedures was 74 percent at 12 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PRIMARY AMPUTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of patients presenting with critical limb ischemia can be offered a reasonable attempt at limb salvage. Overall, only about 25 percent of patients with critical limb ischemia undergo amputation within one year [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines identified the following as risk factors for amputation in patients with limb-threatening ischemia (now called critical limb ischemia) (",
"    <a class=\"graphic graphic_table graphicRef61050 \" href=\"UTD.htm?12/7/12413\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Significant necrosis of weight-bearing parts of the foot in ambulatory patients",
"     </li>",
"     <li>",
"      An uncorrectable flexion contracture",
"     </li>",
"     <li>",
"      Paresis of the extremity",
"     </li>",
"     <li>",
"      Ischemic rest pain",
"     </li>",
"     <li>",
"      Sepsis",
"     </li>",
"     <li>",
"      Limited life expectancy due to comorbid disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One such setting is when gangrene extends into the deeper tissues of the tarsal region of the foot or myonecrosis involves the lower leg; primary amputation at the below-knee level is probably indicated in such patients.",
"   </p>",
"   <p>",
"    If the patient is reasonably healthy, a well-fitting prosthesis will provide excellent functionality. The functional outcome following below-knee amputation is far better than that following amputation at the ankle. This is due, in large part, to the better fit at the leg as opposed to the ankle, and excellent cosmesis of modern prosthetics.",
"   </p>",
"   <p>",
"    An above-knee primary amputation should be considered when the patient is unable to ambulate, communicate, or provide self care. Relative disadvantages of below-knee amputations in this situation include a lesser likelihood of healing than more proximal amputation and the development of severe contractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SPECIFIC ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several clinical settings in which there are specific issues that may alter the above general principles of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Infrainguinal bypass in older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the increasing emphasis on cost containment, the appropriateness of surgical procedures, particularly in older adults, is constantly being scrutinized. Elderly patients with peripheral artery disease have a higher mortality than age-matched controls. On the other hand, elderly patients are also less able to function with a prosthesis, and limb salvage in a previously ambulatory individual may mean the difference between self care, with a good quality of life and independence, and nursing home dependence with markedly increased costs.",
"   </p>",
"   <p>",
"    In an attempt to address this issue, a retrospective study evaluated 88 patients over 80 years of age who underwent revascularization primarily for limb salvage and were then followed for a ten-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/30\">",
"     30",
"    </a>",
"    ]. An infrainguinal bypass was performed in 85 percent, while 15 percent had an extraanatomic bypass (eg, axillobifemoral or femoral-femoral grafting). Perioperative mortality rate was 6 percent with a mean hospital stay of 18 days. The following results were noted at one and three years:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Primary graft patency &ndash; 88 and 66 percent",
"     </li>",
"     <li>",
"      Limb salvage &ndash; 94 and 91 percent",
"     </li>",
"     <li>",
"      Patient survival &ndash; 73 and 51 percent",
"     </li>",
"     <li>",
"      Survivors living at home and ambulatory &ndash; 100 and 84 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It was concluded that patients over the age of 80 have satisfactory results that do not justify withholding vascular reconstruction on the basis of age alone. Other studies have supported this point of view [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Infrainguinal bypass in chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A longstanding controversy in vascular surgery involves the treatment of critical limb ischemia in patients with chronic kidney disease, particularly those with diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20905?source=see_link\">",
"     \"Peripheral artery disease in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/16/37128?source=see_link\">",
"     \"Lower extremity peripheral artery disease in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of critical limb ischemia in patients with chronic kidney disease was addressed by two retrospective studies. The first involved 56 patients with a serum creatinine level above 2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    who underwent 70 autogenous vein bypass procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/33\">",
"     33",
"    </a>",
"    ]. The operative mortality rate was 11 percent, with a five-year primary graft patency of 74 percent and a limb salvage rate of 77 percent. The overall five-year survival was only 40 percent in the group as a whole and only 21 percent in diabetics who also had a lower limb salvage rate of 63 percent. No patient on dialysis survived beyond three years. Thus, despite the increased mortality, graft patency and limb salvage were similar to results obtained in patients with normal renal function.",
"   </p>",
"   <p>",
"    A second series consisted of 53 patients with end-stage renal disease who underwent 69 distal arterial reconstructions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/34\">",
"     34",
"    </a>",
"    ]. The mortality rate was 10 percent at 30 days, with a two-year survival rate of 38 percent. The primary patency rate was 68 percent at two years; however, 59 percent of amputations were performed in patients with a patent graft. Failure of foot salvage in these patients was often due to impaired wound healing rather than graft thrombosis.",
"   </p>",
"   <p>",
"    It would seem wise to attempt revascularization in patients with advanced renal disease before extensive gangrene is present. However, primary amputation should be considered in those with an infected, gangrenous foot. Further study may help to improve patient selection for bypass versus primary amputation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     MEDICAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H909635263\">",
"    <span class=\"h2\">",
"     Risk factor reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiplatelet therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    75 to 325 mg) is indicated to reduce the risk of MI, stroke, and vascular death in individuals with symptomatic atherosclerotic lower extremity PAD, including those with critical limb ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/4\">",
"     4",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     Clopidogrel",
"    </a>",
"    is an effective alternative to aspirin in those who cannot take aspirin. Risk factor reduction strategies including control of hypertension, hyperlipidemia, and blood sugar, as well as smoking cessation are essential. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link&amp;anchor=H2#H2\">",
"     \"Medical management of claudication\", section on 'Risk factor modification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H909635301\">",
"    <span class=\"h2\">",
"     Aggressive wound care",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of patients with critical limb ischemia can be successfully treated with conservative management consisting of medical optimization and aggressive wound care. At a Veterans Health Care Administration Hospitals involved in their mandatory Prevention of Amputation Care Team (PACT) programs, 49 patients were assigned to conservative management [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/35\">",
"     35",
"    </a>",
"    ]. Inclusion criteria included the presence of a nonhealing wound (ulcer, gangrene, surgical wound) for at least six weeks, ABI &lt;0.9 but a TcPO2 &ge;30 mmHg. Patients were expected to be compliant with weekly or biweekly follow-up. Wounds healed with conservative management alone in 67 percent of the patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link\">",
"     \"Basic principles of wound management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data to support the routine use of primary pharmacologic therapy in patients with critical leg ischemia, and the best therapeutic options are revascularization with surgery or PTA. However, many patients are poor candidates for either procedure because of concomitant diseases or unfavorable anatomy. Medical therapies would be desirable in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Prostaglandin E1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostaglandin E1 (PGE1) is a vasodilator and inhibitor of platelet aggregation. However, it is rapidly inactivated in the lungs, and must be given intra-arterially or intravenously using large doses. One study randomly assigned 1560 patients with chronic critical leg ischemia (rest pain for &ge;2 weeks, foot ulceration, or gangrene) to treatment with intravenous PGE1 (alprostadil) or no PGE1 for 28 days [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/36\">",
"     36",
"    </a>",
"    ]. At hospital discharge, the combined endpoint (death, amputation, persistence of critical leg ischemia, acute myocardial infarction, or stroke) was significantly lower in the treated patients (64 versus 74 percent for no treatment, p&lt;0.001). However, there was no long-term clinical benefit and at six months there was no significant difference in the end point (53 versus 58 percent).",
"   </p>",
"   <p>",
"    The 2007 TASC II consensus document on the management of PAD does not recommend PGE1 or any other prostanoids for the management of limb-threatening ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Stimulation of angiogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stimulation of angiogenesis is an investigational approach to the therapy of critical limb ischemia. Two modalities have been studied: therapeutic angiogenesis and autologous implantation of bone marrow mononuclear cells. Therapeutic angiogenesis is also being evaluated in patients with intermittent claudication and refractory angina. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/4/6216?source=see_link\">",
"     \"Therapeutic angiogenesis for management of refractory angina\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link&amp;anchor=H29#H29\">",
"     \"Medical management of claudication\", section on 'Investigational agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapeutic angiogenesis involves the administration of angiogenic growth factors, as recombinant protein or naked DNA, to augment the collateral circulation and enhance blood flow to ischemic tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/37\">",
"     37",
"    </a>",
"    ]. The intravenous or intramuscular gene transfer of naked plasmid DNA, encoding for vascular endothelial growth factor, can induce marked improvement in endothelial function, flow reserve, collateral vessel development, healing of ischemic ulcers, and limb salvage, eliminating the need for amputation in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential efficacy of autologous implantation of bone marrow mononuclear cells to stimulate angiogenesis has been suggested by studies that have found improvement in several measures of limb ischemia such as ankle brachial index, toe pressures, pain-free walking time and rest pain after injection of autologous bone marrow compared with control injections of peripheral blood mononuclear cells or saline in patients who are not candidates for revascularization (surgical or nonsurgical) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/41-44\">",
"     41-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A multicenter trial of patients with critical limb ischemia and no option for revascularization (RESTORE-CLI) randomly assigned 86 patients to bone marrow aspiration injected into 20 sites in the ischemic lower extremity versus sham aspiration (no injection). The interim analysis reported on 33 patients completing the trial with 12 months of follow-up, and 46 patients who completed at least 6 months of follow-up. Bone marrow injection was associated with significant increases in the time to treatment failure and amputation-free survival. There were no differences in adverse or serious adverse events between the groups. The incidence of major amputation was lower in the treated group (19 versus 43 percent).",
"   </p>",
"   <p>",
"    Similar benefits may be achieved by multiple intramuscular injections of autologous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    mobilized peripheral blood mononuclear cells into ischemic limbs. In a pilot randomized trial of 28 diabetic patients with critical limb ischemia, this approach compared with controls was associated with improved lower limb perfusion, as demonstrated by Doppler studies and an increase in the mean ankle-brachial pressure index and a doubling of the rate of healing of ischemic ulcers (14 of 18 versus 7 of 18) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effectiveness of intramuscular fibroblast growth factor is disputed. One trial involving 125 patients found a significantly reduced risk of major amputation (16 versus 34 percent) for intramuscular NV1FGF compared with placebo in patients with critical limb ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/46\">",
"     46",
"    </a>",
"    ]. However, a later trial that randomly assigned 525 patients to fibroblast growth factor",
"    <span class=\"nowrap\">",
"     (NV1FGF/TAMARIS)",
"    </span>",
"    or placebo found no significant differences in the primary combined endpoint of major amputation or death [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Spinal cord stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial uncontrolled studies suggested that spinal cord stimulation was effective for pain relief and might prevent or delay amputation and improve limb survival [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. However, a controlled trial that randomly assigned 120 patients to spinal cord stimulation in addition to best medical therapy or to best medical therapy alone found that the rates of survival and amputation were the same in both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/50\">",
"     50",
"    </a>",
"    ]. Pain scores were also similar, although the spinal cord stimulation group was able to reduce pain medications by approximately 50 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H519589146\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommend periodic follow-up after surgery for claudication [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/2\">",
"     2",
"    </a>",
"    ]. Follow-up consists of periodic clinical evaluations that should note any return or progression of symptoms of claudication, the presence of pulses, and measurement of the ankle-brachial pressure index (ABI) at both rest and after exercise, as needed, and for infrainguinal bypass duplex imaging of the entire length of the graft with measurement of peak systolic velocity and calculation of velocity ratio across all lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H58544655#H58544655\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Ankle-brachial index'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H909633736\">",
"    <span class=\"h2\">",
"     Duplex ultrasound surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful surveillance is recommended following vascular reconstruction. Assisted patency refers to grafts that undergo a revision (such as balloon angioplasty or bypass of a stenosis) prior to actual thrombosis of the graft. Grafts that are carefully monitored following grafting and in which a detected stenosis is addressed (eg, balloon angioplasty or bypass of the stenotic segment) do far better in the long term than grafts that are revised only following complete thrombosis. Similarly, early and ongoing surveillance of following infrainguinal percutaneous intervention may identify impending failures, but the use of duplex following percutaneous intervention continues to be defined [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Failure is a major concern for vein bypass grafts and its prevention requires surveillance. There are three major time periods for graft failure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Failure in the immediate or early postoperative period (&lt;30 days) is most often due to technical complications or judgmental error. Other causes include inadequate outflow, infection, and an unrecognized hypercoagulable state.",
"     </li>",
"     <li>",
"      Failure between 30 days and two years is most often the result of myointimal hyperplasia within the vein graft or at anastomotic sites.",
"     </li>",
"     <li>",
"      Late graft failure is usually due to the natural progression of atherosclerotic disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is estimated that vein graft stenosis develops in 20 to 30 percent of infrainguinal vein bypasses during the first year, which can often lead to graft thrombosis and failure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/53\">",
"     53",
"    </a>",
"    ]. Intervention based upon a duplex surveillance protocol has resulted in five-year assisted patency rates of 82 to 93 percent, significantly higher than the 30 to 50 percent secondary patency rates of thrombosed vein grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A typical surveillance protocol would include duplex ultrasonography to measure flow velocity and the velocity ratio across a stenosis. We perform examinations perioperatively and six weeks postoperatively, at three-month intervals for two years, and every six months thereafter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H519589542\">",
"    <span class=\"h2\">",
"     Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommend the following surveillance approach after bypass has been performed for limb-threatening ischemia (now called critical limb ischemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients in whom aortobifemoral bypass has been performed should have periodic evaluations by a vascular specialist at least twice yearly that note any return or progression of ischemic symptoms, the presence of femoral pulses, and measurement of the ABI.",
"     </li>",
"     <li>",
"      Patients in whom lower extremity bypass with an autogenous vein graft has been performed should have periodic evaluations at least twice yearly for at least two years to detect any return or progression of ischemic symptoms, a physical examination with emphasis on examination of the pulse of the proximal, graft, and outflow vessels, and duplex imaging of the entire length of the graft, with measurement across all lesions of peak systolic velocities and calculation of velocity ratios.",
"     </li>",
"     <li>",
"      Further evaluation is indicated in vein grafts which develop global flow velocities less than 45",
"      <span class=\"nowrap\">",
"       cm/sec,",
"      </span>",
"      or develop a stenosis manifested by a peak systolic velocity &gt;300",
"      <span class=\"nowrap\">",
"       cm/sec",
"      </span>",
"      and a velocity ratio of more than 3.5 across the stenosis. Serial measurement of the ABI can also be performed. A decrease of more than 0.15 between examinations is considered significant. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14486?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical manifestations and evaluation of chronic critical limb ischemia\", section on 'Patient evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients in whom a synthetic lower extremity bypass graft has been placed should have periodic evaluations at least twice yearly for at least two years that note any return of ischemic symptoms, examination of the pulse of the proximal, graft, and outflow vessels, and measurement of the ABI at rest.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H519589654\">",
"    <span class=\"h1\">",
"     ANTITHROMBOTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following lower extremity arterial bypass, the benefits of the long-term administration of antithrombotic therapy remain unclear. Antiplatelet agents or anticoagulants are often used to prevent graft occlusion, although data about their efficacy are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A Cochrane review of trials of antiplatelet therapy found a beneficial effect of treatment on graft patency, with an odds ratio (OR) for primary occlusion at 12 months of 0.59 (95% CI 0.45-0.79) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/55\">",
"     55",
"    </a>",
"    ]. Patients receiving a prosthetic graft (OR 0.22) were more likely to benefit from an antiplatelet agent than those receiving a vein graft (OR 0.69). No significant effect on cardiovascular outcomes or survival was detected. Similar conclusions were reached in another meta-analysis, which also found a benefit from anticoagulant therapy (OR 0.54), but it was not statistically significant because of the small numbers of patients available for analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral anticoagulants may be better than antiplatelet agents for preventing vein graft occlusion, while the reverse may be true for prosthetic grafts. The following studies illustrate this point:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (80 mg daily) with oral anticoagulation (titrated to an INR of 3 to 4.5) in 2690 patients who had undergone infrainguinal grafting [",
"      <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/57\">",
"       57",
"      </a>",
"      ]. After a mean follow-up of 21 months, the primary endpoint of graft occlusion was the same for the two therapies for all grafts; however, the risk of graft occlusion tended to be lower in patients with vein grafts on oral anticoagulants (hazard ratio [HR] 0.69, 95% CI 0.82-1.11), and patients with nonautogenous grafts taking aspirin (HR 1.26, 95% CI 1.03-1.55). There was no significant difference in the composite endpoint of vascular death, nonfatal myocardial infarction, nonfatal stroke, or amputation.",
"     </li>",
"     <li>",
"      A trial randomly assigned 831 patients with prosthetic or vein grafts to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (target INR 1.4 to 2.8) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (325",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or aspirin (325",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      alone [",
"      <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/58\">",
"       58",
"      </a>",
"      ]. No differences were seen in long-term patency rates for vein grafts or 8 mm prosthetic grafts, but there was a significantly increased patency rate for patients taking warfarin who had 6 mm prosthetic bypass grafts (71.4 versus 57.9 percent). However, there were significantly more deaths in the warfarin group (31.8 versus 23 percent) compared with the ASA group with more major hemorrhagic events occurring in those on warfarin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of dual antiplatelet therapy is speculated to improve lower extremity bypass patency based upon a beneficial effect seen in patients with acute coronary syndromes. A multicenter trial that randomized 851 patients to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (75 to 100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    versus placebo plus aspirin found no differences in the incidence of graft occlusion, amputation or death between the treatment groups [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/59\">",
"     59",
"    </a>",
"    ]. However, a preplanned subgroup analysis of patients who received prosthetic grafts (N = 253) found a significantly reduced risk of graft occlusion (0.63, 95% CI 0.42-0.93) and amputation (0.48, 95% CI 0.24-0.96) in those treated with dual antiplatelet therapy compared with aspirin alone. The incidence of severe bleeding (2.7 versus 1.0 percent) was not significantly different between the groups, although significantly more episodes of bleeding were recorded in the clopidogrel group overall (15.8 versus 6.1 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H519589661\">",
"    <span class=\"h2\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Chest Physicians (ACCP) guideline on antithrombotic therapy for peripheral artery occlusive disease made the following recommendations for the use of antithrombotic agents in patients undergoing infrainguinal vascular surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/58/19370/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      therapy (75 to 100",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      should begin preoperatively and continue indefinitely in all patients undergoing infrainguinal bypass or arterial reconstruction.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      , or other vitamin K antagonist, is not routinely recommended in patients undergoing infrainguinal arterial reconstruction or bypass, except in those at high risk of bypass occlusion and limb loss.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We agree with major society guidelines that recommend long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    for all patients with atherosclerotic peripheral artery disease. As stated above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    can be considered for patients at high risk for graft thrombosis, but may provide more benefit for those with a vein bypass graft while dual antiplatelet therapy (aspirin plus clopidogrel) may be more appropriate for high risk patients with a prosthetic graft. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link&amp;anchor=H40#H40\">",
"     \"Medical management of claudication\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H519577942\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower extremity critical limb ischemia occurs in 1 to 2 percent of patients with peripheral artery disease &ge;50 years of age resulting in approximately 500 to 1,000 new cases of critical limb ischemia per million each year. In contrast to the typically benign natural history of mild and moderate claudication, the natural history of critical limb ischemia is one of progression, usually leading to the need for amputation unless an intervention resulting in improved arterial perfusion is undertaken. (See",
"      <a class=\"local\" href=\"#H554865745\">",
"       'Introduction and definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with lower extremity critical ischemia present with rest pain, which is pain across the base of the metatarsal heads at rest relieved by dependency, or with tissue loss, which can be ulceration, dry gangrene or wet gangrene. An ankle-brachial index &lt;0.4, flat waveforms on pulse volume recording, and low or absent pedal flow on duplex ultrasonography are consistent with critical limb ischemia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with peripheral artery disease should be treated with antiplatelet agents to reduce their cardiovascular risk, and for patients who undergo infrainguinal bypass, to improve graft patency. Antiplatelet therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      75 to 325 mg) is effective at reducing the risk of MI, stroke, and vascular death in individuals with symptomatic atherosclerotic lower extremity PAD, including those with critical limb ischemia.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       Clopidogrel",
"      </a>",
"      is an alternative to aspirin in those who cannot take aspirin. Other risk factor reduction strategies include smoking cessation, and controlling hypertension, hyperlipidemia, and blood sugar. (See",
"      <a class=\"local\" href=\"#H909635263\">",
"       'Risk factor reduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"       \"Secondary prevention of cardiovascular disease\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H519589654\">",
"       'Antithrombotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients presenting with critical limb ischemia can be offered a reasonable attempt at limb salvage; however, primary amputation may be more appropriate for some patients. Factors that may indicate a need for primary amputation include sepsis, paresis of the extremity, uncorrectable flexion contracture, significant necrosis of weight-bearing parts of the foot in ambulatory patients and limited life expectancy. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Primary amputation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are poor candidates for intervention because of comorbidities or unfavorable arterial anatomy but who do not wish to proceed with primary amputation can be managed with conservative therapy consisting of pain control, aggressive wound care and pharmacologic therapies aimed at improving wound healing such as therapeutic angiogenesis and prostaglandin therapy. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Depending upon the characterization of a given lesion, a patient with critical limb ischemia might benefit from a surgery-first or an angioplasty-first approach. Based upon overall success rates for treating aortoiliac, femoral and popliteal lesions using endovascular or surgical means, the TASC classification groups arterial lesions into those favoring endovascular therapy (Type A, Type B) and those favoring surgery (Type D, Type C). The TASC classification, however, does not provide guidance for the treatment of tibial vessel disease and does not address multilevel disease which is typical for patients with critical limb ischemia. (See",
"      <a class=\"local\" href=\"#H909632825\">",
"       'TASC classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with inflow (aortoiliac) and outflow (infrainguinal) disease, the",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines recommend that inflow lesions be addressed first (surgery or percutaneous intervention). Once this has been accomplished, infrainguinal revascularization is warranted for persistent infection, ischemic ulcers, or gangrene, and the ankle-brachial pressure index (ABI) is &lt;0.8. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Surgery for inflow disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Percutaneous intervention (angioplasty, stent) is a less invasive alternative to surgery in patients with critical limb ischemia. The bypass versus angioplasty in severe ischemia of the leg (BASIL) trial found less short-term morbidity with percutaneous transluminal angioplasty compared with surgery, but the long-term outcomes appeared to favor a surgery-first approach. As a result, the",
"      <span class=\"nowrap\">",
"       ACC/ACA",
"      </span>",
"      guidelines recommend that PTA be offered first to patients with significant comorbidities who are not expected to live more than one to two years. For patients expected to live longer than two years and who are good surgical candidates with adequate autogenous vein, the reduced intervention rate and durability of bypass surgery probably outweighs the short-term increase in morbidity. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Percutaneous intervention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When surgery is needed for infrapopliteal occlusive disease, autogenous vein as the bypass conduit is preferred. Ipsilateral or contralateral saphenous vein should be used preferentially, or if not available, arm vein (basilic vein, cephalic vein) can be used as an alternative. If the length of available vein is limited, alternative grafts can be effective including splicing together more than one vein segment, use of composite grafts (vein and prosthetic), or use of prosthetic with a vein patch at the distal anastomosis. Antithrombotic therapy appears to decrease the risk of long-term graft thrombosis.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      can be considered for patients at high risk for graft thrombosis, but may provide more benefit for those with a vein bypass graft while dual antiplatelet therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      ) may be more appropriate for high-risk patients with a prosthetic graft. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Surgery for infrainguinal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following revascularization, periodic clinical evaluations should note the regression of symptoms, wound healing progression, the presence of pulses, and measurement of the ankle-brachial pressure index (ABI), and for infrainguinal bypass, duplex imaging of the entire length of the graft to evaluate for graft stenosis. Vein graft stenosis develops in 20 to 30 percent of infrainguinal vein bypasses during the first year, and can lead to graft failure. We prefer to examine grafts perioperatively and at six weeks postoperatively, then at three-month intervals for two years, and every six months thereafter. Grafts that are monitored and treated when a significant stenosis is identified have better long-term patency rates (82 to 93 percent versus 30 to 50 percent) compared with those that require thrombectomy and revision following a complete thrombosis. (See",
"      <a class=\"local\" href=\"#H909633736\">",
"       'Duplex ultrasound surveillance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/1\">",
"      Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45 Suppl S:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/2\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/3\">",
"      Dormandy J, Heeck L, Vig S. The fate of patients with critical leg ischemia. Semin Vasc Surg 1999; 12:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/4\">",
"      2011 WRITING GROUP MEMBERS, 2005 WRITING COMMITTEE MEMBERS, ACCF/AHA TASK FORCE MEMBERS. 2011 ACCF/AHA Focused Update of the Guideline for the Management of patients with peripheral artery disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011; 124:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/5\">",
"      Wolf GL, Wilson SE, Cross AP, et al. Surgery or balloon angioplasty for peripheral vascular disease: a randomized clinical trial. Principal investigators and their Associates of Veterans Administration Cooperative Study Number 199. J Vasc Interv Radiol 1993; 4:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/6\">",
"      Adam DJ, Beard JD, Cleveland T, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet 2005; 366:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/7\">",
"      Bradbury AW, Adam DJ, Bell J, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: An intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy. J Vasc Surg 2010; 51:5S.",
"     </a>",
"    </li>",
"    <li>",
"     Abbott, WM, Kwolek, CJ. Aortofemoral bypass for atherosclerotic aortoiliac occlusive disease. In: Current Therapy in Vascular Surgery, Ernst, CB, Stanley, JC (Eds), Mosby-Year Book, St. Louis 1995. p.355.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/9\">",
"      Harris RA, Hardman DT, Fisher C, et al. Aortic reconstructive surgery for limb ischaemia: immediate and long-term follow-up to provide a standard for endovascular procedures. Cardiovasc Surg 1998; 6:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/10\">",
"      Poulias GE, Doundoulakis N, Prombonas E, et al. Aorto-femoral bypass and determinants of early success and late favourable outcome. Experience with 1000 consecutive cases. J Cardiovasc Surg (Torino) 1992; 33:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/11\">",
"      Valentine RJ, Clagett GP. Aortic graft infections: replacement with autogenous vein. Cardiovasc Surg 2001; 9:419.",
"     </a>",
"    </li>",
"    <li>",
"     Mannick, JA, Whittemore, AD. Aortoiliac occlusive disease. In: Vascular Surgery: A Comprehensive Review, Moore, WS (Ed), WB Saunders, Philadelphia 1991. p.350.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/13\">",
"      Pursell R, Sideso E, Magee TR, Galland RB. Critical appraisal of femorofemoral crossover grafts. Br J Surg 2005; 92:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/14\">",
"      Ahn SS, Hiyama DT, Rudkin GH, et al. Laparoscopic aortobifemoral bypass. J Vasc Surg 1997; 26:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/15\">",
"      Wain RA, Veith FJ, Marin ML, et al. Analysis of endovascular graft treatment for aortoiliac occlusive disease: what is its role based on midterm results? Ann Surg 1999; 230:145.",
"     </a>",
"    </li>",
"    <li>",
"     Veith, FJ, Gupta, SK, Wengerter, KR, et al. Femoral-popliteal-tibial occlusive disease. In: Vascular Surgery: A Comprehensive Review, Moore, WS (Ed), WB Saunders, Philadelphia 1991. p.364.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/17\">",
"      Suggested standards for reports dealing with lower extremity ischemia. Prepared by the Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery/North American Chapter, International Society for Cardiovascular Surgery. J Vasc Surg 1986; 4:80.",
"     </a>",
"    </li>",
"    <li>",
"     Dalman, RL, Taylor, LM Jr. Infrainguinal revascularization procedures. In: Basic Data Underlying Clinical Decision Making in Vascular Surgery, Porter, JM, Taylor, LM, Jr (Eds), Quality Medical Publishing, St. Louis 1994. p.141.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/19\">",
"      Veith FJ, Gupta SK, Ascer E, et al. Six-year prospective multicenter randomized comparison of autologous saphenous vein and expanded polytetrafluoroethylene grafts in infrainguinal arterial reconstructions. J Vasc Surg 1986; 3:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/20\">",
"      Berlakovich GA, Herbst F, Mittlb&ouml;ck M, Kretschmer G. The choice of material for above-knee femoropopliteal bypass. A 20-year experience. Arch Surg 1994; 129:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/21\">",
"      Wilson YG, Wyatt MG, Currie IC, et al. Preferential use of vein for above-knee femoropopliteal grafts. Eur J Vasc Endovasc Surg 1995; 10:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/22\">",
"      Green RM, Abbott WM, Matsumoto T, et al. Prosthetic above-knee femoropopliteal bypass grafting: five-year results of a randomized trial. J Vasc Surg 2000; 31:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/23\">",
"      Johnson WC, Lee KK. A comparative evaluation of polytetrafluoroethylene, umbilical vein, and saphenous vein bypass grafts for femoral-popliteal above-knee revascularization: a prospective randomized Department of Veterans Affairs cooperative study. J Vasc Surg 2000; 32:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/24\">",
"      Qui&ntilde;ones-Baldrich WJ, Prego AA, Ucelay-Gomez R, et al. Long-term results of infrainguinal revascularization with polytetrafluoroethylene: a ten-year experience. J Vasc Surg 1992; 16:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/25\">",
"      Fichelle JM, Marzelle J, Colacchio G, et al. Infrapopliteal polytetrafluoroethylene and composite bypass: factors influencing patency. Ann Vasc Surg 1995; 9:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/26\">",
"      Raftery KB, Belkin M, Mackey WC, O'Donnell TF. Are peroneal artery bypass grafts hemodynamically inferior to other tibial artery bypass grafts? J Vasc Surg 1994; 19:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/27\">",
"      Nadal LL, Cynamon J, Lipsitz EC, Bolia A. Subintimal angioplasty for chronic arterial occlusions. Tech Vasc Interv Radiol 2004; 7:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/28\">",
"      London NJ, Srinivasan R, Naylor AR, et al. Subintimal angioplasty of femoropopliteal artery occlusions: the long-term results. Eur J Vasc Surg 1994; 8:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/29\">",
"      Lipsitz EC, Ohki T, Veith FJ, et al. Does subintimal angioplasty have a role in the treatment of severe lower extremity ischemia? J Vasc Surg 2003; 37:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/30\">",
"      Nehler MR, Moneta GL, Edwards JM, et al. Surgery for chronic lower extremity ischemia in patients eighty or more years of age: operative results and assessment of postoperative independence. J Vasc Surg 1993; 18:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/31\">",
"      O'Brien TS, Lamont PM, Crow A, et al. Lower limb ischaemia in the octogenarian: is limb salvage surgery worthwhile? Ann R Coll Surg Engl 1993; 75:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/32\">",
"      Hearn AT, Smith JM, Welling RE, et al. Analysis of autogenous vein femoral-infrapopliteal bypass for limb salvage in the elderly. Cardiovasc Surg 1996; 4:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/33\">",
"      Whittemore AD, Donaldson MC, Mannick JA. Infrainguinal reconstruction for patients with chronic renal insufficiency. J Vasc Surg 1993; 17:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/34\">",
"      Johnson BL, Glickman MH, Bandyk DF, Esses GE. Failure of foot salvage in patients with end-stage renal disease after surgical revascularization. J Vasc Surg 1995; 22:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/35\">",
"      Chiriano J, Bianchi C, Teruya TH, et al. Management of lower extremity wounds in patients with peripheral arterial disease: a stratified conservative approach. Ann Vasc Surg 2010; 24:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/36\">",
"      Prostanoids for chronic critical leg ischemia. A randomized, controlled, open-label trial with prostaglandin E1. The ICAI Study Group. Ischemia Cronica degli Arti Inferiori. Ann Intern Med 1999; 130:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/37\">",
"      Takeshita S, Zheng LP, Brogi E, et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994; 93:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/38\">",
"      Isner JM, Pieczek A, Schainfeld R, et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996; 348:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/39\">",
"      Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/40\">",
"      Rajagopalan S, Shah M, Luciano A, et al. Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve. Circulation 2001; 104:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/41\">",
"      Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002; 360:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/42\">",
"      Higashi Y, Kimura M, Hara K, et al. Autologous bone-marrow mononuclear cell implantation improves endothelium-dependent vasodilation in patients with limb ischemia. Circulation 2004; 109:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/43\">",
"      Murphy MP, Lawson JH, Rapp BM, et al. Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia. J Vasc Surg 2011; 53:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/44\">",
"      Franz RW, Shah KJ, Johnson JD, et al. Short- to mid-term results using autologous bone-marrow mononuclear cell implantation therapy as a limb salvage procedure in patients with severe peripheral arterial disease. Vasc Endovascular Surg 2011; 45:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/45\">",
"      Huang P, Li S, Han M, et al. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 2005; 28:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/46\">",
"      Nikol S, Baumgartner I, Van Belle E, et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther 2008; 16:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/47\">",
"      Belch J, Hiatt WR, Baumgartner I, et al. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 2011; 377:1929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/48\">",
"      Horsch S, Claeys L. Epidural spinal cord stimulation in the treatment of severe peripheral arterial occlusive disease. Ann Vasc Surg 1994; 8:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/49\">",
"      Mingoli A, Sciacca V, Tamorri M, et al. Clinical results of epidural spinal cord electrical stimulation in patients affected with limb-threatening chronic arterial obstructive disease. Angiology 1993; 44:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/50\">",
"      Klomp HM, Spincemaille GH, Steyerberg EW, et al. Spinal-cord stimulation in critical limb ischaemia: a randomised trial. ESES Study Group. Lancet 1999; 353:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/51\">",
"      Humphries MD, Pevec WC, Laird JR, et al. Early duplex scanning after infrainguinal endovascular therapy. J Vasc Surg 2011; 53:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/52\">",
"      Shames ML. Duplex surveillance of lower extremity endovascular interventions. Perspect Vasc Surg Endovasc Ther 2007; 19:370.",
"     </a>",
"    </li>",
"    <li>",
"     Bandyk, DF. Surveillance of lower extremity bypass grafts. In: Current Therapy in Vascular Surgery, Ernst, CB, Stanley, JC (Eds), Mosby-Year Book, St. Louis 1995. p. 492.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/54\">",
"      Lindblad B, Wakefield TW, Stanley TJ, et al. Pharmacological prophylaxis against postoperative graft occlusion after peripheral vascular surgery: a world-wide survey. Eur J Vasc Endovasc Surg 1995; 9:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/55\">",
"      D&ouml;rffler-Melly J, Koopman MM, Adam DJ, et al. Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev 2003; :CD000535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/56\">",
"      Collins TC, Souchek J, Beyth RJ. Benefits of antithrombotic therapy after infrainguinal bypass grafting: a meta-analysis. Am J Med 2004; 117:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/57\">",
"      Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet 2000; 355:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/58\">",
"      Johnson WC, Williford WO, Department of Veterans Affairs Cooperative Study #362. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg 2002; 35:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/59\">",
"      Belch JJ, Dormandy J, CASPAR Writing Committee, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 2010; 52:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/60\">",
"      Sobel M, Verhaeghe R, American College of Chest Physicians, American College of Chest Physicians. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:815S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/58/19370/abstract/61\">",
"      Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e669S.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8215 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.76.133-59BD6D52C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_58_19370=[""].join("\n");
var outline_f18_58_19370=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H519577942\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H554865745\">",
"      INTRODUCTION AND DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H909632825\">",
"      TASC classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Bypass surgery first versus angioplasty first",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Thrombolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SURGERY FOR INFLOW DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Aortofemoral bypass graft",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H909633631\">",
"      - In situ autogenous reconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Extra-anatomic reconstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Axillobifemoral bypass graft",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Femorofemoral bypass",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H909633572\">",
"      - Axillopopliteal bypass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H909633610\">",
"      Profundoplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Minimally invasive operative alternatives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Endovascular grafts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SURGERY FOR INFRAINGUINAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Femoropopliteal bypass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Distal bypass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PERCUTANEOUS INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PRIMARY AMPUTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SPECIFIC ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Infrainguinal bypass in older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Infrainguinal bypass in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H909635263\">",
"      Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H909635301\">",
"      Aggressive wound care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Prostaglandin E1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Stimulation of angiogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Spinal cord stimulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H519589146\">",
"      POSTOPERATIVE FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H909633736\">",
"      Duplex ultrasound surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H519589542\">",
"      Guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H519589654\">",
"      ANTITHROMBOTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H519589661\">",
"      Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H519577942\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8215\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8215|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/7/12413\" title=\"table 1\">",
"      ACC AHA Treatment critical limb ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/63/32763\" title=\"table 2\">",
"      ACC AHA Prevention of critical limb ischemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13368?source=related_link\">",
"      Acute arterial occlusion of the lower extremities (acute limb ischemia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=related_link\">",
"      Basic principles of wound management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/0/1031?source=related_link\">",
"      Classification of lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30201?source=related_link\">",
"      Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14486?source=related_link\">",
"      Clinical manifestations and evaluation of chronic critical limb ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/16/37128?source=related_link\">",
"      Lower extremity peripheral artery disease in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=related_link\">",
"      Medical management of claudication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20905?source=related_link\">",
"      Peripheral artery disease in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/4/6216?source=related_link\">",
"      Therapeutic angiogenesis for management of refractory angina",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_58_19371="Laboratory findings in catatonia";
var content_f18_58_19371=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F57370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F57370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Laboratory findings in catatonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Laboratory finding",
"       </td>",
"       <td class=\"subtitle1\">",
"        Implication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukocytosis",
"       </td>",
"       <td>",
"        Non-specific; levels between 15,000 and 25,000 per mL correlate with malignant catatonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased creatinine kinase (CK)",
"       </td>",
"       <td>",
"        Non-specific; levels exceeding 1000 IU/L (normal range &lt;150 IU/L) strongly correlate with malignant catatonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low serum iron",
"       </td>",
"       <td>",
"        Observed in 40 percent of persons with malignant catatonia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Northoff G, Wenke J, Pflug B. Increase of serum creatine phosphokinase in catatonia: an investigation in 32 acute catatonic patients. Psychol Med 1996; 26:547.",
"       </li>",
"       <li>",
"        Lee JW. Serum iron in catatonia and neuroleptic malignant syndrome. Biol Psychiatry 1998; 44:499.",
"       </li>",
"       <li>",
"        Carroll BT, Goforth HW. Serum iron in catatonia. Biol Psychiatry 1995; 38:776.",
"       </li>",
"       <li>",
"        Singerman B, Raheja R. Malignant catatonia - a continuing reality. Ann Clin Psychiatry 1994; 6:259.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_58_19371=[""].join("\n");
var outline_f18_58_19371=null;
var title_f18_58_19372="Causes decr RBC production";
var content_f18_58_19372=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F80295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F80295&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of anemia with decreased red cell production",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Bone marrow failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Congenital pure red cell aplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Blackfan Diamond anemia*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Aase syndrome*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Aquired pure red cell aplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Autoimmune processes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Transient erythroblastopenia of childhood*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Bone marrow failure syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Aplastic anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fanconi's anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Others",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Mylelofibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Renal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vitamin D deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hypoparathyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Bone diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Osteopetrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Impaired erythropoietin production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Starvation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic renal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia of chronic disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disorders of erythroid maturation/ineffective erythropoiesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sideroblastic anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lead toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Megaloblastic anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital dyserythropoietic anemias",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Causes unique to the pediatric age group.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_58_19372=[""].join("\n");
var outline_f18_58_19372=null;
var title_f18_58_19373="Carrier testing for genetic disease based on ethnicity";
var content_f18_58_19373=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54288&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Carrier testing for genetic disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Population to screen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Method",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alpha thalassemia",
"       </td>",
"       <td>",
"        <p>",
"         Chinese",
"        </p>",
"        <p>",
"         Southeast Asians",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         CBC",
"        </p>",
"        <p>",
"         Hemoglobin electrophoresis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beta thalassemia",
"       </td>",
"       <td>",
"        <p>",
"         Chinese",
"        </p>",
"        <p>",
"         Southeast Asians",
"        </p>",
"        <p>",
"         Asian Indians",
"        </p>",
"        <p>",
"         Pakistanis",
"        </p>",
"        <p>",
"         Bangladeshis",
"        </p>",
"        <p>",
"         Middle Easterners",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         CBC",
"        </p>",
"        <p>",
"         Hemoglobin electrophoresis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bloom syndrome",
"       </td>",
"       <td>",
"        Ashkenazi Jews",
"       </td>",
"       <td>",
"        Mutation analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Canavan disease",
"       </td>",
"       <td>",
"        Ashkenazi Jews",
"       </td>",
"       <td>",
"        Mutation analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystic fibrosis",
"       </td>",
"       <td>",
"        <p>",
"         Ashkenazi Jews",
"        </p>",
"        <p>",
"         Other Caucasians",
"        </p>",
"       </td>",
"       <td>",
"        Mutation analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dihydrolipoamide dehydrogenase deficiency",
"       </td>",
"       <td>",
"        Ashkenazi Jews",
"       </td>",
"       <td>",
"        Mutation analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial dysautonomia",
"       </td>",
"       <td>",
"        <p>",
"         Hispanics",
"        </p>",
"        <p>",
"         Ashkenazi Jews",
"        </p>",
"       </td>",
"       <td>",
"        Mutation analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial hyperinsulinism",
"       </td>",
"       <td>",
"        Ashkenazi Jews",
"       </td>",
"       <td>",
"        Mutation analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fanconi anemia",
"       </td>",
"       <td>",
"        Ashkenazi Jews",
"       </td>",
"       <td>",
"        Mutation analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gaucher disease",
"       </td>",
"       <td>",
"        Ashkenazi Jews",
"       </td>",
"       <td>",
"        Mutation analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glycogen storage disease type 1A",
"       </td>",
"       <td>",
"        Ashkenazi Jews",
"       </td>",
"       <td>",
"        Mutation analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Joubert syndrome",
"       </td>",
"       <td>",
"        Ashkenazi Jews",
"       </td>",
"       <td>",
"        Mutation analysis&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maple syrup urine disease",
"       </td>",
"       <td>",
"        Ashkenazi Jews",
"       </td>",
"       <td>",
"        Mutation analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mucolipidosis IV",
"       </td>",
"       <td>",
"        Ashkenazi Jews",
"       </td>",
"       <td>",
"        Mutation analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nemaline myopathy",
"       </td>",
"       <td>",
"        Ashkenazi Jews",
"       </td>",
"       <td>",
"        Mutation analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Niemann-Pick disease",
"       </td>",
"       <td>",
"        Ashkenazi Jews",
"       </td>",
"       <td>",
"        Mutation analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sickle cell disease and other structural hemoglobinopathies",
"       </td>",
"       <td>",
"        <p>",
"         African-Americans",
"        </p>",
"        <p>",
"         Others of African origin",
"        </p>",
"        <p>",
"         Hispanics",
"        </p>",
"        <p>",
"         Italians",
"        </p>",
"        <p>",
"         Greeks",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         CBC",
"        </p>",
"        <p>",
"         Hemoglobin electrophoresis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spinal muscular atrophy&nbsp;",
"       </td>",
"       <td>",
"        All populations&nbsp;",
"       </td>",
"       <td>",
"        Mutation analysis&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tay-Sachs",
"       </td>",
"       <td>",
"        <p>",
"         Ashkenazi Jews",
"        </p>",
"        <p>",
"         French Canadians",
"        </p>",
"        <p>",
"         Cajuns",
"        </p>",
"       </td>",
"       <td>",
"        Enzyme and mutation analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Usher syndrome",
"       </td>",
"       <td>",
"        Ashkenazi Jews",
"       </td>",
"       <td>",
"        Mutation analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Walker-Warburg syndrome&nbsp;",
"       </td>",
"       <td>",
"        Ashkenazi Jews&nbsp;",
"       </td>",
"       <td>",
"        Mutation analysis&nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CBC: complete blood count, including red blood cell indices.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_58_19373=[""].join("\n");
var outline_f18_58_19373=null;
var title_f18_58_19374="Stroke probability by stenosis";
var content_f18_58_19374=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F73498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F73498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 491px\">",
"   <div class=\"ttl\">",
"    Stroke probability by stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 471px; height: 390px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Product-limit estimate of the cumulative probability of an ischemic stroke in the territory of the stenotic artery versus years after randomization, according to percent stenosis (&ge;70 percent stenosis shown as red solid line, &lt;70 percent stenosis as blue dashed line); log-rank test P 0.0010.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Kasner, SE, Chimowitz, MI, Lynn, MJ, et al. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation 2006; 113:555. Copyright &copy;2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_58_19374=[""].join("\n");
var outline_f18_58_19374=null;
var title_f18_58_19375="Fertility rate and age";
var content_f18_58_19375=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F80807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F80807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 595px\">",
"   <div class=\"ttl\">",
"    Fertility rate in women declines with age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 575px; height: 302px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fertility rates in different groups of women from the 16th to the 20th centuries. The fertility rate declined with age in all the groups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Maroulis, GB, Seminars Reprod Endocrinol 1991; 9:165.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_58_19375=[""].join("\n");
var outline_f18_58_19375=null;
